WO2019234228A1 - Beta-amino-alpha-hydroxyalkylphenyl derivatives and their use for cancer treatment - Google Patents
Beta-amino-alpha-hydroxyalkylphenyl derivatives and their use for cancer treatment Download PDFInfo
- Publication number
- WO2019234228A1 WO2019234228A1 PCT/EP2019/064970 EP2019064970W WO2019234228A1 WO 2019234228 A1 WO2019234228 A1 WO 2019234228A1 EP 2019064970 W EP2019064970 W EP 2019064970W WO 2019234228 A1 WO2019234228 A1 WO 2019234228A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- alkyl
- compound
- independently
- occurrence
- phenyl
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 94
- 201000011510 cancer Diseases 0.000 title claims abstract description 63
- 238000011282 treatment Methods 0.000 title claims description 30
- 150000001875 compounds Chemical class 0.000 claims abstract description 140
- 238000000034 method Methods 0.000 claims description 127
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 63
- 125000005843 halogen group Chemical group 0.000 claims description 49
- -1 Ci-C6-haloalkyl Chemical group 0.000 claims description 45
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims description 40
- 125000001072 heteroaryl group Chemical group 0.000 claims description 28
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 28
- 150000003839 salts Chemical class 0.000 claims description 24
- 125000004429 atom Chemical group 0.000 claims description 23
- 239000004305 biphenyl Substances 0.000 claims description 22
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 22
- 235000010290 biphenyl Nutrition 0.000 claims description 20
- 229910052799 carbon Inorganic materials 0.000 claims description 16
- 125000005647 linker group Chemical group 0.000 claims description 14
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 13
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 13
- 229910052760 oxygen Inorganic materials 0.000 claims description 13
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 11
- 125000000217 alkyl group Chemical group 0.000 claims description 11
- 125000001624 naphthyl group Chemical group 0.000 claims description 10
- 229910052717 sulfur Inorganic materials 0.000 claims description 10
- 229910052757 nitrogen Inorganic materials 0.000 claims description 9
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 125000002947 alkylene group Chemical group 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 5
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 4
- 125000003342 alkenyl group Chemical group 0.000 claims description 4
- 125000000304 alkynyl group Chemical group 0.000 claims description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 4
- 239000001301 oxygen Substances 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 229910003827 NRaRb Inorganic materials 0.000 claims description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 2
- 239000005864 Sulphur Substances 0.000 claims description 2
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 claims description 2
- 229910052739 hydrogen Inorganic materials 0.000 claims description 2
- 230000019522 cellular metabolic process Effects 0.000 abstract description 8
- XYFCBTPGUUZFHI-UHFFFAOYSA-O phosphonium Chemical compound [PH4+] XYFCBTPGUUZFHI-UHFFFAOYSA-O 0.000 abstract description 7
- 238000011275 oncology therapy Methods 0.000 abstract description 4
- 230000003915 cell function Effects 0.000 abstract description 3
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 abstract description 2
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 120
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 114
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 56
- 210000004027 cell Anatomy 0.000 description 43
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 42
- 238000006243 chemical reaction Methods 0.000 description 36
- 150000002500 ions Chemical class 0.000 description 34
- 239000007787 solid Substances 0.000 description 29
- 239000000377 silicon dioxide Substances 0.000 description 28
- 238000004440 column chromatography Methods 0.000 description 26
- 125000001424 substituent group Chemical group 0.000 description 26
- 239000003960 organic solvent Substances 0.000 description 24
- 239000000243 solution Substances 0.000 description 24
- 150000002430 hydrocarbons Chemical group 0.000 description 23
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 17
- 239000000460 chlorine Substances 0.000 description 17
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 16
- 125000004432 carbon atom Chemical group C* 0.000 description 16
- 229910052801 chlorine Inorganic materials 0.000 description 16
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 16
- 230000002265 prevention Effects 0.000 description 16
- 125000004122 cyclic group Chemical group 0.000 description 15
- 239000003112 inhibitor Substances 0.000 description 15
- 239000011541 reaction mixture Substances 0.000 description 15
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 14
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 14
- 239000002253 acid Substances 0.000 description 14
- 125000005842 heteroatom Chemical group 0.000 description 14
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 13
- 229910052794 bromium Inorganic materials 0.000 description 13
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
- 239000002246 antineoplastic agent Substances 0.000 description 12
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 12
- 230000002829 reductive effect Effects 0.000 description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- 150000001412 amines Chemical class 0.000 description 10
- 150000001450 anions Chemical class 0.000 description 10
- 125000003118 aryl group Chemical group 0.000 description 9
- 150000001768 cations Chemical class 0.000 description 9
- 125000004433 nitrogen atom Chemical group N* 0.000 description 9
- 239000003921 oil Substances 0.000 description 9
- 235000019198 oils Nutrition 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 238000000746 purification Methods 0.000 description 9
- 125000004076 pyridyl group Chemical group 0.000 description 9
- 238000006467 substitution reaction Methods 0.000 description 9
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 8
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
- 230000004663 cell proliferation Effects 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 239000013543 active substance Substances 0.000 description 7
- 150000001721 carbon Chemical group 0.000 description 7
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 7
- 235000019439 ethyl acetate Nutrition 0.000 description 7
- 229910052731 fluorine Inorganic materials 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- 229910001868 water Inorganic materials 0.000 description 7
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 6
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical group OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical group CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 6
- 150000001540 azides Chemical class 0.000 description 6
- XGRJZXREYAXTGV-UHFFFAOYSA-N chlorodiphenylphosphine Chemical compound C=1C=CC=CC=1P(Cl)C1=CC=CC=C1 XGRJZXREYAXTGV-UHFFFAOYSA-N 0.000 description 6
- 238000001816 cooling Methods 0.000 description 6
- ILRSCQWREDREME-UHFFFAOYSA-N dodecanamide Chemical compound CCCCCCCCCCCC(N)=O ILRSCQWREDREME-UHFFFAOYSA-N 0.000 description 6
- 238000010438 heat treatment Methods 0.000 description 6
- 230000006872 improvement Effects 0.000 description 6
- PQNFLJBBNBOBRQ-UHFFFAOYSA-N indane Chemical compound C1=CC=C2CCCC2=C1 PQNFLJBBNBOBRQ-UHFFFAOYSA-N 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 229910000073 phosphorus hydride Inorganic materials 0.000 description 6
- 150000003141 primary amines Chemical class 0.000 description 6
- FDDDEECHVMSUSB-UHFFFAOYSA-N sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 description 6
- 239000001828 Gelatine Substances 0.000 description 5
- 230000003115 biocidal effect Effects 0.000 description 5
- AOGYCOYQMAVAFD-UHFFFAOYSA-M carbonochloridate Chemical compound [O-]C(Cl)=O AOGYCOYQMAVAFD-UHFFFAOYSA-M 0.000 description 5
- 229920000159 gelatin Polymers 0.000 description 5
- 235000019322 gelatine Nutrition 0.000 description 5
- 125000004366 heterocycloalkenyl group Chemical group 0.000 description 5
- 229910052740 iodine Inorganic materials 0.000 description 5
- 230000035755 proliferation Effects 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 239000003643 water by type Substances 0.000 description 5
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 description 4
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 4
- YYKBWYBUCFHYPR-UHFFFAOYSA-N 12-bromododecanoic acid Chemical compound OC(=O)CCCCCCCCCCCBr YYKBWYBUCFHYPR-UHFFFAOYSA-N 0.000 description 4
- HBEDSQVIWPRPAY-UHFFFAOYSA-N 2,3-dihydrobenzofuran Chemical compound C1=CC=C2OCCC2=C1 HBEDSQVIWPRPAY-UHFFFAOYSA-N 0.000 description 4
- XVMSFILGAMDHEY-UHFFFAOYSA-N 6-(4-aminophenyl)sulfonylpyridin-3-amine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=N1 XVMSFILGAMDHEY-UHFFFAOYSA-N 0.000 description 4
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 201000009030 Carcinoma Diseases 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical group CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 4
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 4
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 4
- 206010025323 Lymphomas Diseases 0.000 description 4
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 4
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 4
- 239000002202 Polyethylene glycol Chemical group 0.000 description 4
- 206010039491 Sarcoma Diseases 0.000 description 4
- 125000000129 anionic group Chemical group 0.000 description 4
- 239000003242 anti bacterial agent Substances 0.000 description 4
- 229940088710 antibiotic agent Drugs 0.000 description 4
- 125000002619 bicyclic group Chemical group 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 4
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 4
- 239000012043 crude product Substances 0.000 description 4
- 125000000392 cycloalkenyl group Chemical group 0.000 description 4
- 239000003480 eluent Substances 0.000 description 4
- 239000011737 fluorine Substances 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 125000004404 heteroalkyl group Chemical group 0.000 description 4
- 239000003456 ion exchange resin Substances 0.000 description 4
- 229920003303 ion-exchange polymer Polymers 0.000 description 4
- 229940043355 kinase inhibitor Drugs 0.000 description 4
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 4
- 229920001223 polyethylene glycol Chemical group 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 125000006239 protecting group Chemical group 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 229930195734 saturated hydrocarbon Natural products 0.000 description 4
- 239000012453 solvate Substances 0.000 description 4
- QAHVHSLSRLSVGS-UHFFFAOYSA-N sulfamoyl chloride Chemical compound NS(Cl)(=O)=O QAHVHSLSRLSVGS-UHFFFAOYSA-N 0.000 description 4
- 229940124530 sulfonamide Drugs 0.000 description 4
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical compound OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- CMSYDJVRTHCWFP-UHFFFAOYSA-N triphenylphosphane;hydrobromide Chemical compound Br.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 CMSYDJVRTHCWFP-UHFFFAOYSA-N 0.000 description 4
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 4
- 229930195735 unsaturated hydrocarbon Natural products 0.000 description 4
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 3
- BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 description 3
- XZRCOFWWCNTSOW-UHFFFAOYSA-N 11-carboxyundecyl-(1-methylpyrazol-4-yl)-diphenylphosphanium bromide Chemical compound [Br-].C(=O)(O)CCCCCCCCCCC[P+](C1=CC=CC=C1)(C1=CC=CC=C1)C=1C=NN(C=1)C XZRCOFWWCNTSOW-UHFFFAOYSA-N 0.000 description 3
- IWGNALJWRWHBFZ-UHFFFAOYSA-N 11-carboxyundecyl-(1-methyltriazol-4-yl)-diphenylphosphanium bromide Chemical compound [Br-].C(=O)(O)CCCCCCCCCCC[P+](C1=CC=CC=C1)(C1=CC=CC=C1)C=1N=NN(C=1)C IWGNALJWRWHBFZ-UHFFFAOYSA-N 0.000 description 3
- IYZFZCHWLKRJIZ-UHFFFAOYSA-N 11-carboxyundecyl-dimethyl-phenylphosphanium bromide Chemical compound [Br-].C(=O)(O)CCCCCCCCCCC[P+](C1=CC=CC=C1)(C)C IYZFZCHWLKRJIZ-UHFFFAOYSA-N 0.000 description 3
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 3
- ZDEBEPAZWJSOBS-UHFFFAOYSA-N 4-diphenylphosphoryl-1-methyltriazole Chemical compound C1(=CC=CC=C1)P(=O)(C1=CC=CC=C1)C=1N=NN(C=1)C ZDEBEPAZWJSOBS-UHFFFAOYSA-N 0.000 description 3
- HOTUCDKXRHQHPA-UHFFFAOYSA-N 7-carboxyheptyl-(1-methylpyrazol-4-yl)-diphenylphosphanium bromide Chemical compound [Br-].C(=O)(O)CCCCCCC[P+](C1=CC=CC=C1)(C1=CC=CC=C1)C=1C=NN(C=1)C HOTUCDKXRHQHPA-UHFFFAOYSA-N 0.000 description 3
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 3
- NQNUEGKXUSAXTM-UHFFFAOYSA-N 8-carboxyoctyl-(1-methylpyrazol-4-yl)-diphenylphosphanium bromide Chemical compound [Br-].C(=O)(O)CCCCCCCC[P+](C1=CC=CC=C1)(C1=CC=CC=C1)C=1C=NN(C=1)C NQNUEGKXUSAXTM-UHFFFAOYSA-N 0.000 description 3
- CEDLSHKYGLXUSH-UHFFFAOYSA-N 9-carboxynonyl-(1-methylpyrazol-4-yl)-diphenylphosphanium bromide Chemical compound [Br-].C(=O)(O)CCCCCCCCC[P+](C1=CC=CC=C1)(C1=CC=CC=C1)C=1C=NN(C=1)C CEDLSHKYGLXUSH-UHFFFAOYSA-N 0.000 description 3
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 3
- 0 CCC=CC=C(C(*)C(C*)N(*)*)C=CCN Chemical compound CCC=CC=C(C(*)C(C*)N(*)*)C=CCN 0.000 description 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 102000014150 Interferons Human genes 0.000 description 3
- 108010050904 Interferons Proteins 0.000 description 3
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- RSONAYFAHJYEKW-UHFFFAOYSA-N [Br-].C(=O)(O)CCCCCCCCCCC[P+](C1=CC=CC=C1)(C1=CC=CC=C1)C Chemical compound [Br-].C(=O)(O)CCCCCCCCCCC[P+](C1=CC=CC=C1)(C1=CC=CC=C1)C RSONAYFAHJYEKW-UHFFFAOYSA-N 0.000 description 3
- 230000001594 aberrant effect Effects 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 150000004945 aromatic hydrocarbons Chemical group 0.000 description 3
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 3
- 230000005587 bubbling Effects 0.000 description 3
- 229920001429 chelating resin Polymers 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000013066 combination product Substances 0.000 description 3
- 229940127555 combination product Drugs 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- 229910052736 halogen Inorganic materials 0.000 description 3
- 150000002367 halogens Chemical class 0.000 description 3
- 150000003944 halohydrins Chemical class 0.000 description 3
- OFFQPEBWIQOAIP-UHFFFAOYSA-N hexadecanamide Chemical compound CCCCCCCCCCCCCCCC(N)=O.CCCCCCCCCCCCCCCC(N)=O OFFQPEBWIQOAIP-UHFFFAOYSA-N 0.000 description 3
- 229940081141 hexadecanamide Drugs 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 239000011630 iodine Substances 0.000 description 3
- 208000032839 leukemia Diseases 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 150000003431 steroids Chemical class 0.000 description 3
- BDHFUVZGWQCTTF-UHFFFAOYSA-N sulfonic acid Chemical compound OS(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-N 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical compound C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 3
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- NBMKJKDGKREAPL-CXSFZGCWSA-N (8s,9r,10s,11s,13s,14s,16r,17r)-9-chloro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-CXSFZGCWSA-N 0.000 description 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 2
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 description 2
- OBMSTIRQZKKBPW-UHFFFAOYSA-N 10-carboxydecyl-(1-methylpyrazol-4-yl)-diphenylphosphanium bromide Chemical compound [Br-].C(=O)(O)CCCCCCCCCC[P+](C1=CC=CC=C1)(C1=CC=CC=C1)C=1C=NN(C=1)C OBMSTIRQZKKBPW-UHFFFAOYSA-N 0.000 description 2
- AFABGHUZZDYHJO-UHFFFAOYSA-N 2-Methylpentane Chemical compound CCCC(C)C AFABGHUZZDYHJO-UHFFFAOYSA-N 0.000 description 2
- RTQWWZBSTRGEAV-PKHIMPSTSA-N 2-[[(2s)-2-[bis(carboxymethyl)amino]-3-[4-(methylcarbamoylamino)phenyl]propyl]-[2-[bis(carboxymethyl)amino]propyl]amino]acetic acid Chemical compound CNC(=O)NC1=CC=C(C[C@@H](CN(CC(C)N(CC(O)=O)CC(O)=O)CC(O)=O)N(CC(O)=O)CC(O)=O)C=C1 RTQWWZBSTRGEAV-PKHIMPSTSA-N 0.000 description 2
- MMVPRLPUYZBHQC-UHFFFAOYSA-N 2-methoxyethyl(diphenyl)phosphane Chemical compound C=1C=CC=CC=1P(CCOC)C1=CC=CC=C1 MMVPRLPUYZBHQC-UHFFFAOYSA-N 0.000 description 2
- BKJFDZSBZWHRNH-UHFFFAOYSA-N 8-bromooctanoic acid Chemical compound OC(=O)CCCCCCCBr BKJFDZSBZWHRNH-UHFFFAOYSA-N 0.000 description 2
- KUVIULQEHSCUHY-XYWKZLDCSA-N Beclometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O KUVIULQEHSCUHY-XYWKZLDCSA-N 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N Formic acid Chemical compound OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 2
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 239000004721 Polyphenylene oxide Chemical group 0.000 description 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- RPZMEEOBYFRGDF-RJRRMMCTSA-N [11-[[(1R,2R)-1,3-dihydroxy-1-(4-nitrophenyl)propan-2-yl]amino]-11-oxoundecyl]-(1-methylpyrazol-4-yl)-diphenylphosphanium chloride Chemical compound [Cl-].O[C@@H]([C@@H](CO)NC(=O)CCCCCCCCCC[P+](C1=CC=CC=C1)(C1=CC=CC=C1)C=1C=NN(C=1)C)C1=CC=C(C=C1)[N+](=O)[O-] RPZMEEOBYFRGDF-RJRRMMCTSA-N 0.000 description 2
- KLVGYUOTVCIZCF-ZHESDOBJSA-N [12-[[(1R,2R)-1,3-dihydroxy-1-(4-nitrophenyl)propan-2-yl]amino]-12-oxododecyl]-dimethyl-phenylphosphanium chloride Chemical compound [Cl-].O[C@@H]([C@@H](CO)NC(=O)CCCCCCCCCCC[P+](C1=CC=CC=C1)(C)C)C1=CC=C(C=C1)[N+](=O)[O-] KLVGYUOTVCIZCF-ZHESDOBJSA-N 0.000 description 2
- HAFHRXXNJKMVPO-DODPVVESSA-N [12-[[(1R,2R)-1,3-dihydroxy-1-(4-nitrophenyl)propan-2-yl]amino]-12-oxododecyl]-diphenyl-pyridin-2-ylphosphanium chloride Chemical compound [Cl-].O[C@@H]([C@@H](CO)NC(=O)CCCCCCCCCCC[P+](C1=NC=CC=C1)(C1=CC=CC=C1)C1=CC=CC=C1)C1=CC=C(C=C1)[N+](=O)[O-] HAFHRXXNJKMVPO-DODPVVESSA-N 0.000 description 2
- JDCIPTAOFUUESV-NJWRWCCFSA-N [8-[[(1R,2R)-1,3-dihydroxy-1-(4-nitrophenyl)propan-2-yl]amino]-8-oxooctyl]-(1-methylpyrazol-4-yl)-diphenylphosphanium chloride Chemical compound [Cl-].O[C@@H]([C@@H](CO)NC(=O)CCCCCCC[P+](C1=CC=CC=C1)(C1=CC=CC=C1)C=1C=NN(C=1)C)C1=CC=C(C=C1)[N+](=O)[O-] JDCIPTAOFUUESV-NJWRWCCFSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- FJXOGVLKCZQRDN-PHCHRAKRSA-N alclometasone Chemical compound C([C@H]1Cl)C2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O FJXOGVLKCZQRDN-PHCHRAKRSA-N 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- MWPLVEDNUUSJAV-UHFFFAOYSA-N anthracene Chemical compound C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000012267 brine Substances 0.000 description 2
- HUCVOHYBFXVBRW-UHFFFAOYSA-M caesium hydroxide Chemical compound [OH-].[Cs+] HUCVOHYBFXVBRW-UHFFFAOYSA-M 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 229960005091 chloramphenicol Drugs 0.000 description 2
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 2
- VZWXIQHBIQLMPN-UHFFFAOYSA-N chromane Chemical compound C1=CC=C2CCCOC2=C1 VZWXIQHBIQLMPN-UHFFFAOYSA-N 0.000 description 2
- 201000002758 colorectal adenoma Diseases 0.000 description 2
- 238000011284 combination treatment Methods 0.000 description 2
- 239000007822 coupling agent Substances 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- FEBLZLNTKCEFIT-VSXGLTOVSA-N fluocinolone acetonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O FEBLZLNTKCEFIT-VSXGLTOVSA-N 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 125000001188 haloalkyl group Chemical group 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 2
- 229960001001 ibritumomab tiuxetan Drugs 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000005342 ion exchange Methods 0.000 description 2
- 239000012948 isocyanate Substances 0.000 description 2
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000001394 metastastic effect Effects 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- UJNZOIKQAUQOCN-UHFFFAOYSA-N methyl(diphenyl)phosphane Chemical compound C=1C=CC=CC=1P(C)C1=CC=CC=C1 UJNZOIKQAUQOCN-UHFFFAOYSA-N 0.000 description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 2
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 210000000441 neoplastic stem cell Anatomy 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- UBAOFCNBCAZEBL-UHFFFAOYSA-N octanamide Chemical compound CCCCCCCC(N)=O.CCCCCCCC(N)=O UBAOFCNBCAZEBL-UHFFFAOYSA-N 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 238000005897 peptide coupling reaction Methods 0.000 description 2
- 125000004437 phosphorous atom Chemical group 0.000 description 2
- 229920000570 polyether Chemical group 0.000 description 2
- 229920001451 polypropylene glycol Chemical group 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 235000013772 propylene glycol Nutrition 0.000 description 2
- 229960004063 propylene glycol Drugs 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical compound O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- BISFDZNIUZIKJD-XDANTLIUSA-N tixocortol pivalate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)CSC(=O)C(C)(C)C)(O)[C@@]1(C)C[C@@H]2O BISFDZNIUZIKJD-XDANTLIUSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 229960005294 triamcinolone Drugs 0.000 description 2
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- XRALRSQLQXKXKP-UHFFFAOYSA-N tris(3,5-dimethylphenyl)phosphane Chemical compound CC1=CC(C)=CC(P(C=2C=C(C)C=C(C)C=2)C=2C=C(C)C=C(C)C=2)=C1 XRALRSQLQXKXKP-UHFFFAOYSA-N 0.000 description 2
- FPVKHBSQESCIEP-UHFFFAOYSA-N (8S)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol Natural products C1C(O)C(CO)OC1N1C(NC=NCC2O)=C2N=C1 FPVKHBSQESCIEP-UHFFFAOYSA-N 0.000 description 1
- 125000006716 (C1-C6) heteroalkyl group Chemical group 0.000 description 1
- LKJPYSCBVHEWIU-KRWDZBQOSA-N (R)-bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 description 1
- OCYJXSUPZMNXEN-RKDXNWHRSA-N (R,R)-2-amino-1-(4-nitrophenyl)propane-1,3-diol Chemical compound OC[C@@H](N)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 OCYJXSUPZMNXEN-RKDXNWHRSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- CIISBYKBBMFLEZ-UHFFFAOYSA-N 1,2-oxazolidine Chemical compound C1CNOC1 CIISBYKBBMFLEZ-UHFFFAOYSA-N 0.000 description 1
- CZSRXHJVZUBEGW-UHFFFAOYSA-N 1,2-thiazolidine Chemical compound C1CNSC1 CZSRXHJVZUBEGW-UHFFFAOYSA-N 0.000 description 1
- GWYPDXLJACEENP-UHFFFAOYSA-N 1,3-cycloheptadiene Chemical compound C1CC=CC=CC1 GWYPDXLJACEENP-UHFFFAOYSA-N 0.000 description 1
- OGYGFUAIIOPWQD-UHFFFAOYSA-N 1,3-thiazolidine Chemical compound C1CSCN1 OGYGFUAIIOPWQD-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- GQIRIWDEZSKOCN-UHFFFAOYSA-N 1-chloro-n,n,2-trimethylprop-1-en-1-amine Chemical compound CN(C)C(Cl)=C(C)C GQIRIWDEZSKOCN-UHFFFAOYSA-N 0.000 description 1
- FPIRBHDGWMWJEP-UHFFFAOYSA-N 1-hydroxy-7-azabenzotriazole Chemical compound C1=CN=C2N(O)N=NC2=C1 FPIRBHDGWMWJEP-UHFFFAOYSA-N 0.000 description 1
- PGVRSPIEZYGOAD-UHFFFAOYSA-N 10-bromodecanoic acid Chemical compound OC(=O)CCCCCCCCCBr PGVRSPIEZYGOAD-UHFFFAOYSA-N 0.000 description 1
- KUJPLLZKKCBLDR-UHFFFAOYSA-N 11-carboxyundecyl(triphenyl)phosphanium;bromide Chemical compound [Br-].C=1C=CC=CC=1[P+](C=1C=CC=CC=1)(CCCCCCCCCCCC(=O)O)C1=CC=CC=C1 KUJPLLZKKCBLDR-UHFFFAOYSA-N 0.000 description 1
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
- ZESRJSPZRDMNHY-YFWFAHHUSA-N 11-deoxycorticosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 ZESRJSPZRDMNHY-YFWFAHHUSA-N 0.000 description 1
- PFNCOYVEMJYEED-UHFFFAOYSA-N 16-bromohexadecanoic acid Chemical compound OC(=O)CCCCCCCCCCCCCCCBr PFNCOYVEMJYEED-UHFFFAOYSA-N 0.000 description 1
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
- 125000000453 2,2,2-trichloroethyl group Chemical group [H]C([H])(*)C(Cl)(Cl)Cl 0.000 description 1
- YJUFGFXVASPYFQ-UHFFFAOYSA-N 2,3-dihydro-1-benzothiophene Chemical compound C1=CC=C2SCCC2=C1 YJUFGFXVASPYFQ-UHFFFAOYSA-N 0.000 description 1
- JKTCBAGSMQIFNL-UHFFFAOYSA-N 2,3-dihydrofuran Chemical compound C1CC=CO1 JKTCBAGSMQIFNL-UHFFFAOYSA-N 0.000 description 1
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 1
- JECYNCQXXKQDJN-UHFFFAOYSA-N 2-(2-methylhexan-2-yloxymethyl)oxirane Chemical compound CCCCC(C)(C)OCC1CO1 JECYNCQXXKQDJN-UHFFFAOYSA-N 0.000 description 1
- YGTUPRIZNBMOFV-UHFFFAOYSA-N 2-(4-hydroxybenzoyl)benzoic acid Chemical compound OC(=O)C1=CC=CC=C1C(=O)C1=CC=C(O)C=C1 YGTUPRIZNBMOFV-UHFFFAOYSA-N 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- VSWICNJIUPRZIK-UHFFFAOYSA-N 2-piperideine Chemical compound C1CNC=CC1 VSWICNJIUPRZIK-UHFFFAOYSA-N 0.000 description 1
- RSEBUVRVKCANEP-UHFFFAOYSA-N 2-pyrroline Chemical compound C1CC=CN1 RSEBUVRVKCANEP-UHFFFAOYSA-N 0.000 description 1
- VHMICKWLTGFITH-UHFFFAOYSA-N 2H-isoindole Chemical compound C1=CC=CC2=CNC=C21 VHMICKWLTGFITH-UHFFFAOYSA-N 0.000 description 1
- NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 description 1
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
- IXJSDKIJPVSPKF-UHFFFAOYSA-N 4-bromo-1-methylpyrazole Chemical compound CN1C=C(Br)C=N1 IXJSDKIJPVSPKF-UHFFFAOYSA-N 0.000 description 1
- RQZZFHDFPSNDKV-UHFFFAOYSA-N 4-bromo-1-methyltriazole Chemical compound CN1C=C(Br)N=N1 RQZZFHDFPSNDKV-UHFFFAOYSA-N 0.000 description 1
- MSXWMYHJMFYUCL-UHFFFAOYSA-N 4-diphenylphosphoryl-1-methylpyrazole Chemical compound C1(=CC=CC=C1)P(=O)(C1=CC=CC=C1)C=1C=NN(C=1)C MSXWMYHJMFYUCL-UHFFFAOYSA-N 0.000 description 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 1
- DNPJAMMRVRYLOB-UHFFFAOYSA-N 5-phenylbenzo[b]phosphindole Chemical compound C1=CC=CC=C1P1C2=CC=CC=C2C2=CC=CC=C21 DNPJAMMRVRYLOB-UHFFFAOYSA-N 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- KPSRRRHHYOTMEU-UHFFFAOYSA-N 8-carboxyoctyl(triphenyl)phosphanium;bromide Chemical compound [Br-].C=1C=CC=CC=1[P+](C=1C=CC=CC=1)(CCCCCCCCC(=O)O)C1=CC=CC=C1 KPSRRRHHYOTMEU-UHFFFAOYSA-N 0.000 description 1
- XEGRKZRPTBNSMN-UHFFFAOYSA-N 9-bromononanoic acid Chemical compound OC(=O)CCCCCCCCBr XEGRKZRPTBNSMN-UHFFFAOYSA-N 0.000 description 1
- MBBYHWZVGHKEBI-UHFFFAOYSA-N 9-carboxynonyl(triphenyl)phosphanium;bromide Chemical compound [Br-].C=1C=CC=CC=1[P+](C=1C=CC=CC=1)(CCCCCCCCCC(=O)O)C1=CC=CC=C1 MBBYHWZVGHKEBI-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 description 1
- PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 description 1
- PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 229920000945 Amylopectin Polymers 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 description 1
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
- 102000008096 B7-H1 Antigen Human genes 0.000 description 1
- 108010074708 B7-H1 Antigen Proteins 0.000 description 1
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 1
- 239000012664 BCL-2-inhibitor Substances 0.000 description 1
- 108700020463 BRCA1 Proteins 0.000 description 1
- 102000036365 BRCA1 Human genes 0.000 description 1
- 101150072950 BRCA1 gene Proteins 0.000 description 1
- 102000052609 BRCA2 Human genes 0.000 description 1
- 108700020462 BRCA2 Proteins 0.000 description 1
- 229940123711 Bcl2 inhibitor Drugs 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 101150008921 Brca2 gene Proteins 0.000 description 1
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 1
- 108010037003 Buserelin Proteins 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- RKWITMWEJPZACJ-RSCFEQGXSA-N C1(=CC=CC=C1)P(=O)(C1=CC=CC=C1)C=1C=NN(C1)C.[Cl-].O[C@@H]([C@@H](CO)NC(=O)CCCCCCCCCCC[P+](C1=CC=CC=C1)(C1=CC=CC=C1)C=1C=NN(C1)C)C1=CC=C(C=C1)[N+](=O)[O-] Chemical compound C1(=CC=CC=C1)P(=O)(C1=CC=CC=C1)C=1C=NN(C1)C.[Cl-].O[C@@H]([C@@H](CO)NC(=O)CCCCCCCCCCC[P+](C1=CC=CC=C1)(C1=CC=CC=C1)C=1C=NN(C1)C)C1=CC=C(C=C1)[N+](=O)[O-] RKWITMWEJPZACJ-RSCFEQGXSA-N 0.000 description 1
- VNAAEXZVURCRRF-QZCRLSDHSA-N CC(C)(C)P(CCCCCCCCCCCC(N[C@H](CO)[C@@H](c(cc1)ccc1[N+]([O-])=O)O)=O)(c1ccccc1)c1ccccc1 Chemical compound CC(C)(C)P(CCCCCCCCCCCC(N[C@H](CO)[C@@H](c(cc1)ccc1[N+]([O-])=O)O)=O)(c1ccccc1)c1ccccc1 VNAAEXZVURCRRF-QZCRLSDHSA-N 0.000 description 1
- RCCQKKYAKUJEOG-QZCRLSDHSA-N CC(C)P(CCCCCCCCCCCC(N[C@H](CO)[C@@H](c(cc1)ccc1[N+]([O-])=O)O)=O)(c1ccccc1)c1ccccc1 Chemical compound CC(C)P(CCCCCCCCCCCC(N[C@H](CO)[C@@H](c(cc1)ccc1[N+]([O-])=O)O)=O)(c1ccccc1)c1ccccc1 RCCQKKYAKUJEOG-QZCRLSDHSA-N 0.000 description 1
- ALMVDRLNDMXONP-ZADIWHOSSA-N C[C@H]([C@@H](c(cc1)ccc1[N+]([O-])=O)O)NC(CCCCCCCCCCP(c1c[n](C)nc1)(c1ccccc1)c1ccccc1)=O Chemical compound C[C@H]([C@@H](c(cc1)ccc1[N+]([O-])=O)O)NC(CCCCCCCCCCP(c1c[n](C)nc1)(c1ccccc1)c1ccccc1)=O ALMVDRLNDMXONP-ZADIWHOSSA-N 0.000 description 1
- PDRUJUUYJLJOHU-ZFEZZJPFSA-N C[n]1ncc(P(CCCCCCCCC(N[C@H](CO)[C@@H](c(cc2)ccc2[N+]([O-])=O)O)=O)(c2ccccc2)c2ccccc2)c1 Chemical compound C[n]1ncc(P(CCCCCCCCC(N[C@H](CO)[C@@H](c(cc2)ccc2[N+]([O-])=O)O)=O)(c2ccccc2)c2ccccc2)c1 PDRUJUUYJLJOHU-ZFEZZJPFSA-N 0.000 description 1
- JFSFOSWPAHGXGJ-VLZNPVHKSA-N C[n]1ncc(P(CCCCCCCCCC(N[C@H](CO)[C@@H](c(cc2)ccc2[N+]([O-])=O)O)=O)(c2ccccc2)c2ccccc2)c1 Chemical compound C[n]1ncc(P(CCCCCCCCCC(N[C@H](CO)[C@@H](c(cc2)ccc2[N+]([O-])=O)O)=O)(c2ccccc2)c2ccccc2)c1 JFSFOSWPAHGXGJ-VLZNPVHKSA-N 0.000 description 1
- YZWANYIFXMUESW-QZCRLSDHSA-N C[n]1ncc(P(CCCCCCCCCCC(N[C@H](CO)[C@@H](c(cc2)ccc2[N+]([O-])=O)O)=O)(c2ccccc2)c2ccccc2)c1 Chemical compound C[n]1ncc(P(CCCCCCCCCCC(N[C@H](CO)[C@@H](c(cc2)ccc2[N+]([O-])=O)O)=O)(c2ccccc2)c2ccccc2)c1 YZWANYIFXMUESW-QZCRLSDHSA-N 0.000 description 1
- KSTGTGFEECEFCI-KYJPYPDVSA-N C[n]1ncc(P(CCCCCCCCCCCC(N[C@H](CO)[C@@H](c(cc2)ccc2[N+]([O-])=O)O)=O)(c2ccccc2)c(cc2)ccc2-c(cc2)cc3c2-c2ccccc2P3(CCCCCCCCCCCC(N[C@H](CO)[C@@H](c(cc2)ccc2[N+]([O-])=O)O)=O)c2ccccc2)c1 Chemical compound C[n]1ncc(P(CCCCCCCCCCCC(N[C@H](CO)[C@@H](c(cc2)ccc2[N+]([O-])=O)O)=O)(c2ccccc2)c(cc2)ccc2-c(cc2)cc3c2-c2ccccc2P3(CCCCCCCCCCCC(N[C@H](CO)[C@@H](c(cc2)ccc2[N+]([O-])=O)O)=O)c2ccccc2)c1 KSTGTGFEECEFCI-KYJPYPDVSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229940124957 Cervarix Drugs 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 1
- FBRAWBYQGRLCEK-AVVSTMBFSA-N Clobetasone butyrate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CCl)(OC(=O)CCC)[C@@]1(C)CC2=O FBRAWBYQGRLCEK-AVVSTMBFSA-N 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- ITRJWOMZKQRYTA-RFZYENFJSA-N Cortisone acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)CC2=O ITRJWOMZKQRYTA-RFZYENFJSA-N 0.000 description 1
- 108010024986 Cyclin-Dependent Kinase 2 Proteins 0.000 description 1
- 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 description 1
- 102100036239 Cyclin-dependent kinase 2 Human genes 0.000 description 1
- 102100036252 Cyclin-dependent kinase 4 Human genes 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- DSLZVSRJTYRBFB-LLEIAEIESA-N D-glucaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O DSLZVSRJTYRBFB-LLEIAEIESA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 description 1
- WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- BUDQDWGNQVEFAC-UHFFFAOYSA-N Dihydropyran Chemical compound C1COC=CC1 BUDQDWGNQVEFAC-UHFFFAOYSA-N 0.000 description 1
- ZQZFYGIXNQKOAV-OCEACIFDSA-N Droloxifene Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=C(O)C=CC=1)\C1=CC=C(OCCN(C)C)C=C1 ZQZFYGIXNQKOAV-OCEACIFDSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 239000004150 EU approved colour Substances 0.000 description 1
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 1
- 241000400611 Eucalyptus deanei Species 0.000 description 1
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 1
- 102100031706 Fibroblast growth factor 1 Human genes 0.000 description 1
- WJOHZNCJWYWUJD-IUGZLZTKSA-N Fluocinonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)COC(=O)C)[C@@]2(C)C[C@@H]1O WJOHZNCJWYWUJD-IUGZLZTKSA-N 0.000 description 1
- WHZRCUIISKRTJL-YTZKRAOUSA-N Fluocortolone caproate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@@H](C)[C@H](C(=O)COC(=O)CCCCC)[C@@]2(C)C[C@@H]1O WHZRCUIISKRTJL-YTZKRAOUSA-N 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- POPFMWWJOGLOIF-XWCQMRHXSA-N Flurandrenolide Chemical compound C1([C@@H](F)C2)=CC(=O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O POPFMWWJOGLOIF-XWCQMRHXSA-N 0.000 description 1
- VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 229940124897 Gardasil Drugs 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 description 1
- 108010069236 Goserelin Proteins 0.000 description 1
- 102000009465 Growth Factor Receptors Human genes 0.000 description 1
- 108010009202 Growth Factor Receptors Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- MUQNGPZZQDCDFT-JNQJZLCISA-N Halcinonide Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CCl)[C@@]1(C)C[C@@H]2O MUQNGPZZQDCDFT-JNQJZLCISA-N 0.000 description 1
- 102100024025 Heparanase Human genes 0.000 description 1
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 1
- 102100021866 Hepatocyte growth factor Human genes 0.000 description 1
- 101000904173 Homo sapiens Progonadoliberin-1 Proteins 0.000 description 1
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 1
- FOGXJPFPZOHSQS-AYVLZSQQSA-N Hydrocortisone butyrate propionate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)CC)(OC(=O)CCC)[C@@]1(C)C[C@@H]2O FOGXJPFPZOHSQS-AYVLZSQQSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 1
- 229940127590 IRAK4 inhibitor Drugs 0.000 description 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- WRYCSMQKUKOKBP-UHFFFAOYSA-N Imidazolidine Chemical compound C1CNCN1 WRYCSMQKUKOKBP-UHFFFAOYSA-N 0.000 description 1
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 description 1
- 102100023915 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 1
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 1
- 239000002147 L01XE04 - Sunitinib Substances 0.000 description 1
- 239000005511 L01XE05 - Sorafenib Substances 0.000 description 1
- 239000002067 L01XE06 - Dasatinib Substances 0.000 description 1
- 239000002136 L01XE07 - Lapatinib Substances 0.000 description 1
- 239000003798 L01XE11 - Pazopanib Substances 0.000 description 1
- 239000002118 L01XE12 - Vandetanib Substances 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- XNRVGTHNYCNCFF-UHFFFAOYSA-N Lapatinib ditosylate monohydrate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1.CC1=CC=C(S(O)(=O)=O)C=C1.O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 XNRVGTHNYCNCFF-UHFFFAOYSA-N 0.000 description 1
- 108010000817 Leuprolide Proteins 0.000 description 1
- 229940124041 Luteinizing hormone releasing hormone (LHRH) antagonist Drugs 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100028123 Macrophage colony-stimulating factor 1 Human genes 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- QZUPHAGRBBOLTB-UHFFFAOYSA-N NSC 244302 Chemical compound C=1C=CC=CC=1P(C(C)(C)C)C1=CC=CC=C1 QZUPHAGRBBOLTB-UHFFFAOYSA-N 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- WYNCHZVNFNFDNH-UHFFFAOYSA-N Oxazolidine Chemical compound C1COCN1 WYNCHZVNFNFDNH-UHFFFAOYSA-N 0.000 description 1
- 229910021188 PF6 Inorganic materials 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- MKPDWECBUAZOHP-AFYJWTTESA-N Paramethasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]2(C)C[C@@H]1O MKPDWECBUAZOHP-AFYJWTTESA-N 0.000 description 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 1
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 1
- 108030005449 Polo kinases Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 102100024028 Progonadoliberin-1 Human genes 0.000 description 1
- 229940079156 Proteasome inhibitor Drugs 0.000 description 1
- 108091008611 Protein Kinase B Proteins 0.000 description 1
- 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 description 1
- 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 102100033810 RAC-alpha serine/threonine-protein kinase Human genes 0.000 description 1
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 101000996723 Sus scrofa Gonadotropin-releasing hormone receptor Proteins 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 1
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- 102000002689 Toll-like receptor Human genes 0.000 description 1
- 108020000411 Toll-like receptor Proteins 0.000 description 1
- IVTVGDXNLFLDRM-HNNXBMFYSA-N Tomudex Chemical compound C=1C=C2NC(C)=NC(=O)C2=CC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)S1 IVTVGDXNLFLDRM-HNNXBMFYSA-N 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical class [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 102000004504 Urokinase Plasminogen Activator Receptors Human genes 0.000 description 1
- 108010042352 Urokinase Plasminogen Activator Receptors Proteins 0.000 description 1
- 108091008605 VEGF receptors Proteins 0.000 description 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 1
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 229940122803 Vinca alkaloid Drugs 0.000 description 1
- JSOJGDZFMMUZOZ-LFXJZBHMSA-N [10-[[(1R,2R)-1,3-dihydroxy-1-(4-nitrophenyl)propan-2-yl]amino]-10-oxodecyl]-(1-methylpyrazol-4-yl)-diphenylphosphanium chloride Chemical compound [Cl-].O[C@@H]([C@@H](CO)NC(=O)CCCCCCCCC[P+](C1=CC=CC=C1)(C1=CC=CC=C1)C=1C=NN(C=1)C)C1=CC=C(C=C1)[N+](=O)[O-] JSOJGDZFMMUZOZ-LFXJZBHMSA-N 0.000 description 1
- ZQRITMJXJFLVPV-ZIGOZFPZSA-M [12-[[(1R,2R)-1,3-dihydroxy-1-(4-nitrophenyl)propan-2-yl]-methylamino]-12-oxododecyl]-triphenylphosphanium chloride Chemical compound [Cl-].O[C@@H]([C@@H](CO)N(C(=O)CCCCCCCCCCC[P+](C1=CC=CC=C1)(C1=CC=CC=C1)C1=CC=CC=C1)C)C1=CC=C(C=C1)[N+](=O)[O-] ZQRITMJXJFLVPV-ZIGOZFPZSA-M 0.000 description 1
- SOAPDPYAZIHQKG-LGWLCBCNSA-N [12-[[(1R,2R)-1,3-dihydroxy-1-(4-nitrophenyl)propan-2-yl]amino]-12-oxododecyl]-(1-methyltriazol-4-yl)-diphenylphosphanium chloride Chemical compound [Cl-].O[C@@H]([C@@H](CO)NC(=O)CCCCCCCCCCC[P+](C1=CC=CC=C1)(C1=CC=CC=C1)C=1N=NN(C=1)C)C1=CC=C(C=C1)[N+](=O)[O-] SOAPDPYAZIHQKG-LGWLCBCNSA-N 0.000 description 1
- FBRAWBYQGRLCEK-UHFFFAOYSA-N [17-(2-chloroacetyl)-9-fluoro-10,13,16-trimethyl-3,11-dioxo-7,8,12,14,15,16-hexahydro-6h-cyclopenta[a]phenanthren-17-yl] butanoate Chemical compound C1CC2=CC(=O)C=CC2(C)C2(F)C1C1CC(C)C(C(=O)CCl)(OC(=O)CCC)C1(C)CC2=O FBRAWBYQGRLCEK-UHFFFAOYSA-N 0.000 description 1
- MVXSDVYMMONQPY-XGNOVQTOSA-N [9-[[(1R,2R)-1,3-dihydroxy-1-(4-nitrophenyl)propan-2-yl]amino]-9-oxononyl]-(1-methylpyrazol-4-yl)-diphenylphosphanium chloride Chemical compound [Cl-].O[C@@H]([C@@H](CO)NC(=O)CCCCCCCC[P+](C1=CC=CC=C1)(C1=CC=CC=C1)C=1C=NN(C=1)C)C1=CC=C(C=C1)[N+](=O)[O-] MVXSDVYMMONQPY-XGNOVQTOSA-N 0.000 description 1
- YNEHQMCPSXHLHF-FKADFNGNSA-N [Cl-].C(C)(C)(C)C(CCCCCCC[PH+](C1=CC=CC=C1)C1=CC=CC=C1)CCCC(N[C@@H]([C@@H](C1=CC=C(C=C1)[N+](=O)[O-])O)CO)=O Chemical compound [Cl-].C(C)(C)(C)C(CCCCCCC[PH+](C1=CC=CC=C1)C1=CC=CC=C1)CCCC(N[C@@H]([C@@H](C1=CC=C(C=C1)[N+](=O)[O-])O)CO)=O YNEHQMCPSXHLHF-FKADFNGNSA-N 0.000 description 1
- YNNLTVSPGUTIGO-UNCJQMLCSA-N [Cl-].O[C@@H]([C@@H](CO)NC(=O)CCCCCCC[P+](C1=CC=CC=C1)(C1=CC=CC=C1)CCOC)C1=CC=C(C=C1)[N+](=O)[O-] Chemical compound [Cl-].O[C@@H]([C@@H](CO)NC(=O)CCCCCCC[P+](C1=CC=CC=C1)(C1=CC=CC=C1)CCOC)C1=CC=C(C=C1)[N+](=O)[O-] YNNLTVSPGUTIGO-UNCJQMLCSA-N 0.000 description 1
- AQJPLGTZUBQBAQ-XCEDALPCSA-N [O-][N+](c1ccc([C@H]([C@@H](CO)NC(CCCCCCCCCCCP(c2ccccc2)(c2ccccc2)c2ccccc2)=O)O)cc1)=O Chemical compound [O-][N+](c1ccc([C@H]([C@@H](CO)NC(CCCCCCCCCCCP(c2ccccc2)(c2ccccc2)c2ccccc2)=O)O)cc1)=O AQJPLGTZUBQBAQ-XCEDALPCSA-N 0.000 description 1
- QXUXIEBCCOPVBD-FOYYQAIFSA-N [O-][N+](c1ccc([C@H]([C@@H](CO)NC(CCCCCCCCCCCP(c2ccccc2)(c2ccccc2)c2ncccc2)=O)O)cc1)=O Chemical compound [O-][N+](c1ccc([C@H]([C@@H](CO)NC(CCCCCCCCCCCP(c2ccccc2)(c2ccccc2)c2ncccc2)=O)O)cc1)=O QXUXIEBCCOPVBD-FOYYQAIFSA-N 0.000 description 1
- HVRXPFFVVKAEEX-XXKIVBBDSA-N [O-][N+](c1ccc([C@H]([C@@H](CO)NC(CCCCCCCCCCP(c2ccccc2)(c2ccccc2)c2ccccc2)=O)O)cc1)=O Chemical compound [O-][N+](c1ccc([C@H]([C@@H](CO)NC(CCCCCCCCCCP(c2ccccc2)(c2ccccc2)c2ccccc2)=O)O)cc1)=O HVRXPFFVVKAEEX-XXKIVBBDSA-N 0.000 description 1
- MQCURSLOTHIEAB-QZCRLSDHSA-N [O-][N+](c1ccc([C@H]([C@@H](CO)NC(CCCCCCCCP(c2ccccc2)(c2ccccc2)c2ccccc2)=O)O)cc1)=O Chemical compound [O-][N+](c1ccc([C@H]([C@@H](CO)NC(CCCCCCCCP(c2ccccc2)(c2ccccc2)c2ccccc2)=O)O)cc1)=O MQCURSLOTHIEAB-QZCRLSDHSA-N 0.000 description 1
- VXPCGMVSFXUOKE-VLZNPVHKSA-N [O-][N+](c1ccc([C@H]([C@@H](CO)NC(CCCCCCCP(C2CCCCC2)(C2CCCCC2)C2CCCCC2)=O)O)cc1)=O Chemical compound [O-][N+](c1ccc([C@H]([C@@H](CO)NC(CCCCCCCP(C2CCCCC2)(C2CCCCC2)C2CCCCC2)=O)O)cc1)=O VXPCGMVSFXUOKE-VLZNPVHKSA-N 0.000 description 1
- MBIHKRDGHZXFMN-XXKIVBBDSA-N [O-][N+](c1ccc([C@H]([C@@H](CO)NC(CCCCCCCP(Cc2ccccc2)(Cc2ccccc2)(Cc2ccccc2)O)=O)O)cc1)=O Chemical compound [O-][N+](c1ccc([C@H]([C@@H](CO)NC(CCCCCCCP(Cc2ccccc2)(Cc2ccccc2)(Cc2ccccc2)O)=O)O)cc1)=O MBIHKRDGHZXFMN-XXKIVBBDSA-N 0.000 description 1
- GUEVDQPWRQHRJL-VLZNPVHKSA-N [O-][N+](c1ccc([C@H]([C@@H](CO)NC(CCCCCCCP(c2ccccc2)(c2ccccc2)c2ccccc2)=O)O)cc1)=O Chemical compound [O-][N+](c1ccc([C@H]([C@@H](CO)NC(CCCCCCCP(c2ccccc2)(c2ccccc2)c2ccccc2)=O)O)cc1)=O GUEVDQPWRQHRJL-VLZNPVHKSA-N 0.000 description 1
- RVRRYKCIOHTPGC-UHFFFAOYSA-N [PH4+].NC([O-])=O Chemical compound [PH4+].NC([O-])=O RVRRYKCIOHTPGC-UHFFFAOYSA-N 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 108700025316 aldesleukin Proteins 0.000 description 1
- 229960005310 aldesleukin Drugs 0.000 description 1
- 229960002478 aldosterone Drugs 0.000 description 1
- 229960000548 alemtuzumab Drugs 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229960003099 amcinonide Drugs 0.000 description 1
- ILKJAFIWWBXGDU-MOGDOJJUSA-N amcinonide Chemical compound O([C@@]1([C@H](O2)C[C@@H]3[C@@]1(C[C@H](O)[C@]1(F)[C@@]4(C)C=CC(=O)C=C4CC[C@H]13)C)C(=O)COC(=O)C)C12CCCC1 ILKJAFIWWBXGDU-MOGDOJJUSA-N 0.000 description 1
- 238000010640 amide synthesis reaction Methods 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 229960001220 amsacrine Drugs 0.000 description 1
- XCPGHVQEEXUHNC-UHFFFAOYSA-N amsacrine Chemical compound COC1=CC(NS(C)(=O)=O)=CC=C1NC1=C(C=CC=C2)C2=NC2=CC=CC=C12 XCPGHVQEEXUHNC-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229960002932 anastrozole Drugs 0.000 description 1
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 150000001448 anilines Chemical class 0.000 description 1
- 229940045799 anthracyclines and related substance Drugs 0.000 description 1
- 230000002280 anti-androgenic effect Effects 0.000 description 1
- 230000003474 anti-emetic effect Effects 0.000 description 1
- 229940046836 anti-estrogen Drugs 0.000 description 1
- 230000001833 anti-estrogenic effect Effects 0.000 description 1
- 230000003432 anti-folate effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001740 anti-invasion Effects 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 230000002137 anti-vascular effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000000051 antiandrogen Substances 0.000 description 1
- 229940030495 antiandrogen sex hormone and modulator of the genital system Drugs 0.000 description 1
- 238000009175 antibody therapy Methods 0.000 description 1
- 239000002111 antiemetic agent Substances 0.000 description 1
- 229940127074 antifolate Drugs 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 239000003080 antimitotic agent Substances 0.000 description 1
- 229940045719 antineoplastic alkylating agent nitrosoureas Drugs 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 239000003886 aromatase inhibitor Substances 0.000 description 1
- 229940046844 aromatase inhibitors Drugs 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 239000003719 aurora kinase inhibitor Substances 0.000 description 1
- 229960003005 axitinib Drugs 0.000 description 1
- RITAVMQDGBJQJZ-FMIVXFBMSA-N axitinib Chemical compound CNC(=O)C1=CC=CC=C1SC1=CC=C(C(\C=C\C=2N=CC=CC=2)=NN2)C2=C1 RITAVMQDGBJQJZ-FMIVXFBMSA-N 0.000 description 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 description 1
- 229960004099 azithromycin Drugs 0.000 description 1
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 description 1
- 229950000210 beclometasone dipropionate Drugs 0.000 description 1
- 229940092705 beclomethasone Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 229960002537 betamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 1
- 229960001102 betamethasone dipropionate Drugs 0.000 description 1
- CIWBQSYVNNPZIQ-XYWKZLDCSA-N betamethasone dipropionate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O CIWBQSYVNNPZIQ-XYWKZLDCSA-N 0.000 description 1
- PLCQGRYPOISRTQ-LWCNAHDDSA-L betamethasone sodium phosphate Chemical compound [Na+].[Na+].C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COP([O-])([O-])=O)(O)[C@@]1(C)C[C@@H]2O PLCQGRYPOISRTQ-LWCNAHDDSA-L 0.000 description 1
- 229960005354 betamethasone sodium phosphate Drugs 0.000 description 1
- 229960004311 betamethasone valerate Drugs 0.000 description 1
- SNHRLVCMMWUAJD-SUYDQAKGSA-N betamethasone valerate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(OC(=O)CCCC)[C@@]1(C)C[C@@H]2O SNHRLVCMMWUAJD-SUYDQAKGSA-N 0.000 description 1
- 229960000397 bevacizumab Drugs 0.000 description 1
- 229960000997 bicalutamide Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M bisulphate group Chemical group S([O-])(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 229960001467 bortezomib Drugs 0.000 description 1
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 1
- UBPYILGKFZZVDX-UHFFFAOYSA-N bosutinib Chemical compound C1=C(Cl)C(OC)=CC(NC=2C3=CC(OC)=C(OCCCN4CCN(C)CC4)C=C3N=CC=2C#N)=C1Cl UBPYILGKFZZVDX-UHFFFAOYSA-N 0.000 description 1
- 229960004436 budesonide Drugs 0.000 description 1
- CUWODFFVMXJOKD-UVLQAERKSA-N buserelin Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 CUWODFFVMXJOKD-UVLQAERKSA-N 0.000 description 1
- 229960002719 buserelin Drugs 0.000 description 1
- 229960002092 busulfan Drugs 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 1
- 229940127093 camptothecin Drugs 0.000 description 1
- 230000004611 cancer cell death Effects 0.000 description 1
- 230000009702 cancer cell proliferation Effects 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 229940022399 cancer vaccine Drugs 0.000 description 1
- 238000009566 cancer vaccine Methods 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- BLMPQMFVWMYDKT-NZTKNTHTSA-N carfilzomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)[C@]1(C)OC1)NC(=O)CN1CCOCC1)CC1=CC=CC=C1 BLMPQMFVWMYDKT-NZTKNTHTSA-N 0.000 description 1
- 229960002438 carfilzomib Drugs 0.000 description 1
- 108010021331 carfilzomib Proteins 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000006721 cell death pathway Effects 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229960005395 cetuximab Drugs 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
- 229960004630 chlorambucil Drugs 0.000 description 1
- 125000002603 chloroethyl group Chemical group [H]C([*])([H])C([H])([H])Cl 0.000 description 1
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 1
- 125000000068 chlorophenyl group Chemical group 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 229960002436 cladribine Drugs 0.000 description 1
- 229960004703 clobetasol propionate Drugs 0.000 description 1
- CBGUOGMQLZIXBE-XGQKBEPLSA-N clobetasol propionate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CCl)(OC(=O)CC)[C@@]1(C)C[C@@H]2O CBGUOGMQLZIXBE-XGQKBEPLSA-N 0.000 description 1
- 229960001146 clobetasone Drugs 0.000 description 1
- 229960005465 clobetasone butyrate Drugs 0.000 description 1
- 229960002219 cloprednol Drugs 0.000 description 1
- YTJIBEDMAQUYSZ-FDNPDPBUSA-N cloprednol Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3C=C(Cl)C2=C1 YTJIBEDMAQUYSZ-FDNPDPBUSA-N 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 229940046044 combinations of antineoplastic agent Drugs 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- BMCQMVFGOVHVNG-TUFAYURCSA-N cortisol 17-butyrate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)CO)(OC(=O)CCC)[C@@]1(C)C[C@@H]2O BMCQMVFGOVHVNG-TUFAYURCSA-N 0.000 description 1
- FZCHYNWYXKICIO-FZNHGJLXSA-N cortisol 17-valerate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)CO)(OC(=O)CCCC)[C@@]1(C)C[C@@H]2O FZCHYNWYXKICIO-FZNHGJLXSA-N 0.000 description 1
- ALEXXDVDDISNDU-JZYPGELDSA-N cortisol 21-acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O ALEXXDVDDISNDU-JZYPGELDSA-N 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- 229960003290 cortisone acetate Drugs 0.000 description 1
- 229960003840 cortivazol Drugs 0.000 description 1
- RKHQGWMMUURILY-UHRZLXHJSA-N cortivazol Chemical compound C([C@H]1[C@@H]2C[C@H]([C@]([C@@]2(C)C[C@H](O)[C@@H]1[C@@]1(C)C2)(O)C(=O)COC(C)=O)C)=C(C)C1=CC1=C2C=NN1C1=CC=CC=C1 RKHQGWMMUURILY-UHRZLXHJSA-N 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000002875 cyclin dependent kinase inhibitor Substances 0.000 description 1
- 229940043378 cyclin-dependent kinase inhibitor Drugs 0.000 description 1
- 125000001047 cyclobutenyl group Chemical group C1(=CCC1)* 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001162 cycloheptenyl group Chemical group C1(=CCCCCC1)* 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000003678 cyclohexadienyl group Chemical group C1(=CC=CCC1)* 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000522 cyclooctenyl group Chemical group C1(=CCCCCCC1)* 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000000058 cyclopentadienyl group Chemical group C1(=CC=CC1)* 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 125000000298 cyclopropenyl group Chemical group [H]C1=C([H])C1([H])* 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 229960000978 cyproterone acetate Drugs 0.000 description 1
- UWFYSQMTEOIJJG-FDTZYFLXSA-N cyproterone acetate Chemical compound C1=C(Cl)C2=CC(=O)[C@@H]3C[C@@H]3[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 UWFYSQMTEOIJJG-FDTZYFLXSA-N 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 229960000640 dactinomycin Drugs 0.000 description 1
- 229960002448 dasatinib Drugs 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- CFCUWKMKBJTWLW-UHFFFAOYSA-N deoliosyl-3C-alpha-L-digitoxosyl-MTM Natural products CC=1C(O)=C2C(O)=C3C(=O)C(OC4OC(C)C(O)C(OC5OC(C)C(O)C(OC6OC(C)C(O)C(C)(O)C6)C5)C4)C(C(OC)C(=O)C(O)C(C)O)CC3=CC2=CC=1OC(OC(C)C1O)CC1OC1CC(O)C(O)C(C)O1 CFCUWKMKBJTWLW-UHFFFAOYSA-N 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 229960003662 desonide Drugs 0.000 description 1
- WBGKWQHBNHJJPZ-LECWWXJVSA-N desonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O WBGKWQHBNHJJPZ-LECWWXJVSA-N 0.000 description 1
- 229960002593 desoximetasone Drugs 0.000 description 1
- VWVSBHGCDBMOOT-IIEHVVJPSA-N desoximetasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@H](C(=O)CO)[C@@]1(C)C[C@@H]2O VWVSBHGCDBMOOT-IIEHVVJPSA-N 0.000 description 1
- 229960003654 desoxycortone Drugs 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960000524 dexamethasone isonicotinate Drugs 0.000 description 1
- VQODGRNSFPNSQE-CXSFZGCWSA-N dexamethasone phosphate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)COP(O)(O)=O)(O)[C@@]1(C)C[C@@H]2O VQODGRNSFPNSQE-CXSFZGCWSA-N 0.000 description 1
- 229960002344 dexamethasone sodium phosphate Drugs 0.000 description 1
- 235000013681 dietary sucrose Nutrition 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- HASCQPSFPAKVEK-UHFFFAOYSA-N dimethyl(phenyl)phosphine Chemical compound CP(C)C1=CC=CC=C1 HASCQPSFPAKVEK-UHFFFAOYSA-N 0.000 description 1
- 229950010286 diolamine Drugs 0.000 description 1
- LLZAIAIZAVMQIG-UHFFFAOYSA-N diphenyl(propan-2-yl)phosphane Chemical compound C=1C=CC=CC=1P(C(C)C)C1=CC=CC=C1 LLZAIAIZAVMQIG-UHFFFAOYSA-N 0.000 description 1
- SVABQOITNJTVNJ-UHFFFAOYSA-N diphenyl-2-pyridylphosphine Chemical compound C1=CC=CC=C1P(C=1N=CC=CC=1)C1=CC=CC=C1 SVABQOITNJTVNJ-UHFFFAOYSA-N 0.000 description 1
- GPAYUJZHTULNBE-UHFFFAOYSA-O diphenylphosphanium Chemical compound C=1C=CC=CC=1[PH2+]C1=CC=CC=C1 GPAYUJZHTULNBE-UHFFFAOYSA-O 0.000 description 1
- MKRTXPORKIRPDG-UHFFFAOYSA-N diphenylphosphoryl azide Chemical compound C=1C=CC=CC=1P(=O)(N=[N+]=[N-])C1=CC=CC=C1 MKRTXPORKIRPDG-UHFFFAOYSA-N 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- XOJNEFQLMRCOMS-UHFFFAOYSA-N ditert-butyl(phenyl)phosphane Chemical compound CC(C)(C)P(C(C)(C)C)C1=CC=CC=C1 XOJNEFQLMRCOMS-UHFFFAOYSA-N 0.000 description 1
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 1
- 239000003534 dna topoisomerase inhibitor Substances 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 229960003722 doxycycline Drugs 0.000 description 1
- XQTWDDCIUJNLTR-CVHRZJFOSA-N doxycycline monohydrate Chemical compound O.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]1[C@H]2O XQTWDDCIUJNLTR-CVHRZJFOSA-N 0.000 description 1
- 229950004203 droloxifene Drugs 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- ZSWFCLXCOIISFI-UHFFFAOYSA-N endo-cyclopentadiene Natural products C1C=CC=C1 ZSWFCLXCOIISFI-UHFFFAOYSA-N 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
- 229960001904 epirubicin Drugs 0.000 description 1
- 229960001433 erlotinib Drugs 0.000 description 1
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 239000000328 estrogen antagonist Substances 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 229960000255 exemestane Drugs 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- DBEPLOCGEIEOCV-WSBQPABSSA-N finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 description 1
- 229960004039 finasteride Drugs 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 229960001440 fluclorolone Drugs 0.000 description 1
- VTWKPILBIUBMDS-OTJLYDAYSA-N fluclorolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(Cl)[C@@H](Cl)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3C[C@H](F)C2=C1 VTWKPILBIUBMDS-OTJLYDAYSA-N 0.000 description 1
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 1
- 229960005304 fludarabine phosphate Drugs 0.000 description 1
- AAXVEMMRQDVLJB-BULBTXNYSA-N fludrocortisone Chemical compound O=C1CC[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 AAXVEMMRQDVLJB-BULBTXNYSA-N 0.000 description 1
- 229960004511 fludroxycortide Drugs 0.000 description 1
- 229960003469 flumetasone Drugs 0.000 description 1
- WXURHACBFYSXBI-GQKYHHCASA-N flumethasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]2(C)C[C@@H]1O WXURHACBFYSXBI-GQKYHHCASA-N 0.000 description 1
- 229960000676 flunisolide Drugs 0.000 description 1
- 229940043075 fluocinolone Drugs 0.000 description 1
- 229960001347 fluocinolone acetonide Drugs 0.000 description 1
- 229960000785 fluocinonide Drugs 0.000 description 1
- XWTIDFOGTCVGQB-FHIVUSPVSA-N fluocortin butyl Chemical group C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@@H](C)[C@H](C(=O)C(=O)OCCCC)[C@@]2(C)C[C@@H]1O XWTIDFOGTCVGQB-FHIVUSPVSA-N 0.000 description 1
- 229950008509 fluocortin butyl Drugs 0.000 description 1
- GAKMQHDJQHZUTJ-ULHLPKEOSA-N fluocortolone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@@H](C)[C@H](C(=O)CO)[C@@]2(C)C[C@@H]1O GAKMQHDJQHZUTJ-ULHLPKEOSA-N 0.000 description 1
- 229960004437 fluocortolone caproate Drugs 0.000 description 1
- XZBJVIQXJHGUBE-HZMVJJPJSA-N fluocortolone pivalate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@@H](C)[C@H](C(=O)COC(=O)C(C)(C)C)[C@@]2(C)C[C@@H]1O XZBJVIQXJHGUBE-HZMVJJPJSA-N 0.000 description 1
- 229960005283 fluocortolone pivalate Drugs 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 125000003784 fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 description 1
- 229960001048 fluorometholone Drugs 0.000 description 1
- FAOZLTXFLGPHNG-KNAQIMQKSA-N fluorometholone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@]2(F)[C@@H](O)C[C@]2(C)[C@@](O)(C(C)=O)CC[C@H]21 FAOZLTXFLGPHNG-KNAQIMQKSA-N 0.000 description 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
- 125000001207 fluorophenyl group Chemical group 0.000 description 1
- 125000005816 fluoropropyl group Chemical group [H]C([H])(F)C([H])([H])C([H])([H])* 0.000 description 1
- 150000005699 fluoropyrimidines Chemical class 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 229960003238 fluprednidene Drugs 0.000 description 1
- YVHXHNGGPURVOS-SBTDHBFYSA-N fluprednidene Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@](C(=C)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 YVHXHNGGPURVOS-SBTDHBFYSA-N 0.000 description 1
- 229960002650 fluprednidene acetate Drugs 0.000 description 1
- DEFOZIFYUBUHHU-IYQKUMFPSA-N fluprednidene acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1CC(=C)[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O DEFOZIFYUBUHHU-IYQKUMFPSA-N 0.000 description 1
- 229960002074 flutamide Drugs 0.000 description 1
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 1
- 229960002714 fluticasone Drugs 0.000 description 1
- MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 description 1
- 229960000289 fluticasone propionate Drugs 0.000 description 1
- WMWTYOKRWGGJOA-CENSZEJFSA-N fluticasone propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 description 1
- 239000004052 folic acid antagonist Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 229940044170 formate Drugs 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 229960002258 fulvestrant Drugs 0.000 description 1
- 229940050411 fumarate Drugs 0.000 description 1
- 229960002584 gefitinib Drugs 0.000 description 1
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 229960001731 gluceptate Drugs 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- KWMLJOLKUYYJFJ-VFUOTHLCSA-N glucoheptonic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)C(O)=O KWMLJOLKUYYJFJ-VFUOTHLCSA-N 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 229940097042 glucuronate Drugs 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- XLXSAKCOAKORKW-UHFFFAOYSA-N gonadorelin Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 XLXSAKCOAKORKW-UHFFFAOYSA-N 0.000 description 1
- 229960002913 goserelin Drugs 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 229960002383 halcinonide Drugs 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 108010037536 heparanase Proteins 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- 125000006038 hexenyl group Chemical group 0.000 description 1
- 125000005980 hexynyl group Chemical group 0.000 description 1
- 229950000177 hibenzate Drugs 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 229960002453 hydrocortisone aceponate Drugs 0.000 description 1
- MFBMYAOAMQLLPK-FZNHGJLXSA-N hydrocortisone aceponate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(C)=O)(OC(=O)CC)[C@@]1(C)C[C@@H]2O MFBMYAOAMQLLPK-FZNHGJLXSA-N 0.000 description 1
- 229960001067 hydrocortisone acetate Drugs 0.000 description 1
- 229960001524 hydrocortisone butyrate Drugs 0.000 description 1
- 229960002846 hydrocortisone probutate Drugs 0.000 description 1
- 229960000631 hydrocortisone valerate Drugs 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 229960001330 hydroxycarbamide Drugs 0.000 description 1
- 229960000908 idarubicin Drugs 0.000 description 1
- 229960003445 idelalisib Drugs 0.000 description 1
- YKLIKGKUANLGSB-HNNXBMFYSA-N idelalisib Chemical compound C1([C@@H](NC=2[C]3N=CN=C3N=CN=2)CC)=NC2=CC=CC(F)=C2C(=O)N1C1=CC=CC=C1 YKLIKGKUANLGSB-HNNXBMFYSA-N 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 1
- 229960002411 imatinib Drugs 0.000 description 1
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 229940046732 interleukin inhibitors Drugs 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 150000002513 isocyanates Chemical class 0.000 description 1
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
- 150000003951 lactams Chemical class 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229960004891 lapatinib Drugs 0.000 description 1
- 229960004942 lenalidomide Drugs 0.000 description 1
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 description 1
- 229960003881 letrozole Drugs 0.000 description 1
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 description 1
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 1
- 229960004338 leuprorelin Drugs 0.000 description 1
- 238000010859 live-cell imaging Methods 0.000 description 1
- DHMTURDWPRKSOA-RUZDIDTESA-N lonafarnib Chemical compound C1CN(C(=O)N)CCC1CC(=O)N1CCC([C@@H]2C3=C(Br)C=C(Cl)C=C3CCC3=CC(Br)=CN=C32)CC1 DHMTURDWPRKSOA-RUZDIDTESA-N 0.000 description 1
- 229950001750 lonafarnib Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229960003646 lysine Drugs 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229940091250 magnesium supplement Drugs 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229960004961 mechlorethamine Drugs 0.000 description 1
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical class ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
- 229960004296 megestrol acetate Drugs 0.000 description 1
- RQZAXGRLVPAYTJ-GQFGMJRRSA-N megestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 description 1
- 229960003194 meglumine Drugs 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- 229960001810 meprednisone Drugs 0.000 description 1
- PIDANAQULIKBQS-RNUIGHNZSA-N meprednisone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)CC2=O PIDANAQULIKBQS-RNUIGHNZSA-N 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000003475 metalloproteinase inhibitor Substances 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- JZMJDSHXVKJFKW-UHFFFAOYSA-M methyl sulfate(1-) Chemical compound COS([O-])(=O)=O JZMJDSHXVKJFKW-UHFFFAOYSA-M 0.000 description 1
- 229960004584 methylprednisolone Drugs 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 239000002395 mineralocorticoid Substances 0.000 description 1
- CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 description 1
- 230000004898 mitochondrial function Effects 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 229960001156 mitoxantrone Drugs 0.000 description 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 229960001664 mometasone Drugs 0.000 description 1
- QLIIKPVHVRXHRI-CXSFZGCWSA-N mometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CCl)(O)[C@@]1(C)C[C@@H]2O QLIIKPVHVRXHRI-CXSFZGCWSA-N 0.000 description 1
- 229960004123 mometasone furoate monohydrate Drugs 0.000 description 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
- 125000001298 n-hexoxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- 125000005487 naphthalate group Chemical group 0.000 description 1
- XTEGVFVZDVNBPF-UHFFFAOYSA-L naphthalene-1,5-disulfonate(2-) Chemical compound C1=CC=C2C(S(=O)(=O)[O-])=CC=CC2=C1S([O-])(=O)=O XTEGVFVZDVNBPF-UHFFFAOYSA-L 0.000 description 1
- 230000035407 negative regulation of cell proliferation Effects 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- HHZIURLSWUIHRB-UHFFFAOYSA-N nilotinib Chemical compound C1=NC(C)=CN1C1=CC(NC(=O)C=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)=CC(C(F)(F)F)=C1 HHZIURLSWUIHRB-UHFFFAOYSA-N 0.000 description 1
- 229960002653 nilutamide Drugs 0.000 description 1
- XWXYUMMDTVBTOU-UHFFFAOYSA-N nilutamide Chemical compound O=C1C(C)(C)NC(=O)N1C1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 XWXYUMMDTVBTOU-UHFFFAOYSA-N 0.000 description 1
- 229960005419 nitrogen Drugs 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 229960002450 ofatumumab Drugs 0.000 description 1
- 229950004864 olamine Drugs 0.000 description 1
- 229940006093 opthalmologic coloring agent diagnostic Drugs 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- PXQPEWDEAKTCGB-UHFFFAOYSA-N orotic acid Chemical compound OC(=O)C1=CC(=O)NC(=O)N1 PXQPEWDEAKTCGB-UHFFFAOYSA-N 0.000 description 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 1
- 229960001756 oxaliplatin Drugs 0.000 description 1
- AHHWIHXENZJRFG-UHFFFAOYSA-N oxetane Chemical compound C1COC1 AHHWIHXENZJRFG-UHFFFAOYSA-N 0.000 description 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 229960001972 panitumumab Drugs 0.000 description 1
- 229960002566 papillomavirus vaccine Drugs 0.000 description 1
- RUVINXPYWBROJD-UHFFFAOYSA-N para-methoxyphenyl Natural products COC1=CC=C(C=CC)C=C1 RUVINXPYWBROJD-UHFFFAOYSA-N 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229960002858 paramethasone Drugs 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229960000639 pazopanib Drugs 0.000 description 1
- CUIHSIWYWATEQL-UHFFFAOYSA-N pazopanib Chemical compound C1=CC2=C(C)N(C)N=C2C=C1N(C)C(N=1)=CC=NC=1NC1=CC=C(C)C(S(N)(=O)=O)=C1 CUIHSIWYWATEQL-UHFFFAOYSA-N 0.000 description 1
- 229960002621 pembrolizumab Drugs 0.000 description 1
- 229960005079 pemetrexed Drugs 0.000 description 1
- QOFFJEBXNKRSPX-ZDUSSCGKSA-N pemetrexed Chemical compound C1=N[C]2NC(N)=NC(=O)C2=C1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QOFFJEBXNKRSPX-ZDUSSCGKSA-N 0.000 description 1
- 235000019371 penicillin G benzathine Nutrition 0.000 description 1
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
- 229960002340 pentostatin Drugs 0.000 description 1
- FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 description 1
- 125000005981 pentynyl group Chemical group 0.000 description 1
- 229950010632 perifosine Drugs 0.000 description 1
- SZFPYBIJACMNJV-UHFFFAOYSA-N perifosine Chemical compound CCCCCCCCCCCCCCCCCCOP([O-])(=O)OC1CC[N+](C)(C)CC1 SZFPYBIJACMNJV-UHFFFAOYSA-N 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- GNLATLQRKNNURK-UHFFFAOYSA-N phosphane sulfonylurea Chemical compound C(=O)(N)N=S(=O)=O.P GNLATLQRKNNURK-UHFFFAOYSA-N 0.000 description 1
- ZULOWTVESKTIOH-UHFFFAOYSA-N phosphane;urea Chemical compound P.NC(N)=O ZULOWTVESKTIOH-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000002935 phosphatidylinositol 3 kinase inhibitor Substances 0.000 description 1
- 229940037129 plain mineralocorticoids for systemic use Drugs 0.000 description 1
- 229960003171 plicamycin Drugs 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229960003975 potassium Drugs 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 229960002794 prednicarbate Drugs 0.000 description 1
- FNPXMHRZILFCKX-KAJVQRHHSA-N prednicarbate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)CC)(OC(=O)OCC)[C@@]1(C)C[C@@H]2O FNPXMHRZILFCKX-KAJVQRHHSA-N 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 239000000583 progesterone congener Substances 0.000 description 1
- 229940095055 progestogen systemic hormonal contraceptives Drugs 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 239000003207 proteasome inhibitor Substances 0.000 description 1
- 239000003528 protein farnesyltransferase inhibitor Substances 0.000 description 1
- 229930182852 proteinogenic amino acid Natural products 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 229940034080 provenge Drugs 0.000 description 1
- USPWKWBDZOARPV-UHFFFAOYSA-N pyrazolidine Chemical compound C1CNNC1 USPWKWBDZOARPV-UHFFFAOYSA-N 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- ZVJHJDDKYZXRJI-UHFFFAOYSA-N pyrroline Natural products C1CC=NC1 ZVJHJDDKYZXRJI-UHFFFAOYSA-N 0.000 description 1
- MIXMJCQRHVAJIO-TZHJZOAOSA-N qk4dys664x Chemical compound O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O MIXMJCQRHVAJIO-TZHJZOAOSA-N 0.000 description 1
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 229960004622 raloxifene Drugs 0.000 description 1
- GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 description 1
- 229960004432 raltitrexed Drugs 0.000 description 1
- 229940124617 receptor tyrosine kinase inhibitor Drugs 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000028617 response to DNA damage stimulus Effects 0.000 description 1
- 238000007142 ring opening reaction Methods 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 229960000714 sipuleucel-t Drugs 0.000 description 1
- 229940083542 sodium Drugs 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 229960003787 sorafenib Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 229960002317 succinimide Drugs 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 229960001796 sunitinib Drugs 0.000 description 1
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 229940063683 taxotere Drugs 0.000 description 1
- WFWLQNSHRPWKFK-ZCFIWIBFSA-N tegafur Chemical compound O=C1NC(=O)C(F)=CN1[C@@H]1OCCC1 WFWLQNSHRPWKFK-ZCFIWIBFSA-N 0.000 description 1
- 229960001674 tegafur Drugs 0.000 description 1
- 229960004964 temozolomide Drugs 0.000 description 1
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
- 229960001278 teniposide Drugs 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 229960003433 thalidomide Drugs 0.000 description 1
- GVIJJXMXTUZIOD-UHFFFAOYSA-N thianthrene Chemical compound C1=CC=C2SC3=CC=CC=C3SC2=C1 GVIJJXMXTUZIOD-UHFFFAOYSA-N 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- FYOWZTWVYZOZSI-UHFFFAOYSA-N thiourea dioxide Chemical compound NC(=N)S(O)=O FYOWZTWVYZOZSI-UHFFFAOYSA-N 0.000 description 1
- PLHJCIYEEKOWNM-HHHXNRCGSA-N tipifarnib Chemical compound CN1C=NC=C1[C@](N)(C=1C=C2C(C=3C=C(Cl)C=CC=3)=CC(=O)N(C)C2=CC=1)C1=CC=C(Cl)C=C1 PLHJCIYEEKOWNM-HHHXNRCGSA-N 0.000 description 1
- 229950009158 tipifarnib Drugs 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 235000010215 titanium dioxide Nutrition 0.000 description 1
- 229960004631 tixocortol Drugs 0.000 description 1
- 229960003114 tixocortol pivalate Drugs 0.000 description 1
- 229940044616 toll-like receptor 7 agonist Drugs 0.000 description 1
- 229940044655 toll-like receptor 9 agonist Drugs 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 229940044693 topoisomerase inhibitor Drugs 0.000 description 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 1
- 229960000303 topotecan Drugs 0.000 description 1
- XFCLJVABOIYOMF-QPLCGJKRSA-N toremifene Chemical compound C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 XFCLJVABOIYOMF-QPLCGJKRSA-N 0.000 description 1
- 229960005026 toremifene Drugs 0.000 description 1
- 229960000575 trastuzumab Drugs 0.000 description 1
- 229960002117 triamcinolone acetonide Drugs 0.000 description 1
- YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
- IFXORIIYQORRMJ-UHFFFAOYSA-N tribenzylphosphane Chemical compound C=1C=CC=CC=1CP(CC=1C=CC=CC=1)CC1=CC=CC=C1 IFXORIIYQORRMJ-UHFFFAOYSA-N 0.000 description 1
- 125000006000 trichloroethyl group Chemical group 0.000 description 1
- 125000004205 trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- UCPYLLCMEDAXFR-UHFFFAOYSA-N triphosgene Chemical compound ClC(Cl)(Cl)OC(=O)OC(Cl)(Cl)Cl UCPYLLCMEDAXFR-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- LFNXCUNDYSYVJY-UHFFFAOYSA-N tris(3-methylphenyl)phosphane Chemical compound CC1=CC=CC(P(C=2C=C(C)C=CC=2)C=2C=C(C)C=CC=2)=C1 LFNXCUNDYSYVJY-UHFFFAOYSA-N 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 238000001946 ultra-performance liquid chromatography-mass spectrometry Methods 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 229960000241 vandetanib Drugs 0.000 description 1
- UHTHHESEBZOYNR-UHFFFAOYSA-N vandetanib Chemical compound COC1=CC(C(/N=CN2)=N/C=3C(=CC(Br)=CC=3)F)=C2C=C1OCC1CCN(C)CC1 UHTHHESEBZOYNR-UHFFFAOYSA-N 0.000 description 1
- YCOYDOIWSSHVCK-UHFFFAOYSA-N vatalanib Chemical compound C1=CC(Cl)=CC=C1NC(C1=CC=CC=C11)=NN=C1CC1=CC=NC=C1 YCOYDOIWSSHVCK-UHFFFAOYSA-N 0.000 description 1
- 229950000578 vatalanib Drugs 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- UGGWPQSBPIFKDZ-KOTLKJBCSA-N vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 description 1
- 229960004355 vindesine Drugs 0.000 description 1
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 1
- 229960002066 vinorelbine Drugs 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 108010069784 vitespin Proteins 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/54—Quaternary phosphonium compounds
- C07F9/5407—Acyclic saturated phosphonium compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Definitions
- This invention relates to compounds that disrupt cell function, such as the disruption of cell metabolism in particular cancer cell metabolism, that are useful as cancer therapies.
- the compounds comprise (3-amino-ohydroxyalkyl)phenyl derivatives having a phosphonium cation tethered to the (3-amino-ohydroxyalkyl)phenyl amine.
- Certain chemicals are based on the (3-amino-ohydroxyalkyl)phenyl portion of chloramphenicol
- the invention also relates to methods of using said compounds and to pharmaceutical formulations comprising said compounds.
- Cancer is the fourth greatest cause of mortality in the developed world. In 2016 it was predicted that more than 1.6 million new cases of cancer would be diagnosed in the U.S. alone, and that cancer would be responsible for nearly 600,000 U.S. deaths.
- Cancer is characterized by the unregulated proliferation of cells, which disrupt the function of tissues.
- the proliferation of cells can be caused by an abnormal increase in cell production or a disruption in the cell death pathway.
- disruptors of cell function can impact the proliferation of cells and in particular cancer cells by reducing or inhibiting cell proliferation.
- the modulation of cancer cell metabolism can lead to the reduction or inhibition of cell proliferation.
- compounds of the invention may reduce, disrupt, or inhibit the growth or proliferation of a cancer cell or it may induce the death of a cancer cell.
- cancer cell metabolism, and reducing cell proliferation is a potential target for disrupting cancer growth and ultimately a therapeutic pathway for cancer treatment.
- the certain embodiments of the invention contemplate compounds that modulate cancer cell metabolism and/or reduce cell proliferation. Reduction in cell proliferation could be achieved either by increasing cell death or by reducing the rate of cell growth.
- The“prevention” of cancer may be taken as including the prevention of the formation of tumours, including primary tumours, metastatic tumours, or tumours associated with cancer onset, resistance or relapse.
- the prevention of cancer may also be taken as encompassing the prevention of the progression of cancer.
- prevention of development of cancer may be demonstrated by preventing an increase in the“stage” of a tumour (using an appropriate cancer staging method) that has been treated using the compounds of the invention.
- the prevention of increase in cancer stage may be compared to progression of an untreated tumour, or compared to the extent of progression that would be expected by a clinician in the event that the tumour was not treated.
- The“treatment” of cancer may be taken as including any improvement of pathology, symptoms or prognosis that is achieved in respect of cancer in a subject receiving compounds of the invention. Treatment may be indicated by a partial improvement of such indications, or by a total improvement (e.g. the absence of cancer following medical use of the compounds of the invention).
- antibiotics may be useful in cancer treatment.
- the mechanisms by which these agents, which include the antibiotics azithromycin and doxycycline, exert a therapeutic effect have been open to markedly different explanations.
- Some authors have suggested that these agents inhibit matrix metalloproteinases (MMPs) and thereby achieve an anti- inflammatory effect, while others suggest that they impair the cells’ response to DNA damage, thereby increasing the effectiveness of chemotherapy or radiotherapy on bulk tumour cells.
- MMPs matrix metalloproteinases
- Still other articles have indicated that the antibiotics target mitochondrial function.
- a therapeutically effective amount of a compound of the invention may be an amount of such a compound sufficient to treat a variety of cancers, including the modulation of cancer cells or other dysfunctional cells (such as tumour initiating cells, stem-like cancer cells, cancer stem cells, or a population of cells with stem cell-like features that exist in tumors and that give rise to the bulk of tumor cells with more differentiated phenotypes).
- cancer cells include hybrid and giant cells. It will be appreciated that the therapeutically effective amount of the compound of the invention may be provided in a single incidence of administration, or cumulatively through multiple incidences of administration.
- -L 1 - is independently absent or is selected from -C(O)-, -C(0)0-, -S(0) 2 -, -C(0)NR 6 , and - S(0) 2 NR 6 -;
- -L 2 - and -L 4 - are each independently at each occurrence -Ci-C4-alkylene-, each alkylene group being unsubstituted or substituted with from 1 to 6 independently selected R 9 groups; provided that any -l_ 2 - or -L 4 - group that is attached at each end to an atom selected from oxygen, nitrogen, sulphur or phosphorous is -C 2 -C4-alkylene-; n is an integer selected from 0, 1 , 2, 3, 4 and 5;
- L 1 , L 2 , L 3 , L 4 and n are selected such that length of the linker formed by those groups is from 3 to 20 atoms;
- R 1a , R 1b and R 1c are each independently selected from phenyl, biphenyl, naphthyl, 5-, 6-,
- R 2 and R 6 are each independently at each occurrence selected from H and Ci-C 6 -alkyl;
- R 3 is independently selected from H, halo, OR 12 and NR 13 R 14 ;
- R 4 is independently at each occurrence selected from: H, and C(0)Ci-C 6 -alkyl
- R 5 and R 10 are each independently at each occurrence selected from: Ci-C 6 -alkyl, C2-C6- alkynyl, C2-C6-alkenyl, Ci-C 6 -haloalkyl, C3-C6-cycloalkyl, 4- to 8-membered
- heterocycloalkyl 5-, 6-, 9- or 10- membered heteroaryl, phenyl, OR 12 , SR 13 , NR 13 R 14 , C(0)OR 13 , C(0)NR 13 R 13 , halo, cyano, nitro, C(0)R 13 , S(0) 2 0R 13 , S(0)R 13 , S(0) 2 R 13 , S(0) 2 NR 13 R 13 , 0C(0)NR 13 R 13 and NR 13 C(0)0R 13 ;
- R 7 and R 14 are each independently at each occurrence selected from: H, Ci-C 6 -alkyl, C(0)Ci-Ce-alkyl and S(0) 2 -Ci-Ce-alkyl;
- R 8 is independently at each occurrence selected from H, Ci-C 4 -alkyl and halo;
- R 9 is independently at each occurrence selected from: Ci-C 6 -alkyl, C2-C6-alkynyl, C2-C6- alkenyl, Ci-C 6 -haloalkyl, OR 12 , SR 13 , NR 13 R 14 , C(0)OR 13 , C(0)NR 13 R 13 , halo, cyano, nitro, C(0)R 13 , S(0) 2 0R 13 , S(0) 2 R 13 , S(0) R 13 , S(0) 2 NR 13 R 13 , 0C(0)NR 13 R 13 and
- R 11 is independently at each occurrence selected from: oxo, Ci-C 6 -alkyl, C2-C6-alkynyl, C2- C 6 -alkenyl, Ci-C 6 -haloalkyl, C3-C6-cycloalkyl, 4- to 8-membered heterocycloalkyl, 5-, 6-, 9- or 10- membered heteroaryl, phenyl, OR 12 , SR 13 , NR 13 R 14 , C(0)OR 13 , C(0)NR 13 R 13 , halo, cyano, nitro, C(0)R 13 , S(0) 2 0R 13 , S(0)R 13 ⁇ S(0) 2 R 13 , S(0) 2 NR 13 R 13 , 0C(0)NR 13 R 13 and NR 13 C(0)0R 13 ;
- R 12 is independently at each occurrence selected from: H, Ci-C 6 -alkyl and Ci-C 6 -haloalkyl
- R 13 is independently at each occurrence selected from: H and Ci-C 6 -alkyl
- m is an integer selected from 0, 1 , 2, 3, 4 and 5;
- heterocycloalkyl, heteroaryl or phenyl groups is optionally substituted where chemically allowable by from 1 to 4 groups independently selected from oxo, Ci-C 6 -alkyl, C2-C6- alkynyl, C2-Ce-alkenyl, Ci-Ce-haloalkyl, OR a , NR a R b , SR a , C(0)0R a , C(0)NR a R a , halo, cyano, nitro, C(0)R a , S(0) 2 0R a , S(0) 2 R a , S(0)R a and S(0) 2 NR a R a ; wherein R a is independently at each occurrence selected from: H and Ci-C 6 -alkyl; and R b is
- H independently at each occurrence selected from: H, Ci-C 6 -alkyl, C(0)Ci-C 6 -alkyl and S(0) 2 -Ci-C 6 -alkyl.
- each -L 3 -L 4 - unit is selected independently of the other each -L 3 -L 4 - unit or -L 3 -L 4 - units.
- each -L 3 -L 4 - unit may be the same or they may be different.
- the atom length of the linkers formed by L 1 , L 2 , L 3 and L 4 is the number of atoms in a straight chain from the phosphorous atom of the phosphonium to the nitrogen atom that is also attached to R 2 .
- the length does not include any substituents or branching that might be present on the chain.
- the ion of formula (I) is an ion of formula (II):
- R 1a , R 1b , R 1c , R 2 , R 3 , R 4 , R 5 , L 1 , L 2 , L 3 , L 4 , n and m are as described above for formula (I).
- the ion of formula (I) is an ion of formula (III):
- R 1a , R 1b , R 1c , R 3 , R 5 , L 1 , L 2 , L 3 , L 4 , n and m are as described above for formula (I).
- the ion of formula (I) is an ion of formula (IV):
- R 1a , R 1b , R 1c , R 3 , L 1 , L 2 , L 3 , L 4 and n are as described above for formula (I).
- the ion of formula (I) is an ion of formula (V):
- R 1a , R 1b , R 1c , R 3 , L 1 , L 2 , L 3 , L 4 and n are as described above for formula (I).
- R 1a , R 1b and R 1c are each independently selected from phenyl, biphenyl, 5- or 6- membered heteroaryl and C 3 to Cs-cycloalkyl, wherein said phenyl, biphenyl and 5- or 6- membered heteroaryl is optionally substituted with from 1 to 5 independently selected R 10 groups, and wherein said C3 to Cs-cycloalkyl is optionally substituted with from 1 to 5 independently selected R 11 groups; provided that R 1a , R 1b and R 1c are not each unsubstituted phenyl.
- R 1a , R 1b and R 1c are each independently selected from phenyl, biphenyl, pyridyl and cyclohexyl, wherein said phenyl, biphenyl and pyridyl is optionally substituted with from 1 to 5 independently selected R 10 groups, and wherein said cyclohexyl group is optionally substituted with from 1 to 5 independently selected R 11 groups; provided that R 1a , R 1b and R 1c are not each unsubstituted phenyl.
- R 1a , R 1b and R 1c are each independently selected from phenyl, biphenyl, pyridyl and cyclohexyl, wherein said phenyl, biphenyl and pyridyl is optionally substituted with 1 to 3 independently selected R 10 groups, and wherein said cyclohexyl group is optionally substituted with 1 to 3 independently selected R 11 groups; provided that R 1a , R 1b and R 1c are not each unsubstituted phenyl.
- R 1a , R 1b and R 1c are each independently selected from phenyl, biphenyl, naphthyl, 5-, 6-, 9- or 10- membered heteroaryl; wherein said phenyl, biphenyl, naphthyl, 5-, 6-, 9- or 10- membered heteroaryl is optionally substituted with from 1 to 5 independently selected R 10 groups, provided that R 1a , R 1b and R 1c are not each
- R 1a , R 1b and R 1c are each independently selected from phenyl, optionally substituted with from 1 to 5 independently selected R 10 groups, provided that R 1a , R 1b and R 1c are not each unsubstituted phenyl.
- R 1a , R 1b and R 1c are each independently selected from phenyl; wherein said phenyl is optionally substituted with from 1 , 2 or 3 independently selected R 10 groups, provided that R 1a , R 1b and R 1c are not each unsubstituted phenyl.
- R 1a , R 1b and R 1c are each independently selected from phenyl; wherein said phenyl is optionally substituted with from 1 , 2 or 3 R 10 groups; provided that R 1a , R 1b and R 1c are not each unsubstituted phenyl.
- R 1a , R 1b and R 1c are each independently selected from C 3 to Cs cycloalkyl, C-i-Cs-alkyl and 4 to 8 membered heterocycloalkyl; wherein said C 3 to Cs cycloalkyl, C-i-Cs-alkyl and 4 to 8 membered heterocycloalkyl is optionally substituted with from 1 to 5 independently selected R 11 groups.
- R 1a , R 1b and R 1c may be different or they may be the same.
- R 11 is independently at each occurrence selected from C1-C6- alkyl, halo, OR 12 , NR 13 R 14 and S(0) 2 0R 13 .
- R 11 is independently at each occurrence selected from OCH 3 , OCH 2 (CH 3 ) 2 , N(CH 3 ) 2 , S0 2 OH, F and Cl.
- R 1a , R 1b and R 1c are each independently selected from phenyl, biphenyl and pyridyl wherein said phenyl, biphenyl and pyridyl is optionally substituted with 1 to 3 independently selected R 10 groups, wherein R 10 is independently at each occurrence selected from Ci-C 6 -alkyl, halo, OR 12 , NR 13 R 14 and S(0) 2 0R 10 .
- R 1a , R 1b and R 1c are each independently selected from phenyl, biphenyl and pyridyl wherein said phenyl, biphenyl and pyridyl is optionally substituted with 1 to 3 independently selected R 10 groups, wherein R 10 is independently at each occurrence selected from OCH3, OCH2(CH3)2, N(CH3)2, SO2OH, F and Cl.
- R 1a is C 3 to Cs-cycloalkyl
- R 1b is C 3 to Cs-cycloalkyl
- R 1c is C 3 to Cs-cycloalkyl
- R 1a and R 1b are each unsubstituted phenyl and R 1c is independently selected from: substituted phenyl, biphenyl, naphthyl, 5-, 6-, 9- or 10- membered heteroaryl, C 3 to Cs-cycloalkyl, Ci-Cs-alkyl and 4- to 8-membered
- R 1a and R 1b are each unsubstituted phenyl and R 1c is substituted phenyl.
- R 1a and R 1b are each unsubstituted phenyl and R 1c is pyridyl.
- R 1a and R 1b are each C3 to Cs-cycloalkyl and R 1c is
- phenyl independently selected from: phenyl, biphenyl, naphthyl, 5-, 6-, 9- or 10- membered heteroaryl, C-i-Cs-alkyl and 4- to 8-membered heterocycloalkyl.
- R 1a and R 1b are each cyclohexyl and R 1c is substituted biphenyl.
- R 1a , R 1b and R 1c are each phenyl. In embodiments, R 1a , R 1b and R 1c are each phenyl. In embodiments, R 1a , R 1b and R 1c are each phenyl. In embodiments, R 1a , R 1b and R 1c are each phenyl. In embodiments, R 1a , R 1b and R 1c are each phenyl. In embodiments, R 1a , R 1b and
- R 1c are each unsubstituted phenyl.
- R 1a , R 1b and R 1c are each substituted phenyl. It may be that R 1a , R 1b and R 1c are each fluorophenyl, e.g. para- fluorophenyl. It may be that R 1a , R 1b and R 1c are each chlorophenyl, e.g. para- chlorophenyl. It may be that R 1a , R 1b and R 1c are each methoxyphenyl, e.g. para- methoxyphenyl.
- R 1a , R 1b and R 1c are each C 3 to Cs-cycloalkyl. In embodiments, R 1a , R 1b and R 1c are each cyclohexyl.
- R 1a , R 1b and R 1c are each benzyl.
- at least one of R 1a , R 1b and R 1c is 5-, 6-, 9- or 10- membered heteroaryl or 4- to 8-membered heterocycloalkyl. It may be that a single one of R 1a , R 1b and R 1c is 5-, 6-, 9- or 10- membered heteroaryl or 4- to 8-membered heterocycloalkyl.
- At least one of R 1a , R 1b and R 1c is 5-, 6-, 9- or 10- membered heteroaryl or 4- to 8-membered heterocycloalkyl, wherein said heteroaryl or heterocycloalkyl group comprises at least one nitrogen atom in the ring. It may be that a single one of R 1a , R 1b and R 1c is 5-, 6-, 9- or 10- membered heteroaryl or 4- to 8-membered heterocycloalkyl, wherein said heteroaryl or heterocycloalkyl group comprises at least one nitrogen atom in the ring.
- At least one of R 1a , R 1b and R 1c is 5- or 6- membered heteroaryl group, wherein said heteroaryl group comprises at least one nitrogen atom in the ring. It may be that a single one of R 1a , R 1b and R 1c is 5- or 6- membered heteroaryl group, wherein said heteroaryl group comprises at least one nitrogen atom in the ring. In these embodiments, it may be that any of R 1a , R 1b and R 1c that are not heteroaryl or
- heterocyclolkyl are phenyl, e.g. unsubstituted phenyl.
- R 1a , R 1b and R 1c are Ci-C 6 -alkyl (e.g. methyl). It may be that a single one of R 1a , R 1b and R 1c is Ci-C 6 -alkyl (e.g. methyl). It may be that two or more of R 1a , R 1b and R 1c is Ci-C 6 -alkyl (e.g. methyl). It may be that each of R 1a , R 1b and R 1c is Ci-C 6 -alkyl (e.g. methyl). In these embodiments, it may be that any of R 1a , R 1b and R 1c that are not Ci-C 6 -alkyl are phenyl, e.g. unsubstituted phenyl.
- R 1a and R 1b are connected to each other via a bond or a group selected from -0-, -S(0) 2 -, NR 6 , and Ci-C3-alkylene. It may be that R 1a and R 1b are connected to each other via a bond or a Ci-C3-alkylene group. It may be that R 1a and R 1b are connected to each other via a bond. It may be that R 1a and R 1b are each phenyl and are connected to each other via a bond or a group selected from -0-, NR 6 , and C1-C3- alkylene.
- R 1a and R 1b are each phenyl and are connected to each other via a bond or a Ci-C3-alkylene group. It may be that R 1a and R 1b are each phenyl and are connected to each other via a bond.
- R 1a and R 1b are not connected to each other via a bond or a group selected from -0-, -S(0) 2 -, NR 6 , and Ci-C3-alkylene.
- R 1a , R 1b and R 1c are unsubstituted or substituted phenyl.
- - + PR 1a R 1b R 1c is selected from PPhi3
- R 2 may be Ci-C4-alkyl, e.g. methyl. Preferably, however, R 2 is H.
- R 3 may be H.
- R 3 may be selected from F and OR 12 .
- R 3 may be selected from F and OH.
- R 3 may be F.
- R 3 may be OR 12 , e.g. OH.
- R 4 may be C(0)Ci-C 4 -aikyl, e.g. C(0)Me. Preferably, however, R 4 is H.
- R 5 may be independently at each occurrence selected from: Ci-C 6 -alkyl, C2-C6- alkynyl, C2-C6-alkenyl, Ci-C 6 -haloalkyl, OR 12 , S(0) 2 Ci-C 4 -alkyl, halo, cyano and nitro.
- R 5 may be independently at each occurrence selected from: Ci-C 6 -alkyl, Ci-C 6 -haloalkyl, S(0) 2 Ci-C 4 -alkyl, halo, cyano and nitro.
- R 5 may be selected from S(0) 2 Ci-C 4 -alkyl and nitro.
- R 5 may be selected from nitro.
- m may be an integer from 0 to 2.
- m may be an integer from 0 to 1.
- m may be an integer from 1 to 3.
- m may be 0.
- m may be 1. Where m is not 0, it may be that one of the R 5 groups is situated para to the point of connection of the rest of the molecule. It may be that m is 1 and the R 5 group is situated para to the point of connection of the rest of the molecule.
- m is 1 and the R 5 group is situated para to the point of connection of the rest of the molecule and is selected from: Ci-C 6 -alkyl, Ci-C 6 -haloalkyl, S(0) 2 Ci-C 4 - alkyl, halo, cyano and nitro. It may be that m is 1 and the R 5 group is situated para to the point of connection of the rest of the molecule and is selected from S(0) 2 Ci-C 4 -alkyl and nitro. It may be that m is 1 and the R 5 group is situated para to the point of connection of the rest of the molecule and is nitro. This is the substitution on the corresponding phenyl group of chloramphenicol.
- R 2 and R 4 are each H. It may be that R 2 and R 4 are each H and R 3 is selected from F and OH. It may be that R 2 and R 4 are each H, R 3 is selected from F and OH, m is 1 and the R 5 group is situated para to the point of connection of the rest of the molecule and is nitro. It may be that R 2 and R 4 are each H, R 3 is OH, m is 1 and the R 5 group is situated para to the point of connection of the rest of the molecule and is nitro. It may be that R 2 and R 4 are each H, m is 1 and the R 5 group is situated para to the point of connection of the rest of the molecule and is nitro. These embodiments apply particularly to compounds of formula (II).
- R 6 is at any particular occurrence H. In embodiments, R 6 is at each occurrence H.
- R 7 is at any particular occurrence H. In embodiments, R 7 is at each occurrence H.
- R 10 may be independently at each occurrence selected from: Ci-C 6 -alkyl, C2-C6- alkynyl, C2-C6-alkenyl, Ci-C 6 -haloalkyl, OR 12 , halo, cyano and nitro.
- R 11 may be independently at each occurrence selected from: oxo, halo, C1-C6- alkyl. R 11 may be independently at each occurrence Ci-C 6 -alkyl. [0061] In embodiments, R 12 is at any particular occurrence H. In embodiments, R 7 is at each occurrence H.
- R 12 is at any particular occurrence Ci-C 4 -alkyl, e.g. methyl. In embodiments, R 12 is at each occurrence Ci-C 4 -alkyl, e.g. methyl.
- R 13 is at any particular occurrence H.
- R 7 is at each occurrence H.
- R 13 is at any particular occurrence Ci-C 4 -alkyl, e.g. methyl. In embodiments, R 13 is at each occurrence Ci-C 4 -alkyl, e.g. methyl. [0065] In embodiments, R 14 is at any particular occurrence selected from H and Ci-C 4 - alkyl, e.g. methyl. In embodiments, R 14 is at each occurrence selected from H and Ci-C 4 - alkyl, e.g. methyl.
- R 14 is at any particular occurrence H.
- R 8 is at each occurrence H.
- R 14 is at any particular occurrence Ci-C 4 -alkyl, e.g. methyl.
- R 8 is at each occurrence Ci-C 4 -alkyl, e.g. methyl.
- L 1 is selected from -C(O)- and -S(0) 2 -. In embodiments, L 1 is absent. In embodiments, L 1 is -C(O)-.
- L 3 is at each occurrence absent.
- the group -L 2 - (L 3 -L 4 ) n - may form an alkylene linker group.
- L 1 is selected from -C(O)- and -S(0) 2 - and L 3 is at each occurrence absent. In embodiments, L 1 is -C(O)- and L 3 is at each occurrence absent.
- L 3 is at each occurrence -O- and -L 4 - is at each occurrence -C2-C 4 -alkylene-.
- the group -(L 3 -L 4 ) n - may form a ether or polyether linker group.
- -L 4 - may at each occurrence represent -CH2CH2- or -CH2CH2CH2-.
- the group -(L 3 -L 4 ) n - may form an ethylene glycol, polyethyleneglycol, propyleneglycol or polypropylene glycol linker group.
- L 3 is at each occurrence selected from -NR 6 C(0)- and - C(0)NR 6 .
- the group— (L 3 -L 4 ) n - may form a peptide linker group.
- -L 4 - is at each occurrence -Ci-alkylene-.
- L 3 is at each occurrence -O- and -L 4 - is at each occurrence -C2-C 4 -alkylene-.
- the group -(L 3 -L 4 ) n - may form a ether or polyether linker group.
- -L 4 - may at each occurrence represent -CH2CH2- or -ChhCI-hCI-h-.
- the group -(L 3 -L 4 ) n - may form a, ethylene glycol, polyethyleneglycol, propyleneglcyol or polypropylene glycol linker group.
- L 1 , L 2 , L 3 , L 4 and n are selected such that length of the linker formed by those groups is from 7 to 17 atoms. In embodiments, L 1 , L 2 , L 3 , L 4 and n are selected such that length of the linker formed by those groups is from 9 to 17 atoms, e.g. 10-17 atoms. [0075] In embodiments the group -L 1 -L 2 -(L 3 -L 4 ) n -P + R 1a R 1b R 1c is: wherein L 5 is a C2-Ci9-alkylene group optionally substituted with from 0 to 10 R 9 groups.
- L 5 may be a C 6 -Ci 6 -alkylene group optionally substituted with from 0 to 10 R 9 groups.
- L 5 may be a Cg-Ci 6 -alkylene group optionally substituted with from 0 to 10 R 9 groups.
- L 5 may be unsubstituted.
- n is an integer selected from 0 or 1.
- the ion of formula (I) is an ion selected from:
- the cation of formula (I) will be associated with an anionic counter ion.
- the cation of formula (I) will be associated with a pharmaceutically acceptable anionic counterion.
- the first aspect of the invention also, therefore, provides a compound comprising the ion of formula (I) and a pharmaceutically acceptable anion.
- the anion may have a single negative charge.
- the anion may be selected from: halo (e.g.
- each anion listed in the preceding sentence possesses a single negative charge.
- the anion may have multiple negative charges, e.g. P0 4 3 or C0 3 2 .
- the anion may be derived from a di- or tri-acid, e.g.
- carboxylate anions may each be accompanied by a pharmaceutically acceptable metal cation or by another cation of formula (I).
- the anions associated with the cations of the invention can be quite labile. It may be therefore that the cation of the invention is present associated with two or more different anions. Ion exchange processes can be used to control the identity of the anion associated with the cation of the invention.
- the anion is Cl, Br, I, PF 6 , CF 3 C(0)0, or HC(0)0.ln an aspect of the invention, the compounds of the invention are for medical use.
- the compounds of the first aspect of the invention are for use in the treatment of cancer.
- the compounds may be effective in treating cancer stem cells.
- the compounds may also be for use in reducing cell proliferation of abnormal cells, such as cancer cells.
- the compounds of the first aspect of the invention are for use in the treatment of solid tumours and other cancers, e.g. cancers classed as not being solid cancers.
- cancers that can be treated by the compounds of the invention are: leukaemia, lymphoma, sarcoma, or carcinoma.
- a method for the treatment of cancer comprising the administration of a therapeutically effective amount of a compound of the first aspect of the invention.
- the method may be effective in treating cancer stem cells.
- the method may also be for use in reducing cell proliferation of abnormal cells, such as cancer cells.
- the method is for the treatment of solid tumours and other cancers, e.g. cancers classed as not being solid cancers.
- cancers that can be treated by the methods of the invention are: leukaemia, lymphoma, sarcoma, or carcinoma.
- The“treatment” of cancer may be taken to include prevention. Treatment also encompasses including any improvement of pathology, symptoms or prognosis that is achieved in respect of cancer in a subject receiving compounds of the invention.
- Treatment may be indicated by a partial improvement of such indications, or by a total improvement (e.g. the absence of cancer following medical use of the compounds of the invention).
- The“prevention” of cancer may be taken as including the prevention of the formation of new tumours, including new primary tumours or new metastatic tumours.
- the prevention of cancer may also be taken as encompassing the prevention of the progression of cancer.
- prevention of development of cancer may be demonstrated by preventing an increase in the“stage” of a tumour (using an appropriate cancer staging method) that has been treated using the compounds of the invention.
- the prevention of increase in cancer stage may be compared to progression of an untreated tumour, or compared to the extent of progression that would be expected by a clinician in the event that the tumour was not treated.
- the compounds of the first aspect of the invention may be for use in increasing cancer cell death or for decreasing cell proliferation by another mechanism, such as inhibiting cell replication.
- the compounds may be used for this purpose in vitro or in vivo.
- the compounds of the invention may be for use in the modulation of cancer cells or other dysfunctional cells (such as tumour initiating cells, stem-like cancer cells, cancer stem cells, or a population of cells with stem cell-like features that exist in tumors and that give rise to the bulk of tumor cells with more differentiated phenotypes). Accordingly, there is provided a method of modulating cancer cells or other dysfunctional cells in vivo or in vitro by exposing the cancer cells or other dysfunctional cells to a compound of the first aspect of the invention. The compound may be exposed to the cancer cells or other dysfunctional cells in an effective amount, for example a therapeutically effective amount such as in the case of a method of treatment or an in vivo method.
- cancer cells or other dysfunctional cells such as tumour initiating cells, stem-like cancer cells, cancer stem cells, or a population of cells with stem cell-like features that exist in tumors and that give rise to the bulk of tumor cells with more differentiated phenotypes.
- composition comprising a compound of the invention and one or more pharmaceutically acceptable excipients.
- pharmaceutical composition may be a combination product comprising one or more different pharmaceutically active agents.
- the one or more additional pharmaceutically active agents may be an anti-cancer agent described below.
- the one or more pharmaceutically active agents may independently be selected from a different therapeutic class, e.g. antibiotic, anti-viral, anti-emetic, pain management, etc.
- halo refers to an atom selected from fluorine, chlorine, bromine and iodine.
- Halo or“halogen” may refer to an atom selected from Cl and F.
- Halo or“halogen” may refer to fluorine.
- alkyl refers to a linear or branched hydrocarbon chain.
- C-i-Cs alkyl refers to a linear or branched hydrocarbon chain containing 1 , 2, 3, 4, 5, 6, 7 or 8 carbon atoms.
- C 1 -C 6 alkyl refers to a linear or branched hydrocarbon chain containing 1 , 2, 3, 4, 5 or 6 carbon atoms.
- the term“C 1 -C 6 alkyl” for example refers to methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, tert-butyl, n-pentyl and n-hexyl.
- the “alkyl” group may be substituted or unsubstituted by one or more substituents.
- alkyl group may be halo (for example fluorine, chlorine, bromine and iodine), OH and C 1 -C 6 alkoxy.
- alkylene groups may be linear or branched and may have two places of attachment to the remainder of the molecule.
- alkylene refers to a divalent group which is a linear or branched hydrocarbon chain. With the“alkylene” group being divalent, the group must form two bonds to other groups.
- C-i-Cs-alkylene may refer to -CH 2 -, -CH 2 CH 2 -, - CH2CH2CH2-, -CH2CH2CH2CH2-, -CH2CH2CH2CH2CH2-, -CH2CH2CH2CH2CH2CH2-, - CH2CH2CH2CH2CH2CH2CH2-, -CH2CH2CH2CH2CH2CH2- or substituted
- alkylene group may be unsubstituted or substituted by one or more substituents.
- cycloalkyl refers to a saturated hydrocarbon ring system.
- C 3 - Ce cycloalkyl refers to a saturated hydrocarbon ring system containing 3, 4, 5, 6, 7 or 8 carbon atoms.
- the ring system may be a single ring or a bi-cyclic or tri-cyclic ring system. Where the ring system is bicyclic one of the rings may be an aromatic ring, for example as in indane.
- the term“cycloalkyl” may refer to, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, and indane.
- the cycloalkyl group may be substituted with one or more substituents.
- haloalkyl refers to a linear or branched hydrocarbon chain which is substituted with at least one halogen atom which are independently selected at each occurrence from fluorine, chlorine, bromine and iodine.
- C1-C6 haloalkyl refers to a linear or branched hydrocarbon chain containing 1 , 2, 3, 4, 5 or 6 carbon atoms. The halogen atom may be at substituted at any position on the
- C1-C6 haloalkyl may refer to, for example, fluoromethyl, trifluoromethyl, chloromethyl, fluoroethyl, trifluoroethyl, chloroethyl, trichloroethyl (such as 1 ,2,2-trichloroethyl and 2,2,2-trichloroethyl), fluoropropyl and chloropropyl.
- the haloalkyl group may be substituted with one or more substituents.
- alkenyl refers to a linear or branched hydrocarbon chain containing at least one carbon-carbon double bond and having at least two carbon atoms.
- C2-C6 alkenyl refers to a linear or branched hydrocarbon chain containing at least one carbon-carbon double bond and having 2, 3, 4, 5 or 6 carbon atoms.
- the double bond or double bonds may be E or Z isomers.
- the double bond may be present at any possible position of the hydrocarbon chain.
- C2-C 6 alkenyl may refer to, for example, ethenyl, propenyl, butenyl, butadienyl, pentenyl, pentadienyl, hexenyl and hexadienyl.
- the alkenyl group may be substituted or unsubstituted by one or more substituents.
- cycloalkenyl refers to an unsaturated hydrocarbon ring system.
- C 3 -C 8 cycloalkenyl refers to an unsaturated hydrocarbon ring system containing 3, 4, 5, 6, 7 or 8 carbon atoms.
- the ring may contain more than one double bond.
- cycloalkenyl may refer to, for example cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclopentadienyl, cyclohexenyl, cyclohexadienyl, cycloheptenyl, cycloheptadiene, cyclooctenyl and cycloocatadienyl.
- the cycloalkenyl group may be substituted with one or more substituents.
- alkynyl refers to a linear or branched hydrocarbon chain contain at least one carbon-carbon triple bond and having at least two carbon atoms.
- C2- C 6 alkynyl refers to a linear or branched hydrocarbon chain containing at least one carbon-carbon triple bond and having 2, 3, 4, 5 or 6 carbon atoms.
- the triple bond or triple bonds may be present at any possible position of the hydrocarbon chain.
- C2-C 6 alkynyl may refer to, for example, ethynyl, propynyl, butynyl, pentynyl and hexynyl.
- the alkynyl group may be unsubstituted or substituted by one or more substituents.
- the term“heteroalkyl” refers to a linear or branched hydrocarbon chain containing at least one heteroatom selected from N, O and S which is positioned between any possible carbon atom in the chain or at the end of the chain.
- the term“C1-C6 heteroalkyl” refers to a linear or branched hydrocarbon chain containing 1 , 2, 3, 4, 5, or 6 carbon atoms and at least one heteroatom selected from N, O and S which is positioned between any possible carbon atom in the chain or at the end of the chain.
- the heteroalkyl may be attached to another group by the heteroatom or the carbon atom.
- the term“C-i- C6 heteroalkyl” may refer to, for example, -CH2NHCH3, -NHCH2CH3 and -CH2CH2NH2.
- the heteroalkyl group may be unsubstituted or substituted by one or more substituents.
- heterocycloalkyl refers to a saturated hydrocarbon ring system containing at least one heteroatom within the ring system selected from N, O and S.
- the term“4- to 8- membered heterocycloalkyl” refers to a saturated hydrocarbon ring with 4, 5, 6, 7, 8, 9 or 10 atoms selected from carbon, N, O and S, at least one being a heteroatom.
- The“heterocycloalkyl” group may also be denoted as a“3 to 10 membered
- heterocycloalkyl which is also a ring system containing 3, 4, 5, 6, 7, 8, 9 or 10 atoms, at least one being a heteroatom.
- the ring system may be a single ring or a bi-cyclic or tri cyclic ring system.
- Bicyclic systems may be spiro-fused, i.e. where the rings are linked to each other through a single carbon atom; vicinally fused, i.e. where the rings are linked to each other through two adjacent carbon or nitrogen atoms; or they may be share a bridgehead, i.e. the rings are linked to each other two non-adjacent carbon or nitrogen atoms.
- one of the rings may be an aromatic ring, for example as in chromane.
- The“heterocycloalkyl” may be bonded to the rest of the molecule through any carbon atom or heteroatom.
- The“heterocycloalkyl” may have one or more, e.g. one or two, bonds to the rest of the molecule: these bonds may be through any of the atoms in the ring.
- the“heterocycloalkyl” may be oxirane, aziridine, azetidine, oxetane, tetrahydrofuran, pyrrolidine, imidazolidine, succinimide, pyrazolidine, oxazolidine, isoxazolidine, thiazolidine, isothiazolidine, piperidine, morpholine,
- heterocycloalkenyl refers to an unsaturated hydrocarbon ring system containing at least one heteroatom selected from N, O or S.
- C 3 -C 8 refers to an unsaturated hydrocarbon ring system containing at least one heteroatom selected from N, O or S.
- heterocycloalkenyl refers to an unsaturated hydrocarbon ring system containing 3, 4, 5,
- the ring system may be a single ring or a bi-cyclic or tri-cyclic ring system.
- one of the rings may be an aromatic ring, for example as in indoline and dihydrobenzofuran.
- the heterocycloalkenyl may be attached to another group by any carbon or heteroatom.
- the term heterocycloalkenyl may refer to, for example tetrahydropyridine, dihydropyran, dihydrofuran, pyrroline, dihydrobenzofuran, dihydrobenzothiophene and indoline.
- the heterocycloalkenyl group may be substituted with one or more substituents.
- aryl refers to an aromatic hydrocarbon ring system which satisfies Huckel’s rule for aromaticity or that contains a ring system which satisfies Huckel’s rule for aromaticity.
- an aryl group may be a single ring or a bi-cyclic or tri-cyclic ring system.
- the term“aryl” may refer to, for example, phenyl, naphthyl, indane, tetralin and anthracene.
- the aryl group may be unsubstituted or substituted with one or more substituents. Any aryl group may be a phenyl ring.
- heteroaryl refers to an aromatic hydrocarbon ring system with at least one heteroatom selected from N, O or S which satisfies Huckel’s rule for aromaticity or a ring system that contains a heteroatom and an aromatic hydrocarbon ring.
- the heteroaryl may be a single ring system or a fused ring system.
- the term“5-, 6-, 9- or 10- membered heteroaryl” refers to an aromatic ring system within 5, 6, 9, or 10 members selected from carbon, N, O or S either in a single ring or a bicyclic ring system.
- heteroaryl may refer to, for example, imidazole, thiazole, oxazole, isothiazole, isoxazole, triazole, tetraazole, thiophene, furan, thianthrene, pyrrole, benzimidazole, pyrazole, pyrazine, pyridine, pyrimidine, indole, isoindole, quinolone, and isoquinoline.
- alkoxy refers to an alkyl group which is linked to another group by oxygen.
- the alkyl group may be linear or branched.
- C1-C6 alkoxy refers to an alkyl group containing 1 , 2, 3, 4, 5 or 6 carbon atoms which is linked to another group by oxygen.
- the alkyl group may be, for example, methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, tert-butyl, n-pentyl and n-hexyl.
- C1-C6 alkoxy may refer to, for example, methoxy, ethoxy, n-propoxy, iso-propoxy, n-butoxy, sec-butoxy, tert-butoxy, n- pentoxy and n-hexoxy.
- the alkyl group may be substituted or unsubstituted by one or more substituents.
- a bond terminating in a“ - rJ ⁇ r ” means that the bond is connected to another group that is not shown.
- a bond terminating inside a cyclic structure and not terminating at an atom of the ring structure represents that the bond may be connected to any of the atoms in the ring structure where allowed by valency.
- a group may be substituted at any point on the group where chemically possible and consistent with valency requirements.
- the group may be substituted by one or more substituents.
- the group may be substituted with 1 , 2, 3 or 4 substituents. Where there are two or more substituents, the substituents may be the same or different.
- Substituent(s) may be, for example, halo, CN, nitro, oxo, C1-C6- alkyl, C2-C6-alkynyl, C2-C6-alkenyl, Ci-C 6 -haloalkyl, OR a , NR a R b , SR a , C(0)0R a ,
- R a is independently at each occurrence selected from: H and Ci-C 6 -alkyl
- R b is independently at each occurrence selected from: H, Ci-C 6 -alkyl, C(0)Ci-C 6 -alkyl and S(0) 2 -Ci-C 6 -alkyl.
- a cyclic substituent may be substituted on a group so as to form a spiro-cycle.
- Meta substitution is a substitution pattern where two substituents are on carbons one carbon removed from each other, i.e with a single carbon atom between the substituted carbons. In other words there is a substituent on the second atom away from the atom with another substituent.
- substituents are on carbons one carbon removed from each other, i.e with a single carbon atom between the substituted carbons.
- substituents are on the second atom away from the atom with another substituent.
- the groups below are meta substituted.
- “Parent” substitution is a substitution pattern where two substituents are on carbons two carbons removed from each other, i.e with two carbon atoms between the substituted carbons. In other words there is a substituent on the third atom away from the atom with another substituent.
- the groups below are para substituted.
- the cation of formula (I) will be associated with a pharmaceutically acceptable anionic counter ion for administration to a subject. Nevertheless, where either the cation of formula (I) or the anionic counter ion comprise either basic or acidic groups, those groups may themselves be protonated or deprotonated and associated with an appropriate counter ion.
- Suitable acid addition salts are formed from acids which form non-toxic salts, for example, acetate, aspartate, benzoate, besylate, bicarbonate/carbonate,
- Suitable base salts are formed from bases which form non-toxic salts, for example including the aluminium, arginine, benzathine, calcium, choline, diethylamine, diolamine, glycine, lysine, magnesium, meglumine, olamine, potassium, sodium, tromethamine and zinc salts. Hemisalts of acids and bases may also be formed, for example, hemisulphate and hemicalcium salts.
- suitable salts can be found in "Handbook of Pharmaceutical Salts: Properties, Selection, and Use” by Stahl and Wermuth (Wiley-VCH, Weinheim, Germany, 2002).
- the salt may be an acid addition salt.
- the salts may be formate or hydrochloride.
- the reactions above are typically carried out in solution and the resulting salt may precipitate out and be collected by filtration or may be recovered by evaporation of the solvent.
- the degree of ionisation in the resulting salt may vary from completely ionised to almost non-ionised.
- the compounds may exist in both unsolvated and solvated forms.
- 'solvate' is used herein to describe a molecular complex comprising the compound of the invention and a stoichiometric amount of one or more pharmaceutically acceptable solvent molecules, for example, ethanol.
- solvent molecules for example, ethanol.
- 'hydrate' is employed when said solvent is water.
- Complexes are contemplated, such as clathrates, drug-host inclusion complexes wherein, in contrast to the aforementioned solvates, the drug and host are present in stoichiometric or non-stoichiometric amounts.
- Complexes of the drug containing two or more organic and/or inorganic components which may be in stoichiometric or non- stoichiometric amounts are also contemplated.
- the resulting complexes may be ionised, partially ionised, or non- ionised. A review of such complexes is found in J Pharm Sci, 64 (8), 1269-1288 by Haleblian (August 1975).
- radionuclides that may be incorporated include 2 H (also written as“D” for deuterium), 3 H (also written as“T” for tritium), 11 C, 13 C, 14 C, 15 0, 17 0, 18 0, 18 F and the like.
- the radionuclide that is used will depend on the specific application of that radio-labelled derivative. For example, for in vitro competition assays, 3 H or 14 C are often useful. For radio-imaging applications, 11 C or 18 F are often useful.
- the radionuclide is 3 H.
- the radionuclide is 14 C.
- the radionuclide is 11 C.
- the radionuclide is 18 F.
- references to compounds of any formula include references to salts, solvates and complexes thereof and to solvates and complexes of salts thereof.
- the compounds include a number of formulae as herein defined, including all polymorphs and crystal habits thereof, prodrugs and isomers thereof (including optical, geometric and tautomeric isomers) as hereinafter defined and isotopically-labelled compounds of the invention.
- the compounds Before purification, the compounds may exist as a mixture of enantiomers depending on the synthetic procedure used.
- the enantiomers can be separated by conventional techniques known in the art. Thus the compounds cover individual enantiomers as well as mixtures thereof.
- any compatible protecting radical can be used.
- methods of protection and deprotection such as those described by T.W. Greene (Protective Groups in Organic Synthesis, A. Wiley- Interscience Publication, 1981 ) or by P. J. Kocienski (Protecting groups, Georg Thieme Verlag, 1994), can be used.
- the compounds as well as intermediates for the preparation thereof can be purified according to various well-known methods, such as for example crystallization or chromatography.
- the method of treatment or the compound for use in the treatment of solid tumours, leukaemia, lymphoma, sarcoma, or carcinoma as defined hereinbefore may be applied as a sole therapy or be a combination therapy with an additional active agent.
- the method of treatment or the compound for use in the treatment of solid tumours, leuekaemia, lymphoma, sarcoma, or carcinoma may involve, in addition to the compound of the invention, conventional surgery or radiotherapy or chemotherapy.
- Such chemotherapy may include one or more of the following categories of anti-cancer agents:
- antiproliferative/antineoplastic drugs and combinations thereof such as alkylating agents (for example cis-platin, oxaliplatin, carboplatin, cyclophosphamide, nitrogen mustard, bendamustin, melphalan, chlorambucil, busulphan, temozolamide and nitrosoureas); antimetabolites (for example gemcitabine and antifolates such as fluoropyrimidines like 5-fluorouracil and tegafur, raltitrexed, methotrexate, pemetrexed, cytosine arabinoside, and hydroxyurea); antibiotics (for example anthracyclines like adriamycin, bleomycin, doxorubicin, daunomycin, epirubicin, idarubicin, mitomycin-C, dactinomycin and mithramycin); antimitotic agents (for example vinca alkaloids like vincristine, vinblastine
- cytostatic agents such as antiestrogens (for example tamoxifen, fulvestrant, toremifene, raloxifene, droloxifene and iodoxyfene), antiandrogens (for example bicalutamide, flutamide, nilutamide and cyproterone acetate), LHRH antagonists or LHRH agonists (for example goserelin, leuprorelin and buserelin), progestogens (for example megestrol acetate), aromatase inhibitors (for example as anastrozole, letrozole, vorazole and exemestane) and inhibitors of 5a-reductase such as finasteride;
- antiestrogens for example tamoxifen, fulvestrant, toremifene, raloxifene, droloxifene and iodoxyfene
- antiandrogens for example bical
- anti-invasion agents for example dasatinib and bosutinib (SKI-606), and metalloproteinase inhibitors, inhibitors of urokinase plasminogen activator receptor function or antibodies to Heparanase;
- inhibitors of growth factor function include growth factor antibodies and growth factor receptor antibodies, for example the anti-erbB2 antibody trastuzumab [HerceptinTM], the anti-EGFR antibody panitumumab, the anti-erbB1 antibody cetuximab, tyrosine kinase inhibitors, for example inhibitors of the epidermal growth factor family (for example EGFR family tyrosine kinase inhibitors such as gefitinib, erlotinib and 6-acrylamido-/V-(3-chloro-4-fluorophenyl)-7-(3-morpholinopropoxy)- quinazolin-4-amine (Cl 1033), erbB2 tyrosine kinase inhibitors such as lapatinib);
- growth factor antibodies and growth factor receptor antibodies for example the anti-erbB2 antibody trastuzumab [HerceptinTM], the anti-EGFR antibody panitumumab, the anti-erbB1 antibody cetux
- inhibitors of the hepatocyte growth factor family include modulators of protein regulators of cell apoptosis (for example Bcl-2 inhibitors); inhibitors of the platelet-derived growth factor family such as imatinib and/or nilotinib (AMN107); inhibitors of serine/threonine kinases (for example Ras/Raf signalling inhibitors such as farnesyl transferase inhibitors, for example sorafenib , tipifarnib and lonafarnib), inhibitors of cell signalling through MEK and/or AKT kinases, c-kit inhibitors, abl kinase inhibitors, PI3 kinase inhibitors, Plt3 kinase inhibitors, CSF-1 R kinase inhibitors, IGF receptor, kinase inhibitors; aurora kinase inhibitors and cyclin dependent kinase inhibitors such as CDK2 and/or CDK4
- antiangiogenic agents such as those which inhibit the effects of vascular endothelial growth factor, for example the anti-vascular endothelial cell growth factor antibody bevacizumab (AvastinTM); thalidomide; lenalidomide; and for example, a VEGF receptor tyrosine kinase inhibitor such as vandetanib, vatalanib, sunitinib, axitinib and pazopanib;
- immunotherapy approaches including checkpoint inhibitors of targets such as PD-1 , PD-L1 and CTCLA-4, for example antibody therapy such as alemtuzumab, rituximab, ibritumomab tiuxetan (Zevalin®), pembrolizumab and ofatumumab; interferons such as interferon a; interleukins such as IL-2 (aldesleukin); interleukin inhibitors for example IRAK4 inhibitors; cancer vaccines including prophylactic and treatment vaccines such as HPV vaccines, for example Gardasil, Cervarix, Oncophage and Sipuleucel-T (Provenge); and toll-like receptor modulators for example TLR-7 or TLR-9 agonists; and
- cytotoxic agents for example fludaribine (fludara), cladribine, pentostatin
- steroids such as corticosteroids, including glucocorticoids and mineralocorticoids, for example aclometasone, aclometasone dipropionate, aldosterone, amcinonide, beclomethasone, beclomethasone dipropionate, betamethasone, betamethasone dipropionate, betamethasone sodium phosphate, betamethasone valerate, budesonide, clobetasone, clobetasone butyrate, clobetasol propionate, cloprednol, cortisone, cortisone acetate, cortivazol, deoxycortone, desonide, desoximetasone, dexamethasone, dexamethasone sodium phosphate, dexamethasone isonicotinate, difluorocortolone, fluclorolone, flumethasone, flunisolide, fluocinolone, fluocinolone acetonide,
- hydrocortisone valerate icomethasone, icomethasone enbutate, meprednisone, methylprednisolone, mometasone paramethasone, mometasone furoate monohydrate, prednicarbate, prednisolone, prednisone, tixocortol, tixocortol pivalate, triamcinolone, triamcinolone acetonide, triamcinolone alcohol and their respective pharmaceutically acceptable derivatives.
- a combination of steroids may be used, for example a
- (x) targeted therapies for example PI3Kd inhibitors, for example idelalisib and perifosine.
- Such combination treatment may be achieved by way of the simultaneous, sequential or separate dosing of the individual components of the treatment.
- Such combination products may be administered so that the combination is provided in a therapeutically effective amount, for example the compounds of this invention may be administered within a therapeutically effective dosage range described herein and the other pharmaceutically-active agent may be administered in an amount of less than or within its approved dosage range.
- a pharmaceutical product comprising a compound of the first aspect of the invention, or a pharmaceutically acceptable salt thereof as defined herein and an additional active agent.
- the additional active agent may be a cancer therapy as defined hereinbefore for the combination treatment of cancer.
- a method of treating cancer comprising administering a therapeutically effective amount of a compound of the invention, or a pharmaceutically acceptable salt thereof simultaneously, sequentially or separately with an additional anti-cancer agent, as defined hereinbefore, to a patient in need thereof.
- a compound of the invention for use simultaneously, sequentially or separately with an additional anti-cancer agent as defined herein, in the treatment of cancer.
- the compound of the invention in combination with an anti-cancer agent, such as those hereinbefore described.
- the compound of the invention may be used simultaneously, sequentially or separately with the additional anti-cancer agent.
- the use may be in a single combination product comprising the compound of the invention and the anti-cancer agent.
- the additional anti-cancer agent may be a further compound of the first aspect of the invention.
- a method of providing a combination product comprising providing a compound of the invention simultaneously, sequentially or separately with an anti-cancer agent, as defined hereinbefore.
- the method may comprise combining the compound of the invention and the anti-cancer agent in a single dosage form.
- the method may comprise providing the anti-cancer agent as separate dosage forms.
- Compounds of the invention may exist in a single crystal form or in a mixture of crystal forms or they may be amorphous.
- compounds of the invention intended for pharmaceutical use may be administered as crystalline or amorphous products. They may be obtained, for example, as solid plugs, powders, or films by methods such as precipitation, crystallization, freeze drying, or spray drying, or evaporative drying.
- Microwave or radio frequency drying may be used for this purpose.
- the dosage administered will, of course, vary with the compound employed, the mode of administration, the treatment desired and the disorder indicated.
- the daily dosage of the compound of the invention may be in the range from 0.01 micrograms per kilogram body weight (pg/kg) to 100 milligrams per kilogram body weight (mg/kg).
- a compound of the invention, or pharmaceutically acceptable salt thereof may be used on their own but will generally be administered in the form of a pharmaceutical composition in which the compounds of the invention, or pharmaceutically acceptable salt thereof, is in association with a pharmaceutically acceptable adjuvant, diluent or carrier.
- a pharmaceutically acceptable adjuvant diluent or carrier.
- Conventional procedures for the selection and preparation of suitable pharmaceutical formulations are described in, for example, "Pharmaceuticals - The Science of Dosage Form Designs", M. E. Aulton, Churchill Livingstone, 1988.
- the pharmaceutical composition which is used to administer the compounds of the invention will preferably comprise from 0.05 to 99 %w (percent by weight) compounds of the invention, more preferably from 0.05 to 80 %w compounds of the invention, still more preferably from 0.10 to 70 %w compounds of the invention, and even more preferably from 0.10 to 50 %w compounds of the invention, all percentages by weight being based on total composition.
- compositions may be administered topically (e.g. to the skin) in the form, e.g., of creams, gels, lotions, solutions, suspensions, or systemically, e.g. by oral administration in the form of tablets, capsules, syrups, powders or granules; or by parenteral administration in the form of a sterile solution, suspension or emulsion for injection (including intravenous, subcutaneous, intramuscular, intravascular or infusion); by rectal administration in the form of suppositories; or by inhalation in the form of an aerosol.
- parenteral administration in the form of a sterile solution, suspension or emulsion for injection (including intravenous, subcutaneous, intramuscular, intravascular or infusion); by rectal administration in the form of suppositories; or by inhalation in the form of an aerosol.
- the compounds of the invention may be admixed with an adjuvant or a carrier, for example, lactose, saccharose, sorbitol, mannitol; a starch, for example, potato starch, corn starch or amylopectin; a cellulose derivative; a binder, for example, gelatine or polyvinylpyrrolidone; and/or a lubricant, for example, magnesium stearate, calcium stearate, polyethylene glycol, a wax, paraffin, and the like, and then compressed into tablets.
- a carrier for example, lactose, saccharose, sorbitol, mannitol
- a starch for example, potato starch, corn starch or amylopectin
- a cellulose derivative for example, gelatine or polyvinylpyrrolidone
- a lubricant for example, magnesium stearate, calcium stearate, polyethylene glycol, a wax, paraffin, and
- the cores may be coated with a concentrated sugar solution which may contain, for example, gum arabic, gelatine, talcum and titanium dioxide.
- a concentrated sugar solution which may contain, for example, gum arabic, gelatine, talcum and titanium dioxide.
- the tablet may be coated with a suitable polymer dissolved in a readily volatile organic solvent.
- the compounds of the invention may be admixed with, for example, a vegetable oil or polyethylene glycol.
- Hard gelatine capsules may contain granules of the compound using either the above-mentioned excipients for tablets.
- liquid or semisolid formulations of the compound of the invention may be filled into hard gelatine capsules.
- Liquid preparations for oral application may be in the form of syrups or suspensions, for example, solutions containing the compound of the invention, the balance being sugar and a mixture of ethanol, water, glycerol and propylene glycol.
- such liquid preparations may contain colouring agents, flavouring agents, sweetening agents (such as saccharine), preservative agents and/or carboxymethylcellulose as a thickening agent or other excipients known to those skilled in art.
- the compounds of the invention may be administered as a sterile aqueous or oily solution.
- the size of the dose for therapeutic purposes of compounds of the invention will naturally vary according to the nature and severity of the conditions, the age and sex of the animal or patient and the route of administration, according to well-known principles of medicine.
- Dosage levels, dose frequency, and treatment durations of compounds of the invention are expected to differ depending on the formulation and clinical indication, age, and co-morbid medical conditions of the patient.
- Certain ions of the invention can be synthesised according to or analogously to methods described in the General Schemes below and/by other techniques known to those of ordinary skill in the art. Certain ions of the invention can be synthesised according to or analogously to the methods described in the Examples.
- Reaction of amine (1 ) with phosphonium acid (2) can furnish phosphonium amide (3).
- the reaction can be performed using standard peptide coupling agents, such as N,N’- diisopropylcarbodiimide (DCC) in an organic solvent, such as DCM at a temperature from 0 to 30 °C or 1-ethyl-3-(3’-dimethyl)amino)carbodiimide HCI, in the presence of a base, such as NaHCC>3 or E ⁇ bN in an organic solvent, such as DCM or DMF at a temperature from 0 to 30 °C.
- DCC diisopropylcarbodiimide
- HCI 1-ethyl-3-(3’-dimethyl)amino)carbodiimide HCI
- a base such as NaHCC>3 or E ⁇ bN
- an organic solvent such as DCM or DMF at a temperature from 0 to 30 °C.
- Phosphonium acid (2) can be
- Phosphonium amide (3) can also be accessed by an alternative sequence of reactions involving amide formation between amine (1 ) and acid (4) using standard peptide coupling agents, followed by displacement of the resultant product halide with phosphine (5), which can be accomplished by heating in an organic solvent, such as MeCN at a temperature from 50 to 80 °C.
- Reaction of amine (1 ) with halo sulphonic acid (6) can furnish halo sulphonamide (7).
- the reaction can be performed using SOCI2 in an organic solvent, such as DMF or DCM at a temperature from 20 to 60 °C.
- Reaction of halo sulphonamide (7) with phosphine (5) can deliver phosphonium sulphonamide (8).
- the reaction can be accomplished by heating in an organic solvent, such as MeCN at a temperature from 50 to 80 °C.
- Certain ions of formula (I) (where R 3 is independently selected form H, halo and OR 12 ) can be made by Scheme C
- the reaction can be performed in a mixed organic solvent comprising of EtOH and DCM, at a temperature from 25 to 40 °C.
- Reaction of halo urea (10) with phosphine (5) can deliver phosphonium urea (11 ).
- the reaction can be accomplished by heating in an organic solvent, such as MeCN at a temperature from 50 to 80 °C.
- reaction can be accomplished with diphenylphosphoryl azide ((Ph0) 2 P(0)N 3 ) in the presence of a base, such as E ⁇ bN in an organic solvent, such as toluene at a temperature from 50 to 100 °C.
- a base such as E ⁇ bN
- organic solvent such as toluene
- the reaction can be performed in the presence of a base, such as E ⁇ bN in an organic solvent, such as toluene at a temperature from 25 to 70 °C.
- Reaction of halo sulphonyl urea (13) with phosphine (5) can deliver phosphonium sulphonyl urea (14).
- the reaction can be accomplished by heating in an organic solvent, such as MeCN at a temperature from 50 to 80 °C.
- a base such as E ⁇ bN
- organic solvent such as DCM
- the reaction can be performed in the presence of an inorganic base, such as Na2CC>3 in an organic solvent, such as DCM at a temperature from 0 to 10 °C.
- Reaction of halo carbamate (17) with phosphine (5) can deliver phosphonium carbamate (18).
- the reaction can be accomplished by heating in an organic solvent, such as MeCN at a temperature from 50 to 80 °C.
- the reaction can be accomplished with triphosgene in the presence of a base, such as pyridine in an organic solvent, such as DCM or THF at a temperature from -10 to 30 °C.
- Alcohol (20) (synthesised from Schemes A - E) can be converted to bromide (21 ).
- the reaction can be accomplished with NBS and PPfi 3 in the presence of pyridine in an organic solvent, such as THF at a temperature from 0 to 30 °C.
- the bromide (21 ) can be transformed to azide (22).
- the reaction can be performed with sodium azide in an organic solvent, such as DMF at a temperature from 20 to 70 °C.
- Reduction of azide (22) can deliver primary amine (23).
- the reaction can be accomplished by standard hydrogenation, techniques, such as Pd/C catalyst systems in organic solvents, such as EtOAc.
- primary amine (23) can be accessed by reduction of azide (22) with PPfi 3 followed by H2O in an organic solvent, such as THF at a temperature from 10 to 30 °C.
- Bromide (21 ) (synthesised from Scheme F) can be converted to secondary amine (24).
- organic solvent such as DMF
- Optional is the addition of CsOH.hhO and 4A molecular sieves.
- Bromide (21 ) (synthesised from Scheme F) can be converted to tertiary amine (25).
- an inorganic base such as K 2 CO 3
- organic solvent such as dioxane
- the reaction can be accomplished in the presence of a base, such as E ⁇ bN or pyridine in an organic solvent, such as DCM or EtOAc at a temperature from -5 to 30 °C.
- the reaction can be accomplished in the presence of a base, such as E ⁇ bN or pyridine in an organic solvent, such as DCM or EtOAc at a temperature from -5 to 30 °C.
- DCC diisopropylcarbodiimide
- DCM dichloromethane
- DMF dimethylformamide
- DMSO dimethyl sulfoxide
- MTBE methyl-t-butylether
- N-bromosuccinimide N-bromosuccinimide
- THF tetrahydrofuran
- Example 11 (11- ⁇ [(1R,2R)-1,3-Dihydroxy-1-(4-nitrophenyl)propan-2- yl]carbamoyl ⁇ undecyl)( 1 -methyl-1 H-pyrazol-4-yl)diphenylphosphonium chloride 4-(diphenylphosphoryl)- 1 -methyl- 1 H-pyrazole
- Example 11 step (b) Prepared following Example 11 step (b) but using 1 1 -bromoundecanoic acid.
- Silica column chromatography was performed using the eluting system 0-10% MeOH in DCM.
- (10-carboxydecyl)(1 -methyl-1 H-pyrazol-4-yl)diphenylphosphonium bromide was isolated as a colourless oil, which was used in the next step.
- Example 11 step (c) The title compound was prepared as a white solid following the procedure described in Example 11 step (c) but using 10-carboxydecyl)(1 -methyl-1 H-pyrazol-4- yl)diphenylphosphonium bromide (prepared as described in Example 13 step (a)).
- Silica column chromatography was performed using the eluting system 0-20% 7M NH3 in MeOH in DCM.
- Example 11 step (b) Prepared following Example 11 step (b) but using 10-bromodecanoic acid.
- Silica column chromatography was performed using the elution system 0-10% MeOH in DCM.
- (9- carboxynonyl)(1 -methyl-1 H-pyrazol-4-yl)diphenylphosphonium bromide was isolated as a light brown oil, which was used in the next step.
- Example 11 step (c) The title compound was prepared as a white solid following the procedure described in Example 11 step (c) but using (9-carboxynonyl)(1 -methyl-1 H-pyrazol-4- yl)diphenylphosphonium bromide (prepared as described in Example 14 step (a)).
- Silica column chromatography was performed using the eluting system 0-20% 7M NH3 in MeOH in DCM.
- Example 11 step (b) Prepared following Example 11 step (b) but using 9-bromononanoic acid.
- Silica column chromatography was performed using the eluting system 0-10% MeOH in DCM.
- (8- carboxyoctyl)(1 -methyl-1 H-pyrazol-4-yl)diphenylphosphonium bromide was isolated as a colourless oil, which was used in the next step.
- Example 11 step (c) The title compound was prepared as a white solid following the procedure described in Example 11 step (c) but using (8-carboxyoctyl)(1 -methyl-1 H-pyrazol-4- yl)diphenylphosphonium bromide (prepared as described in Example 15 step (a)).
- Silica column chromatography was performed using the eluting system 0-20% 7M NH 3 in MeOH in DCM.
- Example 11 step (b) Prepared following Example 11 step (b) but using 8-bromooctanoic acid.
- Silica column chromatography was performed using the eluting system 0-10% MeOH in DCM.
- (7- carboxyheptyl)(1 -methyl-1 H-pyrazol-4-yl)diphenylphosphonium bromide was isolated as a colourless oil, which was used in the next step.
- Example 11 step (c) The title compound was prepared as a white solid following the procedure described in Example 11 step (c) but using (7-carboxyheptyl)(1 -methyl-1 H-pyrazol-4- yl)diphenylphosphonium bromide (prepared as described in Example 16 step (a)).
- Silica column chromatography was performed using the eluting system 0-20% 7M NH 3 in MeOH in DCM.
- Example 6 step (a) Prepared following Example 6 step (a) but using 16-bromohexadecanoic acid.
- Silica column chromatography was performed using the eluting system 0-10% 7M NH 3 in MeOH in DCM.
- 16-bromo-N-[(1 R,2R)-1 ,3-dihydroxy-1 -(4-nitrophenyl)propan-2- yl]hexadecanamide was isolated as a white solid, which was used in the next step.
- Example 20 (11- ⁇ [(1R,2R)-1,3-Dihydroxy-1-(4-nitrophenyl)propan-2- yl]carbamoyl ⁇ undecyl)tris(3,5-dimethylphenyl)phosphonium chloride
- Example 6 step (a) Prepared following Example 6 step (a) but using 8-bromooctanoic acid.
- Silica column purification was performed using the eluting system 0-10% 7M NH 3 in MeOH in DCM.
- 8- bromo-N-[(1 R,2R)-1 ,3-dihydroxy-1-(4-nitrophenyl)propan-2-yl]octanamide was isolated as a colourless oil, which was used in the next step.
- Example 22 (7- ⁇ [(1R,2R)-1,3-Dihydroxy-1-(4-nitrophenyl)propan-2- yl]carbamoyl ⁇ heptyl)tris(3,5-dimethylphenyl)phosphonium chloride
- Example 21 but using tris(3,5-dimethylphenyl)phosphine in step (b).
- the confluence value is a surrogate for cell proliferation and growth.
- the value is expressed as a percent confluence, which represents the fraction of culture dish-surface that is occupied by cells. As the number of cells in the dish increases over time due to proliferation, so will their coverage of that surface increase. Expansion of the cell population on the cell culture-dish surface and confluence have mostly a linear relationship until the cells on the plate surface begin to reach saturation or maximum density.
- Confluence is determined based on image analysis.
- Image based software can identify objects in the image field based on changes to pixel density in a grey scale image. The software can then assign a mask to those pixels within the object. Objects can be ‘gated’ out based on size and shape.
- images of cells are first masked as objects. The surface area of the image that is masked is measured and compared to the total surface area of the culture dish surface to obtain a percent confluence.
- MDA-231 cancer cells were obtained from ATCC. Cells were cultured in Dulbecco’s
- DMEM Modified Eagle Medium
- FBS Fetal Bovine Serum
- NEAA Non Essential Amino Acid
- DMSO Modified Eagle Medium
- FBS Fetal Bovine Serum
- NEAA Non Essential Amino Acid
- DMSO Modified Eagle Medium
- FBS Fetal Bovine Serum
- NEAA Non Essential Amino Acid
- DMSO concentrations were ⁇ 0.1 %. Images were acquired with an IncuCyte Live Cell Imaging microscopy (Essen Bioscience) at every 3 h under cell culture conditions with 10X objective over 4-5 d. Cell confluence was calculated from one field of view per well using the IncuCyte in-built algorithm. Relative confluence values were obtained by normalising each value to the time zero value in each sample.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
This invention relates to compounds that disrupt cell function, such as the disruption of cell metabolism in particular cancer cell metabolism, that are useful as cancer therapies. The compounds comprise (β-amino-α-hydroxyalkyl)phenyl derivatives having a phosphonium cation tethered to the (β-amino-α-hydroxyalkyl)phenyl amine.
Description
BETA-AMINO-ALPHA-HYDROXYALKYLPHENYL DERIVATIVES
AND THEIR USE FOR CANCER TREATMENT
[0001] This invention relates to compounds that disrupt cell function, such as the disruption of cell metabolism in particular cancer cell metabolism, that are useful as cancer therapies. The compounds comprise (3-amino-ohydroxyalkyl)phenyl derivatives having a phosphonium cation tethered to the (3-amino-ohydroxyalkyl)phenyl amine. Certain chemicals are based on the (3-amino-ohydroxyalkyl)phenyl portion of chloramphenicol The invention also relates to methods of using said compounds and to pharmaceutical formulations comprising said compounds.
BACKGROUND
[0002] Cancer is the fourth greatest cause of mortality in the developed world. In 2016 it was predicted that more than 1.6 million new cases of cancer would be diagnosed in the U.S. alone, and that cancer would be responsible for nearly 600,000 U.S. deaths.
[0003] Cancer is characterized by the unregulated proliferation of cells, which disrupt the function of tissues. The proliferation of cells can be caused by an abnormal increase in cell production or a disruption in the cell death pathway. In any event, disruptors of cell function can impact the proliferation of cells and in particular cancer cells by reducing or inhibiting cell proliferation. For example, the modulation of cancer cell metabolism can lead to the reduction or inhibition of cell proliferation. Equally, compounds of the invention may reduce, disrupt, or inhibit the growth or proliferation of a cancer cell or it may induce the death of a cancer cell. As such, cancer cell metabolism, and reducing cell proliferation, is a potential target for disrupting cancer growth and ultimately a therapeutic pathway for cancer treatment. Accordingly, the certain embodiments of the invention contemplate compounds that modulate cancer cell metabolism and/or reduce cell proliferation. Reduction in cell proliferation could be achieved either by increasing cell death or by reducing the rate of cell growth.
[0004] It has been observed that certain compounds having antibiotic activity have a beneficial effect when administered to patients with cancer. The inventors have found that compounds having a phosphonium ion linked to (3-amino-ohydroxyalkyl)phenyl amines are able to modulate cancer cell metabolism in cancer cell lines and, accordingly, prevent and/or treat cancer.
[0005] The“prevention” of cancer may be taken as including the prevention of the formation of tumours, including primary tumours, metastatic tumours, or tumours associated with cancer onset, resistance or relapse. The prevention of cancer may also be taken as encompassing the prevention of the progression of cancer. In this context,
prevention of development of cancer may be demonstrated by preventing an increase in the“stage” of a tumour (using an appropriate cancer staging method) that has been treated using the compounds of the invention. The prevention of increase in cancer stage may be compared to progression of an untreated tumour, or compared to the extent of progression that would be expected by a clinician in the event that the tumour was not treated.
[0006] The“treatment” of cancer may be taken as including any improvement of pathology, symptoms or prognosis that is achieved in respect of cancer in a subject receiving compounds of the invention. Treatment may be indicated by a partial improvement of such indications, or by a total improvement (e.g. the absence of cancer following medical use of the compounds of the invention).
[0007] Accordingly, the prevention and/or treatment as defined above are intended aims of certain embodiments of the invention. The above definitions of treatment or prevention of cancer apply equally to the specific forms of cancer that are also contemplated.
[0008] Recent developments in cancer therapy have suggested that certain antibiotic compounds may be useful in cancer treatment. The mechanisms by which these agents, which include the antibiotics azithromycin and doxycycline, exert a therapeutic effect have been open to markedly different explanations. Some authors have suggested that these agents inhibit matrix metalloproteinases (MMPs) and thereby achieve an anti- inflammatory effect, while others suggest that they impair the cells’ response to DNA damage, thereby increasing the effectiveness of chemotherapy or radiotherapy on bulk tumour cells. Still other articles have indicated that the antibiotics target mitochondrial function.
[0009] However, there have also been reports that antibiotic use can increase risk of colorectal cancer. A recent study identified that increasing duration of antibiotic use was significantly associated with an increased risk of colorectal adenoma (Cao Y, Wu K,
Mehta R, et al,“Long-term use of antibiotics and risk of colorectal adenoma”, Gut, 2017,
0, page 1-7).
[0010] Surprisingly, the inventors have found that compounds having a phosphonium ion linked to (3-amino-ohydroxyalkyl)phenyl have increased activity against certain cancer cell lines compared to related (3-amino-ohydroxyalkyl)phenyl compounds that do not have the phosphonium ion. This is demonstrated by the reduced cancer cell proliferation observed in a cell confluence assay.
[0011] Also provided is a method of preventing and/or treating cancer in a subject needing such prevention and/or treatment, the method comprising administering a therapeutically effective amount of a compound of the invention to the subject. A therapeutically effective amount of a compound of the invention may be an amount of such a compound sufficient to treat a variety of cancers, including the modulation of cancer cells or other dysfunctional cells (such as tumour initiating cells, stem-like cancer cells, cancer stem cells, or a population of cells with stem cell-like features that exist in tumors and that give rise to the bulk of tumor cells with more differentiated phenotypes). References to cancer cells include hybrid and giant cells. It will be appreciated that the therapeutically effective amount of the compound of the invention may be provided in a single incidence of administration, or cumulatively through multiple incidences of administration.
[0012] The same considerations regarding the types of cancers to be treated, and benefits provided by treatment, described with respect to the medical uses of the compounds of the invention also apply to the methods of treatment of the invention.
BRIEF SUMMARY OF THE DISCLOSURE
[0013] In a first aspect of the invention there is provided a compound comprising an ion of formula (I) or a pharmaceutically acceptable salt thereof:
-L1- is independently absent or is selected from -C(O)-, -C(0)0-, -S(0)2-, -C(0)NR6, and - S(0)2NR6-;
-L3- is independently at each occurrence either absent or selected from: -0-, -S-, -NR7-,- C(O)-, -OC(O)-, -0(0)0-, -S(0)2-, -S(O)-, -NR6C(0)-, -C(0)NR6, -NR6S(0)2-, -S(0)2NR6-, - 0C(0)NR6-,-NR6C(0)0-, NR6C(0)NR6, -CR8=CR8- and -CºC-;
-L2- and -L4- are each independently at each occurrence -Ci-C4-alkylene-, each alkylene group being unsubstituted or substituted with from 1 to 6 independently selected R9 groups; provided that any -l_2- or -L4- group that is attached at each end to an atom selected from oxygen, nitrogen, sulphur or phosphorous is -C2-C4-alkylene-;
n is an integer selected from 0, 1 , 2, 3, 4 and 5;
wherein L1, L2, L3, L4 and n are selected such that length of the linker formed by those groups is from 3 to 20 atoms;
R1a, R1b and R1c are each independently selected from phenyl, biphenyl, naphthyl, 5-, 6-,
9- or 10- membered heteroaryl, C3 to Cs-cycloalkyl, Ci-Cs-alkyl and 4- to 8-membered heterocycloalkyl; wherein said phenyl, biphenyl, naphthyl, 5-, 6-, 9- or 10- membered heteroaryl is optionally substituted with from 1 to 5 independently selected R10 groups; and wherein said C3 to Cs-cycloalkyl, C-i-Cs-alkyl and 4- to 8-membered heterocycloalkyl is optionally substituted with from 1 to 5 independently selected R11 groups; wherein R1a and R1b are optionally connected to each other via a bond or a group selected from -0-, - S(0)2-, NR6, and Ci-C3-alkylene;
R2 and R6 are each independently at each occurrence selected from H and Ci-C6-alkyl;
R3 is independently selected from H, halo, OR12 and NR13R14;
R4 is independently at each occurrence selected from: H, and C(0)Ci-C6-alkyl;
R5 and R10 are each independently at each occurrence selected from: Ci-C6-alkyl, C2-C6- alkynyl, C2-C6-alkenyl, Ci-C6-haloalkyl, C3-C6-cycloalkyl, 4- to 8-membered
heterocycloalkyl, 5-, 6-, 9- or 10- membered heteroaryl, phenyl, OR12, SR13, NR13R14, C(0)OR13, C(0)NR13R13, halo, cyano, nitro, C(0)R13, S(0)20R13, S(0)R13, S(0)2R13, S(0)2NR13R13, 0C(0)NR13R13 and NR13C(0)0R13;
R7 and R14 are each independently at each occurrence selected from: H, Ci-C6-alkyl, C(0)Ci-Ce-alkyl and S(0)2-Ci-Ce-alkyl;
R8 is independently at each occurrence selected from H, Ci-C4-alkyl and halo;
R9 is independently at each occurrence selected from: Ci-C6-alkyl, C2-C6-alkynyl, C2-C6- alkenyl, Ci-C6-haloalkyl, OR12, SR13, NR13R14, C(0)OR13, C(0)NR13R13, halo, cyano, nitro, C(0)R13, S(0)20R13, S(0)2R13, S(0) R13, S(0)2NR13R13, 0C(0)NR13R13 and
NR13C(0)0R13;
R11 is independently at each occurrence selected from: oxo, Ci-C6-alkyl, C2-C6-alkynyl, C2- C6-alkenyl, Ci-C6-haloalkyl, C3-C6-cycloalkyl, 4- to 8-membered heterocycloalkyl, 5-, 6-, 9- or 10- membered heteroaryl, phenyl, OR12, SR13, NR13R14, C(0)OR13, C(0)NR13R13, halo, cyano, nitro, C(0)R13, S(0)20R13, S(0)R13· S(0)2R13, S(0)2NR13R13, 0C(0)NR13R13 and NR13C(0)0R13;
R12 is independently at each occurrence selected from: H, Ci-C6-alkyl and Ci-C6-haloalkyl; R13 is independently at each occurrence selected from: H and Ci-C6-alkyl; and
m is an integer selected from 0, 1 , 2, 3, 4 and 5;
and wherein any of the abovementioned alkyl, alkenyl, alkynyl, cycloalkyl,
heterocycloalkyl, heteroaryl or phenyl groups is optionally substituted where chemically allowable by from 1 to 4 groups independently selected from oxo, Ci-C6-alkyl, C2-C6- alkynyl, C2-Ce-alkenyl, Ci-Ce-haloalkyl, ORa, NRaRb, SRa, C(0)0Ra, C(0)NRaRa, halo, cyano, nitro, C(0)Ra, S(0)20Ra, S(0)2Ra, S(0)Ra and S(0)2NRaRa; wherein Ra is independently at each occurrence selected from: H and Ci-C6-alkyl; and Rb is
independently at each occurrence selected from: H, Ci-C6-alkyl, C(0)Ci-C6-alkyl and S(0)2-Ci-C6-alkyl.
[0014] For the absence of doubt, where n is greater than 1 , each -L3-L4- unit is selected independently of the other each -L3-L4- unit or -L3-L4- units. Thus, each -L3-L4- unit may be the same or they may be different.
[0015] For the absence of doubt the atom length of the linkers formed by L1, L2, L3 and L4 is the number of atoms in a straight chain from the phosphorous atom of the phosphonium to the nitrogen atom that is also attached to R2. The length does not include any substituents or branching that might be present on the chain.
[0016] For the absence of doubt where a bivalent group (e.g. L1, L2, L3, L4, or a combination thereof) is represented in text, the left hand portion of the linker group is attached, either directly or indirectly, to the nitrogen atom that is also attached to R2 and the right hand portion of the linker group is attached, either directly or indirectly, to the phosphorous atom of the phosphonium.
[0017] In embodiments, the ion of formula (I) is an ion of formula (II):
wherein R1a, R1b, R1c, R2, R3, R4, R5, L1, L2, L3, L4, n and m are as described above for formula (I).
wherein R1a, R1b, R1c, R3, R5, L1, L2, L3, L4, n and m are as described above for formula (I).
[0019] In embodiments, the ion of formula (I) is an ion of formula (IV):
wherein R1a, R1b, R1c, R3, L1, L2, L3, L4 and n are as described above for formula (I).
[0020] In embodiments, the ion of formula (I) is an ion of formula (V):
wherein R1a, R1b, R1c, R3, L1, L2, L3, L4 and n are as described above for formula (I).
[0021] The following statements apply to compounds of any of formulae (I) to (V).
These statements are independent and interchangeable. In other words, any of the features described in any one of the following statements may (where chemically allowable) be combined with the features described in one or more other statements below. In particular, where a compound is exemplified or illustrated in this specification, any two or more of the statements below which describe a feature of that compound, expressed at any level of generality, may be combined so as to represent subject matter which is contemplated as forming part of the disclosure of this invention in this
specification.
[0022] In embodiments, R1a, R1b and R1c are each independently selected from phenyl, biphenyl, 5- or 6- membered heteroaryl and C3 to Cs-cycloalkyl, wherein said phenyl, biphenyl and 5- or 6- membered heteroaryl is optionally substituted with from 1 to 5 independently selected R10 groups, and wherein said C3 to Cs-cycloalkyl is optionally substituted with from 1 to 5 independently selected R11 groups; provided that R1a, R1b and R1c are not each unsubstituted phenyl.
[0023] In embodiments, R1a, R1b and R1c are each independently selected from phenyl, biphenyl, pyridyl and cyclohexyl, wherein said phenyl, biphenyl and pyridyl is optionally substituted with from 1 to 5 independently selected R10 groups, and wherein said cyclohexyl group is optionally substituted with from 1 to 5 independently selected R11 groups; provided that R1a, R1b and R1c are not each unsubstituted phenyl.
[0024] In embodiments, R1a, R1b and R1c are each independently selected from phenyl, biphenyl, pyridyl and cyclohexyl, wherein said phenyl, biphenyl and pyridyl is optionally substituted with 1 to 3 independently selected R10 groups, and wherein said cyclohexyl group is optionally substituted with 1 to 3 independently selected R11 groups; provided that R1a, R1b and R1c are not each unsubstituted phenyl.
[0025] In embodiments, R1a, R1b and R1c are each independently selected from phenyl, biphenyl, naphthyl, 5-, 6-, 9- or 10- membered heteroaryl; wherein said phenyl, biphenyl, naphthyl, 5-, 6-, 9- or 10- membered heteroaryl is optionally substituted with from 1 to 5 independently selected R10 groups, provided that R1a, R1b and R1c are not each
unsubstituted phenyl.
[0026] In embodiments, R1a, R1b and R1c are each independently selected from phenyl, optionally substituted with from 1 to 5 independently selected R10 groups, provided that R1a, R1b and R1c are not each unsubstituted phenyl.
[0027] In embodiments, R1a, R1b and R1c are each independently selected from phenyl; wherein said phenyl is optionally substituted with from 1 , 2 or 3 independently selected R10 groups, provided that R1a, R1b and R1c are not each unsubstituted phenyl.
[0028] In embodiments, R1a, R1b and R1c are each independently selected from phenyl; wherein said phenyl is optionally substituted with from 1 , 2 or 3 R10 groups; provided that R1a, R1b and R1c are not each unsubstituted phenyl.
[0029] In embodiments, R1a, R1b and R1c are each independently selected from C3 to Cs cycloalkyl, C-i-Cs-alkyl and 4 to 8 membered heterocycloalkyl; wherein said C3 to Cs cycloalkyl, C-i-Cs-alkyl and 4 to 8 membered heterocycloalkyl is optionally substituted with from 1 to 5 independently selected R11 groups.
[0030] R1a, R1b and R1c may be different or they may be the same.
[0031] In embodiments, R11 is independently at each occurrence selected from C1-C6- alkyl, halo, OR12, NR13R14 and S(0)20R13.
[0032] In embodiments, R11 is independently at each occurrence selected from OCH3, OCH2(CH3)2, N(CH3)2, S02OH, F and Cl.
[0033] In embodiments, R1a, R1b and R1c are each independently selected from phenyl, biphenyl and pyridyl wherein said phenyl, biphenyl and pyridyl is optionally substituted with 1 to 3 independently selected R10 groups, wherein R10 is independently at each occurrence selected from Ci-C6-alkyl, halo, OR12, NR13R14 and S(0)20R10.
[0034] In embodiments, R1a, R1b and R1c are each independently selected from phenyl, biphenyl and pyridyl wherein said phenyl, biphenyl and pyridyl is optionally substituted with 1 to 3 independently selected R10 groups, wherein R10 is independently at each occurrence selected from OCH3, OCH2(CH3)2, N(CH3)2, SO2OH, F and Cl.
[0035] In embodiments, R1a is C3 to Cs-cycloalkyl, R1b is C3 to Cs-cycloalkyl and R1c is C3 to Cs-cycloalkyl.
[0036] In embodiments, R1a and R1b are each unsubstituted phenyl and R1c is independently selected from: substituted phenyl, biphenyl, naphthyl, 5-, 6-, 9- or 10- membered heteroaryl, C3 to Cs-cycloalkyl, Ci-Cs-alkyl and 4- to 8-membered
heterocycloalkyl.
[0037] In embodiments, R1a and R1b are each unsubstituted phenyl and R1c is substituted phenyl.
[0038] In embodiments, R1a and R1b are each unsubstituted phenyl and R1c is pyridyl.
[0039] In embodiments, R1a and R1b are each C3 to Cs-cycloalkyl and R1c is
independently selected from: phenyl, biphenyl, naphthyl, 5-, 6-, 9- or 10- membered heteroaryl, C-i-Cs-alkyl and 4- to 8-membered heterocycloalkyl.
[0040] In embodiments, R1a and R1b are each cyclohexyl and R1c is substituted biphenyl.
[0041] In embodiments, R1a, R1b and R1c are each phenyl. In embodiments, R1a, R1b and
R1c are each unsubstituted phenyl. In embodiments, R1a, R1b and R1c are each substituted phenyl. It may be that R1a, R1b and R1c are each fluorophenyl, e.g. para- fluorophenyl. It may be that R1a, R1b and R1c are each chlorophenyl, e.g. para- chlorophenyl. It may be that R1a, R1b and R1c are each methoxyphenyl, e.g. para- methoxyphenyl.
[0042] In embodiments, R1a, R1b and R1c are each C3 to Cs-cycloalkyl. In embodiments, R1a, R1b and R1c are each cyclohexyl.
[0043] In embodiments, R1a, R1b and R1c are each benzyl.
[0044] In embodiments, at least one of R1a, R1b and R1c is 5-, 6-, 9- or 10- membered heteroaryl or 4- to 8-membered heterocycloalkyl. It may be that a single one of R1a, R1b and R1c is 5-, 6-, 9- or 10- membered heteroaryl or 4- to 8-membered heterocycloalkyl. In embodiments, at least one of R1a, R1b and R1c is 5-, 6-, 9- or 10- membered heteroaryl or 4- to 8-membered heterocycloalkyl, wherein said heteroaryl or heterocycloalkyl group comprises at least one nitrogen atom in the ring. It may be that a single one of R1a, R1b and R1c is 5-, 6-, 9- or 10- membered heteroaryl or 4- to 8-membered heterocycloalkyl, wherein said heteroaryl or heterocycloalkyl group comprises at least one nitrogen atom in the ring. In embodiments, at least one of R1a, R1b and R1c is 5- or 6- membered heteroaryl group, wherein said heteroaryl group comprises at least one nitrogen atom in the ring. It may be that a single one of R1a, R1b and R1c is 5- or 6- membered heteroaryl group, wherein said heteroaryl group comprises at least one nitrogen atom in the ring. In these embodiments, it may be that any of R1a, R1b and R1c that are not heteroaryl or
heterocyclolkyl are phenyl, e.g. unsubstituted phenyl.
[0045] In embodiments, at least one of R1a, R1b and R1c is Ci-C6-alkyl (e.g. methyl). It may be that a single one of R1a, R1b and R1c is Ci-C6-alkyl (e.g. methyl). It may be that two or more of R1a, R1b and R1c is Ci-C6-alkyl (e.g. methyl). It may be that each of R1a, R1b and R1c is Ci-C6-alkyl (e.g. methyl). In these embodiments, it may be that any of R1a, R1b and R1c that are not Ci-C6-alkyl are phenyl, e.g. unsubstituted phenyl.
[0046] It may be that R1a and R1b are connected to each other via a bond or a group selected from -0-, -S(0)2-, NR6, and Ci-C3-alkylene. It may be that R1a and R1b are connected to each other via a bond or a Ci-C3-alkylene group. It may be that R1a and R1b are connected to each other via a bond. It may be that R1a and R1b are each phenyl and are connected to each other via a bond or a group selected from -0-, NR6, and C1-C3- alkylene. It may be that R1a and R1b are each phenyl and are connected to each other via a bond or a Ci-C3-alkylene group. It may be that R1a and R1b are each phenyl and are connected to each other via a bond.
[0047] It may be that R1a and R1b are not connected to each other via a bond or a group selected from -0-, -S(0)2-, NR6, and Ci-C3-alkylene.
[0048] It may be that at least two of R1a, R1b and R1c are unsubstituted or substituted phenyl.
[0049] In embodiments, -+PR1aR1bR1c is selected from PPhi3
[0050] R2 may be Ci-C4-alkyl, e.g. methyl. Preferably, however, R2 is H.
[0051] R3 may be H. R3 may be selected from F and OR12. R3 may be selected from F and OH. R3 may be F. R3 may be OR12, e.g. OH.
[0052] R4 may be C(0)Ci-C4-aikyl, e.g. C(0)Me. Preferably, however, R4 is H.
[0053] R5 may be independently at each occurrence selected from: Ci-C6-alkyl, C2-C6- alkynyl, C2-C6-alkenyl, Ci-C6-haloalkyl, OR12, S(0)2Ci-C4-alkyl, halo, cyano and nitro. R5 may be independently at each occurrence selected from: Ci-C6-alkyl, Ci-C6-haloalkyl, S(0)2Ci-C4-alkyl, halo, cyano and nitro. R5 may be selected from S(0)2Ci-C4-alkyl and nitro. R5 may be selected from nitro.
[0054] m may be an integer from 0 to 2. m may be an integer from 0 to 1. m may be an integer from 1 to 3. m may be 0. m may be 1. Where m is not 0, it may be that one of the R5 groups is situated para to the point of connection of the rest of the molecule. It may be that m is 1 and the R5 group is situated para to the point of connection of the rest of the molecule.
[0055] It may be that m is 1 and the R5 group is situated para to the point of connection of the rest of the molecule and is selected from: Ci-C6-alkyl, Ci-C6-haloalkyl, S(0)2Ci-C4- alkyl, halo, cyano and nitro. It may be that m is 1 and the R5 group is situated para to the point of connection of the rest of the molecule and is selected from S(0)2Ci-C4-alkyl and
nitro. It may be that m is 1 and the R5 group is situated para to the point of connection of the rest of the molecule and is nitro. This is the substitution on the corresponding phenyl group of chloramphenicol.
[0056] It may be that R2 and R4 are each H. It may be that R2 and R4 are each H and R3 is selected from F and OH. It may be that R2 and R4 are each H, R3 is selected from F and OH, m is 1 and the R5 group is situated para to the point of connection of the rest of the molecule and is nitro. It may be that R2 and R4 are each H, R3 is OH, m is 1 and the R5 group is situated para to the point of connection of the rest of the molecule and is nitro. It may be that R2 and R4 are each H, m is 1 and the R5 group is situated para to the point of connection of the rest of the molecule and is nitro. These embodiments apply particularly to compounds of formula (II).
[0057] In embodiments, R6 is at any particular occurrence H. In embodiments, R6 is at each occurrence H.
[0058] In embodiments, R7 is at any particular occurrence H. In embodiments, R7 is at each occurrence H.
[0059] R10 may be independently at each occurrence selected from: Ci-C6-alkyl, C2-C6- alkynyl, C2-C6-alkenyl, Ci-C6-haloalkyl, OR12, halo, cyano and nitro.
[0060] R11 may be independently at each occurrence selected from: oxo, halo, C1-C6- alkyl. R11 may be independently at each occurrence Ci-C6-alkyl. [0061] In embodiments, R12 is at any particular occurrence H. In embodiments, R7 is at each occurrence H.
[0062] In embodiments, R12 is at any particular occurrence Ci-C4-alkyl, e.g. methyl. In embodiments, R12 is at each occurrence Ci-C4-alkyl, e.g. methyl.
[0063] In embodiments, R13 is at any particular occurrence H. In embodiments, R7 is at each occurrence H.
[0064] In embodiments, R13 is at any particular occurrence Ci-C4-alkyl, e.g. methyl. In embodiments, R13 is at each occurrence Ci-C4-alkyl, e.g. methyl.
[0065] In embodiments, R14 is at any particular occurrence selected from H and Ci-C4- alkyl, e.g. methyl. In embodiments, R14 is at each occurrence selected from H and Ci-C4- alkyl, e.g. methyl.
[0066] In embodiments, R14 is at any particular occurrence H. In embodiments, R8 is at each occurrence H.
[0067] In embodiments, R14 is at any particular occurrence Ci-C4-alkyl, e.g. methyl. In embodiments, R8 is at each occurrence Ci-C4-alkyl, e.g. methyl.
[0068] In embodiments, L1 is selected from -C(O)- and -S(0)2-. In embodiments, L1 is absent. In embodiments, L1 is -C(O)-.
[0069] In certain embodiments, L3 is at each occurrence absent. Thus, the group -L2- (L3-L4)n- may form an alkylene linker group.
[0070] In embodiments, L1 is selected from -C(O)- and -S(0)2- and L3 is at each occurrence absent. In embodiments, L1 is -C(O)- and L3 is at each occurrence absent.
[0071] In certain embodiments, L3 is at each occurrence -O- and -L4- is at each occurrence -C2-C4-alkylene-. Thus, the group -(L3-L4)n- may form a ether or polyether linker group. -L4- may at each occurrence represent -CH2CH2- or -CH2CH2CH2-. Thus, the group -(L3-L4)n- may form an ethylene glycol, polyethyleneglycol, propyleneglycol or polypropylene glycol linker group.
[0072] In certain embodiments, L3 is at each occurrence selected from -NR6C(0)- and - C(0)NR6. Thus, the group— (L3-L4)n- may form a peptide linker group. In these embodiments, it may be that -L4- is at each occurrence -Ci-alkylene-.
[0073] In certain embodiments, L3 is at each occurrence -O- and -L4- is at each occurrence -C2-C4-alkylene-. Thus, the group -(L3-L4)n- may form a ether or polyether linker group. -L4- may at each occurrence represent -CH2CH2- or -ChhCI-hCI-h-. Thus, the group -(L3-L4)n- may form a, ethylene glycol, polyethyleneglycol, propyleneglcyol or polypropylene glycol linker group.
[0074] In embodiments, L1, L2, L3, L4 and n are selected such that length of the linker formed by those groups is from 7 to 17 atoms. In embodiments, L1, L2, L3, L4 and n are selected such that length of the linker formed by those groups is from 9 to 17 atoms, e.g. 10-17 atoms.
[0075] In embodiments the group -L1-L2-(L3-L4)n-P+R1aR1bR1c is:
wherein L5 is a C2-Ci9-alkylene group optionally substituted with from 0 to 10 R9 groups. L5 may be a C6-Ci6-alkylene group optionally substituted with from 0 to 10 R9 groups. L5 may be a Cg-Ci6-alkylene group optionally substituted with from 0 to 10 R9 groups. L5 may be unsubstituted.
[0076] In embodiments, n is an integer selected from 0 or 1.
[0077] In an embodiment of the invention the ion of formula (I) is an ion selected from:
[0078] In an embodiment of the invention the ion of formula (I) is not
[0079] The cation of formula (I) will be associated with an anionic counter ion. For administration to a subject, the cation of formula (I) will be associated with a
pharmaceutically acceptable anionic counterion. The first aspect of the invention also, therefore, provides a compound comprising the ion of formula (I) and a pharmaceutically acceptable anion. The anion may have a single negative charge. For example the anion may be selected from: halo (e.g. Cl, Br and I), BF4, PF6, CF3C(0)0, HC(0)0, HCO3, (CF3S02)2N, (C2F5)3PF3, HSO4, Ci-Ci5-alkylS04, CH3C(0)0, CF3S03, Tosyl-O, C(CN)3, N(CN)2 or the carboxylate anion of a proteinogenic amino acid. For the avoidance of doubt each anion listed in the preceding sentence possesses a single negative charge. The anion may have multiple negative charges, e.g. P04 3 or C03 2 . The anion may be derived from a di- or tri-acid, e.g. glutamic acid, succinic acid, malic acid, citric acid, tartaric acid. It may be a mono-carboxylate of said di- or tri-acid. The remaining carboxylic acid groups may be in the form of protonated carboxylic acids, Ci-Ci2- alkylesters, or they may likewise be carboxylate anions. Said carboxylate anions may each be accompanied by a pharmaceutically acceptable metal cation or by another cation of formula (I).
[0080] The anions associated with the cations of the invention can be quite labile. It may be therefore that the cation of the invention is present associated with two or more different anions. Ion exchange processes can be used to control the identity of the anion associated with the cation of the invention.
[0081] In embodiments the anion is Cl, Br, I, PF6, CF3C(0)0, or HC(0)0.ln an aspect of the invention, the compounds of the invention are for medical use.
[0082] In an aspect the compounds of the first aspect of the invention are for use in the treatment of cancer. The compounds may be effective in treating cancer stem cells. The compounds may also be for use in reducing cell proliferation of abnormal cells, such as cancer cells.
[0083] In an embodiment the compounds of the first aspect of the invention are for use in the treatment of solid tumours and other cancers, e.g. cancers classed as not being solid cancers. Amongst cancers that can be treated by the compounds of the invention are: leukaemia, lymphoma, sarcoma, or carcinoma.
[0084] In a further aspect of the invention there is provided a method for the treatment of cancer, wherein the method comprises the administration of a therapeutically effective amount of a compound of the first aspect of the invention. The method may be effective in treating cancer stem cells. The method may also be for use in reducing cell proliferation of abnormal cells, such as cancer cells.
[0085] In an embodiment the method is for the treatment of solid tumours and other cancers, e.g. cancers classed as not being solid cancers. Amongst cancers that can be treated by the methods of the invention are: leukaemia, lymphoma, sarcoma, or carcinoma.
[0086] The“treatment” of cancer may be taken to include prevention. Treatment also encompasses including any improvement of pathology, symptoms or prognosis that is achieved in respect of cancer in a subject receiving compounds of the invention.
Treatment may be indicated by a partial improvement of such indications, or by a total improvement (e.g. the absence of cancer following medical use of the compounds of the invention).
[0087] The“prevention” of cancer may be taken as including the prevention of the formation of new tumours, including new primary tumours or new metastatic tumours. The prevention of cancer may also be taken as encompassing the prevention of the progression of cancer. In this context, prevention of development of cancer may be demonstrated by preventing an increase in the“stage” of a tumour (using an appropriate cancer staging method) that has been treated using the compounds of the invention. The prevention of increase in cancer stage may be compared to progression of an untreated tumour, or compared to the extent of progression that would be expected by a clinician in the event that the tumour was not treated.
[0088] The compounds of the first aspect of the invention may be for use in increasing cancer cell death or for decreasing cell proliferation by another mechanism, such as inhibiting cell replication. The compounds may be used for this purpose in vitro or in vivo.
[0089] The compounds of the invention may be for use in the modulation of cancer cells or other dysfunctional cells (such as tumour initiating cells, stem-like cancer cells, cancer stem cells, or a population of cells with stem cell-like features that exist in tumors and that give rise to the bulk of tumor cells with more differentiated phenotypes). Accordingly, there is provided a method of modulating cancer cells or other dysfunctional cells in vivo or in vitro by exposing the cancer cells or other dysfunctional cells to a compound of the first aspect of the invention. The compound may be exposed to the cancer cells or other dysfunctional cells in an effective amount, for example a therapeutically effective amount such as in the case of a method of treatment or an in vivo method.
[0090] In another aspect of the invention there is provided a pharmaceutical composition, wherein the composition comprises a compound of the invention and one or more pharmaceutically acceptable excipients.
[0091] In an embodiment the pharmaceutical composition may be a combination product comprising one or more different pharmaceutically active agents. The one or more additional pharmaceutically active agents may be an anti-cancer agent described below. The one or more pharmaceutically active agents may independently be selected from a different therapeutic class, e.g. antibiotic, anti-viral, anti-emetic, pain management, etc.
DETAILED DESCRIPTION
[0092] Given below are definitions of terms used in this application. Any term not defined herein takes the normal meaning as the skilled person would understand the term.
[0093] The term“halo” or“halogen” refers to an atom selected from fluorine, chlorine, bromine and iodine.“Halo” or“halogen” may refer to an atom selected from Cl and F. “Halo” or“halogen” may refer to fluorine.
[0094] The term“alkyl” refers to a linear or branched hydrocarbon chain. The term“C-i-Cs alkyl” refers to a linear or branched hydrocarbon chain containing 1 , 2, 3, 4, 5, 6, 7 or 8 carbon atoms. The term“C1-C6 alkyl” refers to a linear or branched hydrocarbon chain containing 1 , 2, 3, 4, 5 or 6 carbon atoms. The term“C1-C6 alkyl” for example refers to methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, tert-butyl, n-pentyl and n-hexyl. The “alkyl” group may be substituted or unsubstituted by one or more substituents.
Substituents for the alkyl group may be halo (for example fluorine, chlorine, bromine and iodine), OH and C1-C6 alkoxy. In addition, alkylene groups may be linear or branched and may have two places of attachment to the remainder of the molecule.
[0095] The term“alkylene” refers to a divalent group which is a linear or branched hydrocarbon chain. With the“alkylene” group being divalent, the group must form two bonds to other groups. The term“C-i-Cs-alkylene” may refer to -CH2-, -CH2CH2-, - CH2CH2CH2-, -CH2CH2CH2CH2-, -CH2CH2CH2CH2CH2-, -CH2CH2CH2CH2CH2CH2-, - CH2CH2CH2CH2CH2CH2CH2-, -CH2CH2CH2CH2CH2CH2CH2CH2- or substituted
equivalents thereof. The alkylene group may be unsubstituted or substituted by one or more substituents.
[0096] The term cycloalkyl refers to a saturated hydrocarbon ring system. The term C3- Ce cycloalkyl” refers to a saturated hydrocarbon ring system containing 3, 4, 5, 6, 7 or 8 carbon atoms. The ring system may be a single ring or a bi-cyclic or tri-cyclic ring system. Where the ring system is bicyclic one of the rings may be an aromatic ring, for example as in indane. The term“cycloalkyl” may refer to, for example, cyclopropyl, cyclobutyl,
cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, and indane. The cycloalkyl group may be substituted with one or more substituents.
[0097] The term“haloalkyl” refers to a linear or branched hydrocarbon chain which is substituted with at least one halogen atom which are independently selected at each occurrence from fluorine, chlorine, bromine and iodine. For example, the term“C1-C6 haloalkyl” refers to a linear or branched hydrocarbon chain containing 1 , 2, 3, 4, 5 or 6 carbon atoms. The halogen atom may be at substituted at any position on the
hydrocarbon chain. The term“C1-C6 haloalkyl” may refer to, for example, fluoromethyl, trifluoromethyl, chloromethyl, fluoroethyl, trifluoroethyl, chloroethyl, trichloroethyl (such as 1 ,2,2-trichloroethyl and 2,2,2-trichloroethyl), fluoropropyl and chloropropyl. The haloalkyl group may be substituted with one or more substituents.
[0098] The term“alkenyl” refers to a linear or branched hydrocarbon chain containing at least one carbon-carbon double bond and having at least two carbon atoms. The term “C2-C6 alkenyl” refers to a linear or branched hydrocarbon chain containing at least one carbon-carbon double bond and having 2, 3, 4, 5 or 6 carbon atoms. The double bond or double bonds may be E or Z isomers. The double bond may be present at any possible position of the hydrocarbon chain. The term“C2-C6 alkenyl” may refer to, for example, ethenyl, propenyl, butenyl, butadienyl, pentenyl, pentadienyl, hexenyl and hexadienyl. The alkenyl group may be substituted or unsubstituted by one or more substituents.
[0099] The term“cycloalkenyl” refers to an unsaturated hydrocarbon ring system. The term“C3-C8 cycloalkenyl” refers to an unsaturated hydrocarbon ring system containing 3, 4, 5, 6, 7 or 8 carbon atoms. The ring may contain more than one double bond. The term cycloalkenyl may refer to, for example cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclopentadienyl, cyclohexenyl, cyclohexadienyl, cycloheptenyl, cycloheptadiene, cyclooctenyl and cycloocatadienyl. The cycloalkenyl group may be substituted with one or more substituents.
[00100] The term“alkynyl” refers to a linear or branched hydrocarbon chain contain at least one carbon-carbon triple bond and having at least two carbon atoms. The term“C2- C6 alkynyl” refers to a linear or branched hydrocarbon chain containing at least one carbon-carbon triple bond and having 2, 3, 4, 5 or 6 carbon atoms. The triple bond or triple bonds may be present at any possible position of the hydrocarbon chain. The term “C2-C6 alkynyl” may refer to, for example, ethynyl, propynyl, butynyl, pentynyl and hexynyl. The alkynyl group may be unsubstituted or substituted by one or more substituents.
[00101] The term“heteroalkyl” refers to a linear or branched hydrocarbon chain containing at least one heteroatom selected from N, O and S which is positioned between any possible carbon atom in the chain or at the end of the chain. The term“C1-C6 heteroalkyl” refers to a linear or branched hydrocarbon chain containing 1 , 2, 3, 4, 5, or 6 carbon atoms and at least one heteroatom selected from N, O and S which is positioned between any possible carbon atom in the chain or at the end of the chain. The heteroalkyl may be attached to another group by the heteroatom or the carbon atom. The term“C-i- C6 heteroalkyl” may refer to, for example, -CH2NHCH3, -NHCH2CH3 and -CH2CH2NH2.
The heteroalkyl group may be unsubstituted or substituted by one or more substituents.
[00102] The term“heterocycloalkyl” refers to a saturated hydrocarbon ring system containing at least one heteroatom within the ring system selected from N, O and S. The term“4- to 8- membered heterocycloalkyl” refers to a saturated hydrocarbon ring with 4, 5, 6, 7, 8, 9 or 10 atoms selected from carbon, N, O and S, at least one being a heteroatom. The“heterocycloalkyl” group may also be denoted as a“3 to 10 membered
heterocycloalkyl” which is also a ring system containing 3, 4, 5, 6, 7, 8, 9 or 10 atoms, at least one being a heteroatom. The ring system may be a single ring or a bi-cyclic or tri cyclic ring system. Bicyclic systems may be spiro-fused, i.e. where the rings are linked to each other through a single carbon atom; vicinally fused, i.e. where the rings are linked to each other through two adjacent carbon or nitrogen atoms; or they may be share a bridgehead, i.e. the rings are linked to each other two non-adjacent carbon or nitrogen atoms. Where the ring system is bicyclic one of the rings may be an aromatic ring, for example as in chromane. The“heterocycloalkyl” may be bonded to the rest of the molecule through any carbon atom or heteroatom. The“heterocycloalkyl” may have one or more, e.g. one or two, bonds to the rest of the molecule: these bonds may be through any of the atoms in the ring. For example, the“heterocycloalkyl” may be oxirane, aziridine, azetidine, oxetane, tetrahydrofuran, pyrrolidine, imidazolidine, succinimide, pyrazolidine, oxazolidine, isoxazolidine, thiazolidine, isothiazolidine, piperidine, morpholine,
thiomorpholine, piperazine, tetrahydropyran, and chromane.
[00103] The term“heterocycloalkenyl” refers to an unsaturated hydrocarbon ring system containing at least one heteroatom selected from N, O or S. The term“C3-C8
heterocycloalkenyl” refers to an unsaturated hydrocarbon ring system containing 3, 4, 5,
6, 7 or 8 carbon atoms and at least one heteroatom selected from N, O or S. There may be more than one double bond present. The double bond will typically be between two carbon atoms but may be between a carbon atom and a nitrogen atom. There may also be more than 1 heteroatom present. For example, there may be 1 , 2 or 3 heteroatoms
present. The ring system may be a single ring or a bi-cyclic or tri-cyclic ring system.
Where the ring system is bicyclic one of the rings may be an aromatic ring, for example as in indoline and dihydrobenzofuran. The heterocycloalkenyl may be attached to another group by any carbon or heteroatom. The term heterocycloalkenyl may refer to, for example tetrahydropyridine, dihydropyran, dihydrofuran, pyrroline, dihydrobenzofuran, dihydrobenzothiophene and indoline. The heterocycloalkenyl group may be substituted with one or more substituents.
[00104] The term“aryl” refers to an aromatic hydrocarbon ring system which satisfies Huckel’s rule for aromaticity or that contains a ring system which satisfies Huckel’s rule for aromaticity. As such an aryl group may be a single ring or a bi-cyclic or tri-cyclic ring system. The term“aryl” may refer to, for example, phenyl, naphthyl, indane, tetralin and anthracene. The aryl group may be unsubstituted or substituted with one or more substituents. Any aryl group may be a phenyl ring.
[00105] The term“heteroaryl” refers to an aromatic hydrocarbon ring system with at least one heteroatom selected from N, O or S which satisfies Huckel’s rule for aromaticity or a ring system that contains a heteroatom and an aromatic hydrocarbon ring. The heteroaryl may be a single ring system or a fused ring system. The term“5-, 6-, 9- or 10- membered heteroaryl” refers to an aromatic ring system within 5, 6, 9, or 10 members selected from carbon, N, O or S either in a single ring or a bicyclic ring system. The term heteroaryl may refer to, for example, imidazole, thiazole, oxazole, isothiazole, isoxazole, triazole, tetraazole, thiophene, furan, thianthrene, pyrrole, benzimidazole, pyrazole, pyrazine, pyridine, pyrimidine, indole, isoindole, quinolone, and isoquinoline.
[00106] The term“alkoxy” refers to an alkyl group which is linked to another group by oxygen. The alkyl group may be linear or branched. The term“C1-C6 alkoxy” refers to an alkyl group containing 1 , 2, 3, 4, 5 or 6 carbon atoms which is linked to another group by oxygen. The alkyl group may be, for example, methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, tert-butyl, n-pentyl and n-hexyl. The term“C1-C6 alkoxy” may refer to, for example, methoxy, ethoxy, n-propoxy, iso-propoxy, n-butoxy, sec-butoxy, tert-butoxy, n- pentoxy and n-hexoxy. The alkyl group may be substituted or unsubstituted by one or more substituents.
[00107] A bond terminating in a“ -rJ~r” means that the bond is connected to another group that is not shown. A bond terminating inside a cyclic structure and not terminating at an atom of the ring structure represents that the bond may be connected to any of the atoms in the ring structure where allowed by valency.
[00108] Where a group is substituted, it may be substituted at any point on the group where chemically possible and consistent with valency requirements. The group may be substituted by one or more substituents. For example, the group may be substituted with 1 , 2, 3 or 4 substituents. Where there are two or more substituents, the substituents may be the same or different. Substituent(s) may be, for example, halo, CN, nitro, oxo, C1-C6- alkyl, C2-C6-alkynyl, C2-C6-alkenyl, Ci-C6-haloalkyl, ORa, NRaRb, SRa, C(0)0Ra,
C(0)NRaRa, halo, cyano, nitro, C(0)Ra, S(0)20Ra, S(0)2Ra and S(0)2NRaRa; wherein Ra is independently at each occurrence selected from: H and Ci-C6-alkyl; and Rb is independently at each occurrence selected from: H, Ci-C6-alkyl, C(0)Ci-C6-alkyl and S(0)2-Ci-C6-alkyl.
[00109] If chemically possible to do so, a cyclic substituent may be substituted on a group so as to form a spiro-cycle.
[00110] Substituents are only present at positions where they are chemically possible, the person skilled in the art being able to decide (either experimentally or theoretically) without inappropriate effort which substitutions are chemically possible and which are not.
[00111] Ortho, meta and para substitution are well understood terms in the art. For the absence of doubt,“ortho” substitution is a substitution pattern where adjacent carbons possess a substituent, whether a simple group, for example the fluoro group in the example below, or other portions of the molecule, as indicated by the bond ending in“
[00112]‘ Meta” substitution is a substitution pattern where two substituents are on carbons one carbon removed from each other, i.e with a single carbon atom between the substituted carbons. In other words there is a substituent on the second atom away from the atom with another substituent. For example the groups below are meta substituted.
[00113]“ Para” substitution is a substitution pattern where two substituents are on carbons two carbons removed from each other, i.e with two carbon atoms between the
substituted carbons. In other words there is a substituent on the third atom away from the atom with another substituent. For example the groups below are para substituted.
[00114] The cation of formula (I) will be associated with a pharmaceutically acceptable anionic counter ion for administration to a subject. Nevertheless, where either the cation of formula (I) or the anionic counter ion comprise either basic or acidic groups, those groups may themselves be protonated or deprotonated and associated with an appropriate counter ion.
[00115] Suitable acid addition salts are formed from acids which form non-toxic salts, for example, acetate, aspartate, benzoate, besylate, bicarbonate/carbonate,
bisulphate/sulphate, borate, camsylate, citrate, edisylate, esylate, formate, fumarate, gluceptate, gluconate, glucuronate, hexafluorophosphate, hibenzate,
hydrochloride/chloride, hydrobromide/bromide, hydroiodide/iodide, isethionate, lactate, malate, maleate, malonate, mesylate, methylsulphate, naphthylate, 1 ,5- naphthalenedisulfonate, 2-napsylate, nicotinate, nitrate, orotate, oxalate, palmitate, pamoate, phosphate/hydrogen phosphate/dihydrogen phosphate, saccharate, stearate, succinate, tartrate, tosylate and triflu oroacetate salts.
[00116] Suitable base salts are formed from bases which form non-toxic salts, for example including the aluminium, arginine, benzathine, calcium, choline, diethylamine, diolamine, glycine, lysine, magnesium, meglumine, olamine, potassium, sodium, tromethamine and zinc salts. Hemisalts of acids and bases may also be formed, for example, hemisulphate and hemicalcium salts. A review of suitable salts can be found in "Handbook of Pharmaceutical Salts: Properties, Selection, and Use" by Stahl and Wermuth (Wiley-VCH, Weinheim, Germany, 2002).
[00117] The salt may be an acid addition salt.
[00118] The salts may be formate or hydrochloride.
[00119] Pharmaceutically acceptable salts of ions of formula (I) may be prepared by one or more of the following methods:
(i) reacting the ion of formula (I) with the desired acid or base;
(ii) removing an acid- or base-labile protecting group from a suitable precursor of the ion of formula (I) or by ring-opening a suitable cyclic precursor, for example, a lactone or lactam, using the desired acid or base; or
(iii) converting one salt of the ion of formula (I) to another by reaction with an appropriate acid or base or by means of a suitable ion exchange column.
[00120] The reactions above are typically carried out in solution and the resulting salt may precipitate out and be collected by filtration or may be recovered by evaporation of the solvent. The degree of ionisation in the resulting salt may vary from completely ionised to almost non-ionised.
[00121] The compounds may exist in both unsolvated and solvated forms. The term 'solvate' is used herein to describe a molecular complex comprising the compound of the invention and a stoichiometric amount of one or more pharmaceutically acceptable solvent molecules, for example, ethanol. The term 'hydrate' is employed when said solvent is water.
[00122] Complexes are contemplated, such as clathrates, drug-host inclusion complexes wherein, in contrast to the aforementioned solvates, the drug and host are present in stoichiometric or non-stoichiometric amounts. Complexes of the drug containing two or more organic and/or inorganic components which may be in stoichiometric or non- stoichiometric amounts are also contemplated. The resulting complexes may be ionised, partially ionised, or non- ionised. A review of such complexes is found in J Pharm Sci, 64 (8), 1269-1288 by Haleblian (August 1975).
[00123] Compounds, ions and salts described in this specification may be isotopically-labelled (or“radio-labelled”). Accordingly, one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number typically found in nature. Examples of radionuclides that may be incorporated include 2H (also written as“D” for deuterium), 3H (also written as“T” for tritium), 11C, 13C, 14C, 150, 170, 180, 18F and the like. The radionuclide that is used will depend on the specific application of that radio-labelled derivative. For example, for in vitro competition assays, 3H or 14C are often useful. For radio-imaging applications, 11C or 18F are often useful. In some embodiments, the radionuclide is 3H. In some embodiments, the radionuclide is 14C. In some embodiments, the radionuclide is 11C. And in some embodiments, the radionuclide is 18F.
[00124] Hereinafter all references to compounds of any formula include references to salts, solvates and complexes thereof and to solvates and complexes of salts thereof.
[00125] The compounds include a number of formulae as herein defined, including all polymorphs and crystal habits thereof, prodrugs and isomers thereof (including optical,
geometric and tautomeric isomers) as hereinafter defined and isotopically-labelled compounds of the invention.
[00126] Before purification, the compounds may exist as a mixture of enantiomers depending on the synthetic procedure used. The enantiomers can be separated by conventional techniques known in the art. Thus the compounds cover individual enantiomers as well as mixtures thereof.
[00127] For some of the steps of the process of preparation of the compounds of formula (I), it may be necessary to protect potential reactive functions that are not wished to react, and to cleave said protecting groups in consequence. In such a case, any compatible protecting radical can be used. In particular methods of protection and deprotection such as those described by T.W. Greene (Protective Groups in Organic Synthesis, A. Wiley- Interscience Publication, 1981 ) or by P. J. Kocienski (Protecting groups, Georg Thieme Verlag, 1994), can be used. All of the above reactions and the preparations of novel starting materials used in the preceding methods are conventional and appropriate reagents and reaction conditions for their performance or preparation as well as procedures for isolating the desired products will be well-known to those skilled in the art with reference to literature precedents and the examples and preparations hereto.
[00128] Also, the compounds as well as intermediates for the preparation thereof can be purified according to various well-known methods, such as for example crystallization or chromatography.
[00129] The method of treatment or the compound for use in the treatment of solid tumours, leukaemia, lymphoma, sarcoma, or carcinoma as defined hereinbefore may be applied as a sole therapy or be a combination therapy with an additional active agent.
[00130] The method of treatment or the compound for use in the treatment of solid tumours, leuekaemia, lymphoma, sarcoma, or carcinoma may involve, in addition to the compound of the invention, conventional surgery or radiotherapy or chemotherapy. Such chemotherapy may include one or more of the following categories of anti-cancer agents:
(i) antiproliferative/antineoplastic drugs and combinations thereof, such as alkylating agents (for example cis-platin, oxaliplatin, carboplatin, cyclophosphamide, nitrogen mustard, bendamustin, melphalan, chlorambucil, busulphan, temozolamide and nitrosoureas); antimetabolites (for example gemcitabine and antifolates such as fluoropyrimidines like 5-fluorouracil and tegafur, raltitrexed, methotrexate, pemetrexed, cytosine arabinoside, and hydroxyurea); antibiotics (for example anthracyclines like adriamycin, bleomycin, doxorubicin, daunomycin, epirubicin, idarubicin, mitomycin-C,
dactinomycin and mithramycin); antimitotic agents (for example vinca alkaloids like vincristine, vinblastine, vindesine and vinorelbine and taxoids like taxol and taxotere and polokinase inhibitors); proteasome inhibitors, for example carfilzomib and bortezomib; interferon therapy; and topoisomerase inhibitors (for example epipodophyllotoxins like etoposide and teniposide, amsacrine, topotecan, mitoxantrone and camptothecin);
(ii) cytostatic agents such as antiestrogens (for example tamoxifen, fulvestrant, toremifene, raloxifene, droloxifene and iodoxyfene), antiandrogens (for example bicalutamide, flutamide, nilutamide and cyproterone acetate), LHRH antagonists or LHRH agonists (for example goserelin, leuprorelin and buserelin), progestogens (for example megestrol acetate), aromatase inhibitors (for example as anastrozole, letrozole, vorazole and exemestane) and inhibitors of 5a-reductase such as finasteride;
(iii) anti-invasion agents, for example dasatinib and bosutinib (SKI-606), and metalloproteinase inhibitors, inhibitors of urokinase plasminogen activator receptor function or antibodies to Heparanase;
(iv) inhibitors of growth factor function: for example such inhibitors include growth factor antibodies and growth factor receptor antibodies, for example the anti-erbB2 antibody trastuzumab [Herceptin™], the anti-EGFR antibody panitumumab, the anti-erbB1 antibody cetuximab, tyrosine kinase inhibitors, for example inhibitors of the epidermal growth factor family (for example EGFR family tyrosine kinase inhibitors such as gefitinib, erlotinib and 6-acrylamido-/V-(3-chloro-4-fluorophenyl)-7-(3-morpholinopropoxy)- quinazolin-4-amine (Cl 1033), erbB2 tyrosine kinase inhibitors such as lapatinib);
inhibitors of the hepatocyte growth factor family; inhibitors of the insulin growth factor family; modulators of protein regulators of cell apoptosis (for example Bcl-2 inhibitors); inhibitors of the platelet-derived growth factor family such as imatinib and/or nilotinib (AMN107); inhibitors of serine/threonine kinases (for example Ras/Raf signalling inhibitors such as farnesyl transferase inhibitors, for example sorafenib , tipifarnib and lonafarnib), inhibitors of cell signalling through MEK and/or AKT kinases, c-kit inhibitors, abl kinase inhibitors, PI3 kinase inhibitors, Plt3 kinase inhibitors, CSF-1 R kinase inhibitors, IGF receptor, kinase inhibitors; aurora kinase inhibitors and cyclin dependent kinase inhibitors such as CDK2 and/or CDK4 inhibitors;
(v) antiangiogenic agents such as those which inhibit the effects of vascular endothelial growth factor, for example the anti-vascular endothelial cell growth factor antibody bevacizumab (Avastin™); thalidomide; lenalidomide; and for example, a VEGF
receptor tyrosine kinase inhibitor such as vandetanib, vatalanib, sunitinib, axitinib and pazopanib;
(vi) gene therapy approaches, including for example approaches to replace aberrant genes such as aberrant p53 or aberrant BRCA1 or BRCA2;
(vii) immunotherapy approaches, including checkpoint inhibitors of targets such as PD-1 , PD-L1 and CTCLA-4, for example antibody therapy such as alemtuzumab, rituximab, ibritumomab tiuxetan (Zevalin®), pembrolizumab and ofatumumab; interferons such as interferon a; interleukins such as IL-2 (aldesleukin); interleukin inhibitors for example IRAK4 inhibitors; cancer vaccines including prophylactic and treatment vaccines such as HPV vaccines, for example Gardasil, Cervarix, Oncophage and Sipuleucel-T (Provenge); and toll-like receptor modulators for example TLR-7 or TLR-9 agonists; and
(viii) cytotoxic agents for example fludaribine (fludara), cladribine, pentostatin
(Nipent™);
(ix) steroids such as corticosteroids, including glucocorticoids and mineralocorticoids, for example aclometasone, aclometasone dipropionate, aldosterone, amcinonide, beclomethasone, beclomethasone dipropionate, betamethasone, betamethasone dipropionate, betamethasone sodium phosphate, betamethasone valerate, budesonide, clobetasone, clobetasone butyrate, clobetasol propionate, cloprednol, cortisone, cortisone acetate, cortivazol, deoxycortone, desonide, desoximetasone, dexamethasone, dexamethasone sodium phosphate, dexamethasone isonicotinate, difluorocortolone, fluclorolone, flumethasone, flunisolide, fluocinolone, fluocinolone acetonide, fluocinonide, fluocortin butyl, fluorocortisone, fluorocortolone, fluocortolone caproate, fluocortolone pivalate, fluorometholone, fluprednidene, fluprednidene acetate, flurandrenolone, fluticasone, fluticasone propionate, halcinonide, hydrocortisone, hydrocortisone acetate, hydrocortisone butyrate, hydrocortisone aceponate, hydrocortisone buteprate,
hydrocortisone valerate, icomethasone, icomethasone enbutate, meprednisone, methylprednisolone, mometasone paramethasone, mometasone furoate monohydrate, prednicarbate, prednisolone, prednisone, tixocortol, tixocortol pivalate, triamcinolone, triamcinolone acetonide, triamcinolone alcohol and their respective pharmaceutically acceptable derivatives. A combination of steroids may be used, for example a
combination of two or more steroids mentioned in this paragraph;
(x) targeted therapies, for example PI3Kd inhibitors, for example idelalisib and perifosine.
[00131] Such combination treatment may be achieved by way of the simultaneous, sequential or separate dosing of the individual components of the treatment. Such combination products may be administered so that the combination is provided in a therapeutically effective amount, for example the compounds of this invention may be administered within a therapeutically effective dosage range described herein and the other pharmaceutically-active agent may be administered in an amount of less than or within its approved dosage range.
[00132] According to a further aspect of the invention there is provided a pharmaceutical product comprising a compound of the first aspect of the invention, or a pharmaceutically acceptable salt thereof as defined herein and an additional active agent. The additional active agent may be a cancer therapy as defined hereinbefore for the combination treatment of cancer.
[00133] According to a further aspect of the invention there is provided a method of treating cancer comprising administering a therapeutically effective amount of a compound of the invention, or a pharmaceutically acceptable salt thereof simultaneously, sequentially or separately with an additional anti-cancer agent, as defined hereinbefore, to a patient in need thereof.
[00134] According to a further aspect of the invention there is provided a compound of the invention, or a pharmaceutically acceptable salt thereof for use simultaneously, sequentially or separately with an additional anti-cancer agent as defined herein, in the treatment of cancer.
[00135] According to another aspect of the invention there is provided a use of the compound of the invention in combination with an anti-cancer agent, such as those hereinbefore described. The compound of the invention may be used simultaneously, sequentially or separately with the additional anti-cancer agent. The use may be in a single combination product comprising the compound of the invention and the anti-cancer agent. The additional anti-cancer agent may be a further compound of the first aspect of the invention.
[00136] According to a further aspect there is provided a method of providing a combination product, wherein the method comprises providing a compound of the invention simultaneously, sequentially or separately with an anti-cancer agent, as defined hereinbefore. The method may comprise combining the compound of the invention and the anti-cancer agent in a single dosage form. Alternatively the method may comprise providing the anti-cancer agent as separate dosage forms.
[00137] Compounds of the invention may exist in a single crystal form or in a mixture of crystal forms or they may be amorphous. Thus, compounds of the invention intended for pharmaceutical use may be administered as crystalline or amorphous products. They may be obtained, for example, as solid plugs, powders, or films by methods such as precipitation, crystallization, freeze drying, or spray drying, or evaporative drying.
Microwave or radio frequency drying may be used for this purpose.
[00138] For the above-mentioned compounds of the invention the dosage administered will, of course, vary with the compound employed, the mode of administration, the treatment desired and the disorder indicated. For example, if the compound of the invention is administered orally, then the daily dosage of the compound of the invention may be in the range from 0.01 micrograms per kilogram body weight (pg/kg) to 100 milligrams per kilogram body weight (mg/kg).
[00139] A compound of the invention, or pharmaceutically acceptable salt thereof, may be used on their own but will generally be administered in the form of a pharmaceutical composition in which the compounds of the invention, or pharmaceutically acceptable salt thereof, is in association with a pharmaceutically acceptable adjuvant, diluent or carrier. Conventional procedures for the selection and preparation of suitable pharmaceutical formulations are described in, for example, "Pharmaceuticals - The Science of Dosage Form Designs", M. E. Aulton, Churchill Livingstone, 1988.
[00140] Depending on the mode of administration of the compounds of the invention, the pharmaceutical composition which is used to administer the compounds of the invention will preferably comprise from 0.05 to 99 %w (percent by weight) compounds of the invention, more preferably from 0.05 to 80 %w compounds of the invention, still more preferably from 0.10 to 70 %w compounds of the invention, and even more preferably from 0.10 to 50 %w compounds of the invention, all percentages by weight being based on total composition.
[00141] The pharmaceutical compositions may be administered topically (e.g. to the skin) in the form, e.g., of creams, gels, lotions, solutions, suspensions, or systemically, e.g. by oral administration in the form of tablets, capsules, syrups, powders or granules; or by parenteral administration in the form of a sterile solution, suspension or emulsion for injection (including intravenous, subcutaneous, intramuscular, intravascular or infusion); by rectal administration in the form of suppositories; or by inhalation in the form of an aerosol.
[00142] For oral administration the compounds of the invention may be admixed with an adjuvant or a carrier, for example, lactose, saccharose, sorbitol, mannitol; a starch, for example, potato starch, corn starch or amylopectin; a cellulose derivative; a binder, for example, gelatine or polyvinylpyrrolidone; and/or a lubricant, for example, magnesium stearate, calcium stearate, polyethylene glycol, a wax, paraffin, and the like, and then compressed into tablets. If coated tablets are required, the cores, prepared as described above, may be coated with a concentrated sugar solution which may contain, for example, gum arabic, gelatine, talcum and titanium dioxide. Alternatively, the tablet may be coated with a suitable polymer dissolved in a readily volatile organic solvent.
[00143] For the preparation of soft gelatine capsules, the compounds of the invention may be admixed with, for example, a vegetable oil or polyethylene glycol. Hard gelatine capsules may contain granules of the compound using either the above-mentioned excipients for tablets. Also liquid or semisolid formulations of the compound of the invention may be filled into hard gelatine capsules. Liquid preparations for oral application may be in the form of syrups or suspensions, for example, solutions containing the compound of the invention, the balance being sugar and a mixture of ethanol, water, glycerol and propylene glycol. Optionally such liquid preparations may contain colouring agents, flavouring agents, sweetening agents (such as saccharine), preservative agents and/or carboxymethylcellulose as a thickening agent or other excipients known to those skilled in art.
[00144] For intravenous (parenteral) administration the compounds of the invention may be administered as a sterile aqueous or oily solution.
[00145] The size of the dose for therapeutic purposes of compounds of the invention will naturally vary according to the nature and severity of the conditions, the age and sex of the animal or patient and the route of administration, according to well-known principles of medicine.
[00146] Dosage levels, dose frequency, and treatment durations of compounds of the invention are expected to differ depending on the formulation and clinical indication, age, and co-morbid medical conditions of the patient.
[00147] Throughout the description and claims of this specification, the words“comprise” and“contain” and variations of them mean“including but not limited to”, and they are not intended to (and do not) exclude other moieties, additives, components, integers or steps. Throughout the description and claims of this specification, the singular encompasses the plural unless the context otherwise requires. In particular, where the indefinite article is
used, the specification is to be understood as contemplating plurality as well as singularity, unless the context requires otherwise.
[00148] Features, integers, characteristics, compounds, chemical moieties or groups described in conjunction with a particular aspect, embodiment or example of the invention are to be understood to be applicable to any other aspect, embodiment or example described herein unless incompatible therewith. All of the features disclosed in this specification (including any accompanying claims, abstract and drawings), and/or all of the steps of any method or process so disclosed, may be combined in any combination, except combinations where at least some of such features and/or steps are mutually exclusive. The invention is not restricted to the details of any foregoing embodiments.
The invention extends to any novel one, or any novel combination, of the features disclosed in this specification (including any accompanying claims, abstract and drawings), or to any novel one, or any novel combination, of the steps of any method or process so disclosed.
[00149] The reader's attention is directed to all papers and documents which are filed concurrently with or previous to this specification in connection with this application and which are open to public inspection with this specification, and the contents of all such papers and documents are incorporated herein by reference.
Methods for Synthesizing Compounds
[00150] Certain ions of the invention can be synthesised according to or analogously to methods described in the General Schemes below and/by other techniques known to those of ordinary skill in the art. Certain ions of the invention can be synthesised according to or analogously to the methods described in the Examples.
[00151] Certain ions of formula (I) (where R3 is independently selected form H, halo and OR12) can be made by Scheme A
Scheme A
[00152] Reaction of amine (1 ) with phosphonium acid (2) can furnish phosphonium amide (3). The reaction can be performed using standard peptide coupling agents, such as N,N’- diisopropylcarbodiimide (DCC) in an organic solvent, such as DCM at a temperature from 0 to 30 °C or 1-ethyl-3-(3’-dimethyl)amino)carbodiimide HCI, in the presence of a base, such as NaHCC>3 or EίbN in an organic solvent, such as DCM or DMF at a temperature from 0 to 30 °C. Optional is the addition of 1-hydroxybenzotriazole or 1-hydroxy-7- azabenzotriazole. [00153] Phosphonium acid (2) can be prepared from reaction of halo acid (4) (where X =
Cl or Br) with phosphine (5). The reaction can be accomplished by heating in an organic solvent, such as MeCN at a temperature from 50 to 80 °C. Phosphonium amide (3) can also be accessed by an alternative sequence of reactions involving amide formation between amine (1 ) and acid (4) using standard peptide coupling agents, followed by
displacement of the resultant product halide with phosphine (5), which can be accomplished by heating in an organic solvent, such as MeCN at a temperature from 50 to 80 °C.
[00154] Certain ions of formula (I) (where R3 is independently selected form H, halo and OR12) can be made by Scheme B
Scheme B
[00155] Reaction of amine (1 ) with halo sulphonic acid (6) (where X = Cl or Br) can furnish halo sulphonamide (7). The reaction can be performed using SOCI2 in an organic solvent, such as DMF or DCM at a temperature from 20 to 60 °C. Reaction of halo sulphonamide (7) with phosphine (5) can deliver phosphonium sulphonamide (8). The reaction can be accomplished by heating in an organic solvent, such as MeCN at a temperature from 50 to 80 °C.
[00156] Certain ions of formula (I) (where R3 is independently selected form H, halo and OR12) can be made by Scheme C
Scheme C [00157] Reaction of amine (1 ) with halo isocyanate (9) (where X = Cl or Br) can furnish halo urea (10). The reaction can be performed in a mixed organic solvent comprising of EtOH and DCM, at a temperature from 25 to 40 °C. Reaction of halo urea (10) with phosphine (5) can deliver phosphonium urea (11 ). The reaction can be accomplished by heating in an organic solvent, such as MeCN at a temperature from 50 to 80 °C. Halo
isocyanate (9) can be prepared from halo acid (4) (where X = Cl or Br). The reaction can be accomplished with diphenylphosphoryl azide ((Ph0)2P(0)N3) in the presence of a base, such as EίbN in an organic solvent, such as toluene at a temperature from 50 to 100 °C. [00158] Certain ions of formula (I) (where R3 is independently selected form H, halo and
OR12) can be made by Scheme D
Scheme D
[00159] Reaction of amine (1 ) with halo chlorosulphonylamine (12) (where X = Cl or Br) can furnish halo sulphonyl urea (13). The reaction can be performed in the presence of a base, such as EίbN in an organic solvent, such as toluene at a temperature from 25 to 70 °C. Reaction of halo sulphonyl urea (13) with phosphine (5) can deliver phosphonium sulphonyl urea (14). The reaction can be accomplished by heating in an organic solvent, such as MeCN at a temperature from 50 to 80 °C. Halo chlorosulphonylamine (12) can be prepared from halo amine (15) (where X = Cl or Br). The reaction can be accomplished with SO2CI2 in the presence of a base, such as EίbN in an organic solvent, such as DCM at a temperature from -10 to 10 °C. [00160] Certain ions of formula (I) (where R3 is independently selected form H, halo and
OR12) can be made by Scheme E
Scheme E
[00161] Reaction of amine (1 ) with halo chlorocarbonate (16) (where X = Cl or Br) can furnish halo carbamate (17). The reaction can be performed in the presence of an inorganic base, such as Na2CC>3 in an organic solvent, such as DCM at a temperature from 0 to 10 °C. Reaction of halo carbamate (17) with phosphine (5) can deliver phosphonium carbamate (18). The reaction can be accomplished by heating in an organic solvent, such as MeCN at a temperature from 50 to 80 °C. Halo chlorocarbonate (16) can be prepared from halo alcohol (19) (where X = Cl or Br). The reaction can be
accomplished with triphosgene in the presence of a base, such as pyridine in an organic solvent, such as DCM or THF at a temperature from -10 to 30 °C.
[00162] Certain ions of formula (I) (where R3 is Nhh) can be made by Scheme F
Scheme F
[00163] Alcohol (20) (synthesised from Schemes A - E) can be converted to bromide (21 ). The reaction can be accomplished with NBS and PPfi3 in the presence of pyridine in
an organic solvent, such as THF at a temperature from 0 to 30 °C. The bromide (21 ) can be transformed to azide (22). The reaction can be performed with sodium azide in an organic solvent, such as DMF at a temperature from 20 to 70 °C. Reduction of azide (22) can deliver primary amine (23). The reaction can be accomplished by standard hydrogenation, techniques, such as Pd/C catalyst systems in organic solvents, such as EtOAc. Alternatively, primary amine (23) can be accessed by reduction of azide (22) with PPfi3 followed by H2O in an organic solvent, such as THF at a temperature from 10 to 30 °C.
[00164] Certain ions of formula (I) (where R3 is NHR13 and R13 = Ci-C6-alkyl) can be made by Scheme G
Scheme G
[00165] Bromide (21 ) (synthesised from Scheme F) can be converted to secondary amine (24). The reaction can be accomplished with amine NH2R13 (where R13 = C1-C6- alkyl) in an organic solvent, such as DMF at a temperature from 20 to 50 °C. Optional is the addition of CsOH.hhO and 4A molecular sieves.
[00166] Certain ions of formula (I) (where R3 is NR13R14 and R13 = Ci-C6-alkyl, R14 = C1- C6-alkyl) can be made by Scheme H
Scheme H
[00167] Bromide (21 ) (synthesised from Scheme F) can be converted to tertiary amine (25). The reaction can be accomplished with amine NHR13R14 (where R13 = Ci-C6-alkyl, R14 = Ci-C6-alkyl) in the presence of an inorganic base, such as K2CO3 in an organic solvent, such as dioxane at a temperature from 20 to 50 °C.
[00168] Certain ions of formula (I) (where R13 = H, R14 = COCi-C6-alkyl) can be made by
Scheme I
Scheme I
[00169] Amine (23) (synthesised from Scheme F) can be acylated with acid chloride (27) (where R15 = Ci-C6-alkyl) to give amide (26). The reaction can be accomplished in the presence of a base, such as EίbN or pyridine in an organic solvent, such as DCM or EtOAc at a temperature from -5 to 30 °C.
[00170] Certain ions of formula (I) (where R13 = H, R14 = SC>2Ci-C6-alkyl) can be made by
Scheme J
Scheme J
[00171] Amine (23) (synthesised from Scheme F) can be sulphonated with sulphonyl chloride (29) (where R15 = Ci-C6-alkyl) to sulphonamide (28). The reaction can be accomplished in the presence of a base, such as EίbN or pyridine in an organic solvent, such as DCM or EtOAc at a temperature from -5 to 30 °C.
Experimental
Analytical methods [00172] NMR spectra were obtained on a 400 MHz Bruker AV III (Method A) or 500 MHz
Bruker Avance III HD (Method B)
[00173] UPLC/MS was carried out using a Waters SQ mass detector and Methods A to C or a Walters Acquity QDa mass detector and Method D
[00174] Method A [00175] Column: Waters Acquity UPLC BEH C18, 1.7 pm, 2.1 x 30 mm; Gradient Eluent:
5-95% MeCN/H20 containing 10 mM (NH4)2C03; Time: 0-15 min
[00176] Method B
[00177] Column: Waters Acquity UPLC BEH C18, 1.7 pm, 2.1 x 30 mm; Gradient Eluent: 5-95% MeCN/hhO containing 10 mM (NhU^COs; Time: 0-3 min
[00178] Method C [00179] Column: Waters Acquity UPLC CSH C18, 1.7 pm, 2.1 x 30 mm; Gradient Eluent:
5-95% MeCN/hhO containing 0.1 % HCOOH; Time: 0-15 min
[00180] Method D
[00181] Column: Waters Acquity UPLC CSH C18, 1.7 pm, 2.1 x 30 mm; Gradient Eluent: 5-95% MeCN/H20 containing 0.1 % HCOOH; Time: 0-3 min
[00182] The following abbreviations have been used throughout the specification in the examples and the description: N,N’-diisopropylcarbodiimide (DCC). dichloromethane (DCM), dimethylformamide (DMF), dimethyl sulfoxide (DMSO), methyl-t-butylether (MTBE), N-bromosuccinimide (NBS) andtetrahydrofuran (THF). .
Example 1 - (11-{[(1R,2R)-1,3-Dihydroxy-1-(4-nitrophenyl)propan-2- yl]carbamoyl}undecyl)triphenylphosphonium chloride
[00183] To a solution of (11-carboxyundecyl)triphenylphosphonium bromide (prepared as described in WO2011/146589) (490 mg, 0.91 mmol), (1 R,2R)-2-amino-1-(4-nitrophenyl)- 1 ,3-diol (160 mg, 0.75 mmol) and 1 H-[1 ,2,3]triazolo[4,5-b]pyridine-1-ol hydrate (35 mg, 0,23 mmol) in DCM (10 mL) was added N,N’-diisopropylcarbodiimide (DCC) (130 mί,
0.83 mmol). The resulting reaction mixture was stirred at room temperature. After 16 h the reaction was diluted with further DCM (10 mL) and washed with aqueous saturated NaHCOs (10 mL). The separated aqueous layer was extracted with DCM (2 x 10 mL) and the combined organics dried over Na2S04 and concentrated under reduced pressure. The resulting residue was purified by silica column chromatography eluting with 0-10% 7M
NH3 in MeOH in DCM to give a white solid, which was taken up in MeOH (10 ml.) and filtered through an Amberlite IRA-400(CI) ion exchange resin. The collected MeOH was recycled through the column 3 x, followed by a fresh volume of MeOH. The combined MeOH washings were concentrated under reduced pressure to give the title compound (220 mg, 41 % yield) as a white solid.
[00184] 1 H NMR (Method A) (DMSO-de): d (delta) ppm 8.16-8.09 (m, 2H), 7.95-7.87 (m, 3H), 7.85-7.72 (m, 12H), 7.62-7.55 (m, 2H), 7.50 (d, J = 9.2 Hz, 1 H), 5.86 (d, J = 5.3 Hz,
1 H), 5.05 (dd, J = 5.3, 2.4 Hz, 1 H), 4.87 (dd, J = 6.5, 4.8 Hz, 1 H), 4.08-3.96 (m, 1 H), 3.64- 3.50 (m, 3H), 2.07-1 .85 (m, 2H), 1 .62-1 .38 (m, 4H), 1 .33-1.00 (m, 13H), 0.98-0.74 (m, 2H); 31 P NMR (162 MHz, DMSO-de) d (delta) ppm +24.07 (s); LC-MS (Method A) 655
[M]+; RT 6.16 min
Example 2 - (10-{[(1R,2R)-1,3-Dihydroxy-1-(4-nitrophenyl)propan-2- yl]carbamoyl}decyl)triphenylphosphonium chloride
[00185] The title compound was prepared as a white solid following the procedure described in Example 1 but using (l O-carboxydecyl)triphenylphosphonium bromide. Silica column chromatography was performed using the eluting system 0-20% 7M NH3 in MeOH in DCM.
[00186] 1 H NMR (Method B) (DMSO-de): d (delta) ppm 8.15-8.1 1 (m, 2H), 7.93-7.86 (m, 3H), 7.83-7.74 (m, 12H), 7.60-7.55 (m, 2H), 7.45 (d, J = 9.3 Hz, 1 H), 5.83 (d, J = 5.1 Hz,
1 H), 5.49 (d, J = 7.9 Hz, 1 H), 5.04 (dd, J = 5.4, 2.4 Hz, 1 H), 4.84 (dd, J = 6.5, 4.7 Hz, 1 H), 4.08-3.96 (m, 1 H), 3.59-3.47 (m, 3H), 2.03-1 .84 (m, 2H), 1 .57-1 .47 (m, 2H), 1 .46-1 .38 (m, 2H), 1 .29-1 .15 (m, 4H), 1 .15-1 .01 (m, 6H), 0.98-0.77 (m, 2H); 31 P NMR (202 MHz, DMSO-de) d (delta) ppm +24.05 (s); LC-MS (Method C) 641 [M]+; RT 4.56 min
Example 3 - (9-{[(1R,2R)-1,3-Dihydroxy-1-(4-nitrophenyl)propan-2- yl]carbamoyl}nonyl)triphenylphosphonium chloride
[00187] The title compound was prepared as a white solid following the procedure described in Example 1 but using (9-carboxynonyl)triphenylphosphonium bromide. Silica column purification was performed using the eluting system 0-20% 7M NH3 in MeOH in DCM.
[00188] 1 H NMR (Method B) (DMSO-de): d (delta) ppm 8.13-8.09 (m, 2H), 7.92-7.87 (m, 3H), 7.84-7.73 (m, 12H), 7.57 (d, J = 8.7 Hz, 2H), 7.47 (d, J = 9.3 Hz, 1 H), 5.83 (d, J = 5.2 Hz, 1 H), 5.03 (dd, J = 5.5, 2.4 Hz, 1 H), 4.85 (dd, J = 6.4, 4.7 Hz, 1 H), 4.06-3.96 (m, 1 H), 3.60-3.47 (m, 3H), 3.31 -3.27 (m, 1 H), 2.03-1 .85 (m, 2H), 1 .58-1 .46 (m, 2H), 1.41 (p, J = 7.3 Hz, 2H), 1 .29-1 .10 (m, 4H), 1 .08-0.96 (m, 4H), 0.94-0.76 (m, 2H); 31 P NMR (202 MHz, DMSO-de) d (delta) ppm +24.07 (s); LC-MS (Method C) 627 [M]+; RT 4.23 min
Example 4 - (8-{[(1R,2R)-1,3-Dihydroxy-1-(4-nitrophenyl)propan-2- yl]carbamoyl}octyl)triphenylphosphonium chloride
[00189] The title compound was prepared as a white solid following the procedure described in Example 1 but using (8-carboxyoctyl)triphenylphosphonium bromide. Silica column chromatography was performed using the eluting system 0-20% 7M NH3 in MeOH in DCM.
[00190] 31 P NMR (202 MHz, DMSO-de) d (delta) ppm +24.03 (s); LC-MS (Method C) 613 [M]+; RT 3.98 min
Example 5 (7-{[(1R,2R)-1,3-Dihydroxy-1-(4-nitrophenyi)propan-2- yl]carbamoyl}heptyl) triphenylphosphonium bromide
[00191] The title compound was prepared as an opaque gum following the procedure described in Example 1 but using (8-carboxyheptyl)triphenylphosphonium bromide and avoiding application of an ion exchange resin. Silica column chromatography was performed using the eluting system 0-7% 7M NH3 in MeOH in DCM. [00192] LC-MS (Method B) 599 [M]+; RT 1.13 min
Example 6 (11-{[(1R,2R)-1,3-Dihydroxy-1-(4-nitrophenyl)propan-2- yl]carbamoyl}undecyl)diphenyl(pyridine-2-yl)phosphonium chloride
12-bromo-N-[( 1 R, 2R)- 1, 3-dihydroxy- 1 -(4-nitrophenyl)propan-2-yl]dodecanamide
[00193] To a cold (0-5 °C) solution of 12-bromododecanoic acid (1 g, 3.58 mmol) in THF was added dropwise 1-chloro-N,N-2-trimethyl-1-propenylamine (Ghosez’s reagent) (498 mί, 3.76 mmol). The resulting reaction mixture was warmed to room temperature. After stirring for a further 40 min the solution was added dropwise to a solution of (1 R,2R)-2- amino-1-(4-nitrophenyl)propane-1 ,3-diol (760 mg, 3.58 mmol) in THF (10 mL) and 50% w/w aqueous NaOAc (5 g in 10 mL) at room temperature. The resulting reaction mixture
was stirred for a further 2.5 h, the layers separated and the aqueous extracted with EtOAc (2 x 20 ml_). The combined organics were dried over Na2S04 and concentrated under reduced pressure. The crude product was purified by silica column chromatography eluting with 0-10% 7M NH3 in MeOH in DCM to give 12-bromo-N-[(1 R,2R)-1 ,3-dihydroxy- 1 -(4-nitrophenyl)propan-2-yl)]dodecanamide (1 .5 g, 84% yield) as a colourless gum, which was used in the next step.
[00194] LC-MS (Method A) 473/475 [M+H]+; RT 1 .64 min
(11 -{[ (1R,2R)-1, 3-dihydroxy- 1 -(4-nitrophenyl)propan-2- yl]carbamoyl}undecyl)diphenyl(pyridine-2-yl)phosphonium chloride
[00195] To a degassed solution of 12-bromo-N-[(1 R,2R)-1 ,3-dihydroxy-1 -(4- nitrophenyl)propan-2-yl)]dodecanamide (prepared as described in Example 6 step (a)) (100 mg, 0.21 mmol) and Nal (7.9 mg) in MeCN (5 mL) was added 2- (diphenylphosphino)pyridine (58 mg, 0.22 mmol). The resulting reaction mixture was refluxed for 16 h. On cooling the reaction mixture was concentrated under reduced pressure and the resulting crude product purified by silica column chromatography eluting with 0-10% 7M NH3 in MeOH in DCM. The resulting white solid was taken up in MeOH (5 mL) and filtered through an Amberlite IRA-400(CI) ion exchange resin. The collected MeOH was recycled through the column 3 x, followed by a fresh volume of MeOH. The combined MeOH washings were concentrated under reduced pressure to give the title compound (10 mg, 7% yield) as a white solid.
[00196] 1 H NMR (Method B) (DMSO-d6): d (delta) ppm 9.00 (d, J = 4.1 Hz, 1 H), 8.24- 8.15 (m, 1 H), 8.13 (d, J = 8.3 Hz, 3H), 8.01 -7.94 (m, 1 H), 7.93-7.81 (m, 6H), 7.80-7.72 (m, 4H), 7.58 (d, J = 8.4 Hz, 2H), 7.45 (d, J = 9.1 Hz, 1 H), 5.82 (d, J = 5.2 Hz, 1 H), 5.03 (dd, J = 5.5, 2.4 Hz, 1 H), 5.13-4.97 (m,1 H), 4.84 (t, J = 5.5 Hz, 2H), 4.07-3.95 (m, 1 H), 3.66-3.47 (m, 2H), 2.47-2.38 (m, 1 H), 2.06-1.81 (m, 2H), 1 .66-1 .52 (m, 2H), 1 .47-1 .37 (m, 2H), 1 .30-
1 .18 (m, 4H), 1 .17-1 .08 (m, 4H), 1 .08-0.97 (m, 4H), 0.95-0.78 (m, 2H); 31 P NMR (202 MHz, DMSO-de) d (delta) ppm +20.31 (s); LC-MS (Method A) 656 [M]+; RT 6.12 min
Example 7 - (11-{[(1R,2R)-1,3-Dihydroxy-1-(4-nitrophenyl)propan-2- yl]carbamoyl}undecyl)diphenyl(propan-2-yl)phosphonium chloride
[00197] The title compound was prepared as a white solid following the procedure described in Example 6 but using isopropyldiphenylphosphine in step (b).
[00198] 1 H NMR (Method B) (DMSO-d6): d (delta) ppm 8.12 (d, J = 8.1 Hz, 2H), 7.94- 7.81 (m, 6H), 7.77 (td, J = 7.7, 3.2 Hz, 4H), 7.58 (d, J = 8.7 Hz, 2H), 7.48 (d, J = 9.2 Hz, 1 H), 5.84 (d, J = 5.2 Hz, 1 H), 5.04 (dd, J = 5.5, 2.3 Hz, 1 H), 4.86 (dt, J = 6.4, 4.8 Hz, 1 H),
4.07-3.97 (m, 1 H), 3.68-3.59 (m, 1 H), 3.58-3.51 (m, 1 H), 3.31 -3.24 (m, 1 H), 3.09-3.01 (m, 2H), 2.01 -1 .85 (m, 2H), 1 .39-1 .21 (m, 5H), 1 .20-1 .14 (m, 6H), 1 .14-1 .06 (m, 7H), 1 .06- 0.97 (m, 4H), 0.97-0.76 (m, 2H); 31 P NMR (202 MHz, DMSO-de) d (delta) ppm +34.70 (s); LC-MS (Method A) 621 [M]+; RT 6.02 min Example 8 - tert-Butyl (11-{[(1R,2R)-1,3-dihydroxy-1-(4-nitrophenyl)propan-2- yl]carbamoyl}undecyl)diphenylphosphonium chloride
[00199] The title compound was prepared as a white solid following the procedure described in Example 6 but using tert-butyldiphenylphosphine in step (b). [00200] 1 H NMR (Method B) (DMSO-d6): d (delta) ppm 8.13 (d, J = 8.6 Hz, 2H), 7.98-
7.87 (m, 6H), 7.78 (td, J = 7.8, 3.2 Hz, 4H), 7.59 (d, J = 8.5 Hz, 2H), 7.45 (d, J = 9.3 Hz,
1 H), 5.83 (d, J = 5.1 Hz, 1 H), 5.04 (m, 1 H), 4.85 (t, J = 1 .8 Hz, 1 H), 4.08-3.97 (m, 1 H), 3.60-3.51 (m, 1 H), 3.18-3.09 (m, 2H), 2.04-1 .84 (m, 2H), 1 .50-1.30 (m, 10H), 1 .30-1.22 (m, 3H), 1 .22-1 .14 (m, 3H), 1 .14-1.07 (m, 4H), 1 .07-0.99 (m, 4H), 0.99-0.74 (m, 2H); 31 P NMR (202 MHz, DMSO-de) d (delta) ppm +37.47 (s); LC-MS (Method A) 635 [M]+; RT 6.32 min
Example 9 (11-{[(1R,2R)-1,3-Dihydroxy-1-(4-nitrophenyl)propan-2- yl]carbamoyl}undecyl)(methyl)diphenylphosphonium chloride
(11 -carboxyundecyl)(methyl)diphenylphosphonium bromide
[00201] A suspension of 12-bromododecanoic acid (1 .33 g, 4.76 mmol) in MeCN (20 mL) was warmed to 40 °C until a clear solution was obtained. The resulting solution was degassed with bubbling N2 for 30 min and treated with methyldiphenylphosphine (0.93 mL, 4.99 mmol). The resulting solution was heated at 90 °C under N2for 16 h. On cooling to room temperature the solution was added to MTBE (100 mL) and (1 1 - carboxyundecyl)(methyl)diphenylphosphonium bromide (2.1 g) collected as a colourless gum, which was used in the next step without further purification.
[00202] LC-MS (Method D) 399.4 [M]+; RT 1 .08 min
(11 -{[ (1R,2R)-1, 3-dihydroxy- 1 -(4-nitrophenyl)propan-2
yl]carbamoyl}undecyl)(methyl)diphenylphosphonium chloride
[00203] The title compound was prepared as a colourless gum following the procedure described in Example 1 , but using (1 1 -carboxyundecyl)(methyl)diphenylphosphonium bromide (prepared as described in Example 9 step (a)). Silica column chromatography was performed using the eluting system 0-20% 7M NH3 in MeOH in DCM.
[00204] 1 H NMR (Method B) (DMSO-de): d (delta) ppm 8.16-8.1 1 (m, 2H), 7.95-7.89 (m, 4H), 7.82 (td, J = 7.4, 1.6 Hz, 2H), 7.72 (td, J = 7.7, 3.2 Hz, 4H), 7.62-7.56 (m, 2H), 7.49 (d, J = 9.2 Hz, 1 H), 5.85 (d, J = 5.2 Hz, 1 H), 5.05 (dd, J = 5.4, 2.4 Hz, 1 H), 4.87 (dd, J = 6.4, 4.8 Hz, 1 H), 4.08-3.97 (m, 1 H), 3.61 -3.50 (m, 1 H), 3.32-3.26 (m. 1 H), 3.10-2.99 (m. 2H), 2.67 (d, J = 14.2 Hz, 3H), 2.02-1 .84 (m, 2H), 1 .51 -1 .35 (m, 4H), 1 .30-1.21 (m, 4H), 1 .21 -1 .10 (m, 4H), 1 .10-1.02 (m, 4H), 0.99-0.79 (m, 2H); 31 P NMR (202 MHz, DMSO-de) d (delta) ppm +24.27 (s); LC-MS (Method A) 593 [M]+; RT 5.52 min
Example 10 (11-{[(1R,2R)-1,3-Dihydroxy-1-(4-nitrophenyl)propan-2- yl]carbamoyl}undecyl)dimethylphenylphosphonium chloride
(11 -carboxyundecyl)dimethylphenylphosphonium bromide
[00205] Prepared following the procedure in Example 9 step (a) using
dimethylphenylphosphine. (1 1 -carboxyundecyl)dimethylphenylphosphonium bromide was collected as a white solid and used in the next step without any purification.
[00206] LC-MS (Method D) 337.4 [M]+; 0.96 min
(11 -{[ (1R,2R)-1, 3-dihydroxy- 1 -(4-nitrophenyl)propan-2- yl]carbamoyl}undecyl)dimethylphenylphosphonium chloride
[00207] The title compound was prepared as a colourless gum following the procedure described in Example 1 , but using (1 1 -carboxyundecyl)dimethylphenylphosphonium bromide (prepared as described in Example 10 step (a)). Silica column chromatography was performed using the eluting system 0-20% 7M NH3 in MeOH in DCM.
[00208] 1 H NMR (Method B) (DMSO-de): d (delta) ppm 8.17-8.12 (m, 2H), 8.00-7.92 (m, 4H), 7.82-7.77 (m, 1 H), 7.71 (td, J = 7.7, 3.2 Hz, 2H), 7.61 -7.57 (m, 2H), 7.46 (d, J = 9.2 Hz, 1 H), 5.83 (d, J = 5.1 Hz, 1 H), 5.04 (dd, J = 4.9, 2.3 Hz, 1 H), 4.85 (dd, J = 6.4, 4.7 Hz,
1 H), 4.07-3.97 (m, 1 H), 3.59-3.51 (m, 1 H), 3.35-3.33 (m, 1 H), 2.56-2.52 (m, 2H), 2.21 (d, J = 14.6 Hz, 6H), 2.03-1 .87 (m, 2H), 1 .48-1 .37 (m, 2H), 1 .37-1 .28 (m, 2H), 1 .28-1 .10 (m,
8H), 1.09-1 .02 (m, 4H), 0.96-0.79 (m, 2H); 31 P NMR (202 MHz, DMSO-de) d (delta) ppm +26.09 (s); LC-MS (Method A) 531 [M]+; RT 4.71 min
Example 11 (11-{[(1R,2R)-1,3-Dihydroxy-1-(4-nitrophenyl)propan-2- yl]carbamoyl}undecyl)( 1 -methyl-1 H-pyrazol-4-yl)diphenylphosphonium chloride 4-(diphenylphosphoryl)- 1 -methyl- 1 H-pyrazole
[00209] Butyllithium (2.5 M in hexanes) (2.73 ml_, 6.83 mmol) was added dropwise to a solution of 4-bromo-1 -methyl-1 H-pyrazole (0.64 mL, 6.21 mmol) in toluene (10 mL) at -78 °C. The resulting reaction mixture was allowed to warm to 0 °C. After stirring for 15 min chlorodiphenylphosphine (1 .27 mL, 6.83 mmol) was added dropwise and the reaction mixture allowed to warm to room temperature. After stirring for 1 h the reaction mixture
was diluted with EtOAc (10 mL) and washed with H2O (10 mL) followed by brine (10 ml_). The resulting organics were dried over MgS04 and solvent removed under vacuo. The resulting residue was purified by silica column chromatography eluting with 0-50% TBME in isohexane to give 4-(diphenylphosphonyl)-1 -methyl-1 H-pyrazole (780 mg, 47% yield) as a colourless oil, which was used in the next step without any further purification.
[00210] LC-MS (Method D) 267 [M+H]+; RT 1.56 min
(11 -carboxyundecyl) ( 1 -methyl- 1 H-pyrazol-4-yl)diphenylphosphonium bromide
[00211] A suspension of 12-bromododecanoic acid (440 mg, 1.58 mmol) in MeCN (3.5 mL) was warmed to 40 °C until a clear solution was obtained. The resulting solution was degassed with bubbling N2 for 30 min and treated with 4-(diphenylphosphoryl)-1-methyl- 1 H-pyrazole (460 mg, 1.74 mmol) (prepared as described in Example 11 step (a)). The resulting solution was heated at 80 °C under N2for 48 h. On cooling to room temperature, the solvent was removed under reduced pressure and the resulting residue purified by silica column chromatography eluting with 0-10% MeOH in DCM to give (1 1 - carboxyundecyl)(1 -methyl-1 H-pyrazol-4-yl)diphenylphosphonium bromide (600 mg, 61 % yield) as a colourless sticky oil, which was used in the next step without further purification.
[00212] LC-MS (Method D) 465 [M]+; 1.1 1 min (11-{[(1R,2R)-1, 3-dihydroxy- 1 -(4-nitrophenyl)propan-2-yl]carbamoyl}undecyl)( 1 -methyl-
[00213] The title compound was prepared as a colourless gum following the procedure described in Example 1 , but using (1 1 -carboxyundecyl)(1 -methyl-1 H-pyrazol-4- yl)diphenylphosphonium bromide (prepared as described in Example 11 step (b)). Silica column chromatography was performed using the eluting system 0-20% 7M NH3 in MeOH in DCM.
[00214] 1 H NMR (Method B) (DMSO-d6): d (delta) ppm 8.48 (s, 1 H), 8.15-8.1 1 (m, 2H), 8.05 (s, 1 H), 7.86 (td, J = 7.3, 1.7 Hz, 2H), 7.84-7.77 (m, 4H), 7.74 (td, J = 7.7, 3.5 Hz,
4H), 7.60-7.56 (m, 2H), 7.46 (d, J = 9.2 Hz, 1 H), 5.83 (d, J = 5.1 Hz, 1 H), 5.04 (dd, J = 5.9, 2.3 Hz, 1 H), 4.85 (dd, J = 6.4, 4.7 Hz, 1 H), 4.05-4.00 (m, 1 H), 3.99 (s, 3H), 3.58-3.51 (m,
1 H), 3.40-3.33 (m, 2H), 2.03-1 .86 (m, 2H), 1 .55-1 .45 (m, 2H), 1 .45-1 .37 (m, 2H), 1 .31 - 1 .09 (m, 9H), 1 .09-0.99 (m, 4H), 0.95-0.78 (m, 2H); 31 P NMR (202 MHz, DMSO-de) d (delta) ppm +13.47 (s); LC-MS (Method C) 659 [M]+; RT 4.40 min
Example 12 - 5-(11-{[(1R,2R)-1,3-Dihydroxy-1-(4-nitrophenyl)propan-2- yl]carbamoyl}undecyl)-5-phenyl-5H-benzo[b]phosphindol-5-ium chloride
[00215] The title compound was prepared as a pale brown gum following the procedure described in Example 6 but using 5-phenyl-5H-benzo[b]phosphindole in step (b).
[00216] LC-MS (Method A) 653 [M]+; RT 6.34 min
Example 13 (10-{[(1R,2R)-1,3-Dihydroxy-1-(4-nitrophenyl)propan-2- yl]carbamoyl}decyl)(1 -methyl-1 H-pyrazol-4-yl)diphenylphosphonium chloride
( 10-carboxydecyl) ( 1 -methyl- 1 H-pyrazol-4-yl)diphenylphosphonium bromide
Prepared following Example 11 step (b) but using 1 1 -bromoundecanoic acid. Silica column chromatography was performed using the eluting system 0-10% MeOH in DCM. (10-carboxydecyl)(1 -methyl-1 H-pyrazol-4-yl)diphenylphosphonium bromide was isolated as a colourless oil, which was used in the next step.
LC-MS (Method D) 451 [M]+; RT 1 .02 min
( 10-{[ (1R,2R)-1, 3-dihydroxy- 1 -(4-nitrophenyl)propan-2-yl]carbamoyl}decyl)( 1 -methyl- 1 H- pyrazol-4-yl)diphenylphosphonium chloride
The title compound was prepared as a white solid following the procedure described in Example 11 step (c) but using 10-carboxydecyl)(1 -methyl-1 H-pyrazol-4- yl)diphenylphosphonium bromide (prepared as described in Example 13 step (a)). Silica column chromatography was performed using the eluting system 0-20% 7M NH3 in MeOH in DCM.
LC-MS (Method C) 645 [M]+; RT 4.04 min
Example 14 - (9-{[(1R,2R)-1,3-Dihydroxy-1-(4-nitrophenyl)propan-2- yl]carbamoyl}nonyl)( 1 -methyl-1 H-pyrazol-4-yl)diphenylphosphonium chloride
( 9-carboxynonyl)( 1 -methyl- 1 H-pyrazol-4-yl)diphenylphosphonium bromide
Prepared following Example 11 step (b) but using 10-bromodecanoic acid. Silica column chromatography was performed using the elution system 0-10% MeOH in DCM. (9- carboxynonyl)(1 -methyl-1 H-pyrazol-4-yl)diphenylphosphonium bromide was isolated as a light brown oil, which was used in the next step.
LC-MS (Method D) 437 [M]+; RT 0.98 min
( 9-{[ (1R,2R)-1, 3-dihydroxy- 1 -(4-nitrophenyl)propan-2-yl]carbamoyl}nonyl)( 1 -methyl- 1 H- pyrazol-4-yl)diphenylphosphonium chloride
The title compound was prepared as a white solid following the procedure described in Example 11 step (c) but using (9-carboxynonyl)(1 -methyl-1 H-pyrazol-4- yl)diphenylphosphonium bromide (prepared as described in Example 14 step (a)). Silica column chromatography was performed using the eluting system 0-20% 7M NH3 in MeOH in DCM.
LC-MS (Method C) 631 [M]+; RT 3.66 min
Example 15 (8-{[(1R,2R)-1,3-Dihydroxy-1-(4-nitrophenyl)propan-2- yl]carbamoyl}octyl)(1 -methyl-1 H-pyrazol-4-yl)diphenylphosphonium chloride
( 8-carboxyoctyl)( 1 -methyl- 1 H-pyrazol-4-yl)diphenylphosphonium bromide
Prepared following Example 11 step (b) but using 9-bromononanoic acid. Silica column chromatography was performed using the eluting system 0-10% MeOH in DCM. (8- carboxyoctyl)(1 -methyl-1 H-pyrazol-4-yl)diphenylphosphonium bromide was isolated as a colourless oil, which was used in the next step.
LC-MS (Method C) 423 [M]+; RT 0.91 min
( 8-{[ (1R,2R)-1, 3-dihydroxy- 1 -(4-nitrophenyl)propan-2-yl]carbamoyl}octyl)( 1 -methyl- 1 H- pyrazol-4-yl)diphenylphosphonium chloride
The title compound was prepared as a white solid following the procedure described in Example 11 step (c) but using (8-carboxyoctyl)(1 -methyl-1 H-pyrazol-4- yl)diphenylphosphonium bromide (prepared as described in Example 15 step (a)). Silica column chromatography was performed using the eluting system 0-20% 7M NH3 in MeOH in DCM.
LC-MS (Method C) 617 [M]+; RT 3.38 min
Example 16 (7-{[(1R,2R)-1,3-Dihydroxy-1-(4-nitrophenyl)propan-2- yl]carbamoyl}heptyl)(1 -methyl-1 H-pyrazol-4-yl)diphenylphosphonium chloride
(7-carboxyheptyl)( 1 -methyl- 1 H-pyrazol-4-yl)diphenylphosphonium bromide
Prepared following Example 11 step (b) but using 8-bromooctanoic acid. Silica column chromatography was performed using the eluting system 0-10% MeOH in DCM. (7- carboxyheptyl)(1 -methyl-1 H-pyrazol-4-yl)diphenylphosphonium bromide was isolated as a colourless oil, which was used in the next step.
LC-MS (Method D) 409 [M]+; RT 0.83 min
(7-{[(1R,2R)-1, 3-dihydroxy- 1 -(4-nitrophenyl)propan-2-yl]carbamoyl}heptyl) ( 1 -methyl- 1 H- pyrazol-4-yl)diphenylphosphonium chloride
The title compound was prepared as a white solid following the procedure described in Example 11 step (c) but using (7-carboxyheptyl)(1 -methyl-1 H-pyrazol-4- yl)diphenylphosphonium bromide (prepared as described in Example 16 step (a)). Silica column chromatography was performed using the eluting system 0-20% 7M NH3 in MeOH in DCM.
LC-MS (Method C) 603 [M]+; RT 3.07 min
Example 17 - (15-{[(1R,2R)-1,3-Dihydroxy-1-(4-nitrophenyl)propan-2- yl]carbamoyl}pentadecyl)triphenylphosphonium bromide
16-bromo-N-[( 1 R, 2R)- 1, 3-dihydroxy- 1 -(4-nitrophenyl)propan-2-yl]hexadecanamide
Prepared following Example 6 step (a) but using 16-bromohexadecanoic acid. Silica column chromatography was performed using the eluting system 0-10% 7M NH3 in MeOH in DCM. 16-bromo-N-[(1 R,2R)-1 ,3-dihydroxy-1 -(4-nitrophenyl)propan-2- yl]hexadecanamide was isolated as a white solid, which was used in the next step.
LC-MS (Method B) 473/475 [M+H]+; RT 1.63 min
(15-{[(1 R,2R)-1 ,3-dihydroxy-1 -(4-nitrophenyl)propan-2- yl]carbamoyl}pentadecyl)triphenylphosphonium bromide
To a degassed solution of 16-bromo-N-[(1 R,2R)-1 ,3-dihydroxy-1-(4-nitrophenyl)propan-2- yl]hexadecanamide (prepared as described in Example 17 step (a)) (150 mg, 0.28 mmol) in MeCN (10 mL) was added triphenylphosphine (1 14 mg, 0.44 mmol). The resulting reaction mixture was refluxed for 16 h. On cooling the reaction mixture was concentrated under reduced pressure and the resulting crude product purified by silica column chromatography eluting with 0-10% 7M NH3 in MeOH in DCM to give the title compound (30 mg, 13% yield) as colourless glass.
LC-MS (Method A) 71 1 [M]+; RT 8.16 min
Example 18 - di-tert-Butyl (11-{[(1R,2R)-1,3-dihydroxy-1-(4-nitrophenyl)propan-2- yl]carbamoyl}undecyl)phenylphosphonium chloride
The title compound was prepared as a tan coloured solid following the procedure of Example 6 but using di-tert-butyl(phenyl)phosphine in step (b).
LC-MS (Method A) 615 [M]+; RT 3.00 min; 31 P NMR (202 MHz, DMSO-de) d (delta) ppm +43.87 (s) Example 19 - (11-{[(1R,2R)-1,3-Dihydroxy-1-(4-nitrophenyl)propan-2- yl]carbamoyl}undecyl)(2-methoxyethyl)diphenylphosphonium chloride
The title compound was prepared as a white solid following the procedure of Example 6 but using (2-methoxyethyl)diphenylphosphine in step (b).
LC-MS (Method A) 638 [M]+; RT 6.03 min; 31 P NMR (202 MHz, DMSO-de) d (delta) ppm +27.04 (s)
Example 20 - (11-{[(1R,2R)-1,3-Dihydroxy-1-(4-nitrophenyl)propan-2- yl]carbamoyl}undecyl)tris(3,5-dimethylphenyl)phosphonium chloride
The title compound was prepared as a white solid following the procedure of Example 6 but using tris(3,5-dimethylphenyl)phosphine in step (b).
LC-MS (Method A) 740 [M]+; RT 8.81 min Example 21 - (7-{[(1R,2R)-1,3-Dihydroxy-1-(4-nitrophenyl)propan-2- yl]carbamoyl}heptyl)(2-methoxyethyl)diphenylphosphonium chloride
Prepared following Example 6 step (a) but using 8-bromooctanoic acid. Silica column purification was performed using the eluting system 0-10% 7M NH3 in MeOH in DCM. 8- bromo-N-[(1 R,2R)-1 ,3-dihydroxy-1-(4-nitrophenyl)propan-2-yl]octanamide was isolated as a colourless oil, which was used in the next step.
LC-MS (Method B) 417/419 [M+H]+; RT 1.26 min
(7-{[ (1R, 2R)- 1, 3-dihydroxy- 1-(4-nitrophenyl)propan-2-yl]carbamoyl}heptyl) ( 2- methoxyethyl)diphenylphosphonium chloride
To a degassed solution of 8-bromo-N-[(1 R,2R)-1 ,3-dihydroxy-1 -(4-nitrophenyl)propan-2- yl]octanamide (prepared as described in Example 21 step (a)) (100 mg, 0.24 mmol) and Nal (36 mg) in MeCN (5 mL) was added (2-methoxyethyl)diphenylphosphine (61 mg, 0.25 mmol). The resulting reaction mixture was refluxed for 16 h. On cooling the reaction mixture was concentrated under reduced pressure and the resulting crude product purified by silica column chromatography eluting with 0-10% 7M NH3 in MeOH in DCM. The resulting white solid was taken up in MeOH (20 mL) and filtered through an Amberlite IRA- 400(CI) ion exchange resin. The collected MeOH was recycled through the column 3 x, followed by a fresh volume of MeOH. The combined MeOH washings were concentrated under reduced pressure to give the title compound (25 mg, 16% yield) as a white solid.
LC-MS (Method A) 581 [M]+; RT 4.38 min; 31 P NMR (202 MHz, DMSO-de) d (delta) ppm +26.97 (s)
Example 22 - (7-{[(1R,2R)-1,3-Dihydroxy-1-(4-nitrophenyl)propan-2- yl]carbamoyl}heptyl)tris(3,5-dimethylphenyl)phosphonium chloride
The title compound was prepared as a tan coloured solid following the procedure of
Example 21 , but using tris(3,5-dimethylphenyl)phosphine in step (b).
LC-MS (Method A) 683 [M]+; RT 7.72 min
Example 23 - {[1.1’-Biphenyl]-(7-{[(1R,2R)-1,3-dihydroxy-1-(4-nitrophenyl)propan-2- yl]carbamoyl}heptyl)diphenylphosphonium chloride
The title compound was prepared as a white solid following the procedure of Example 21 but using [1 T-biphenyl]-2-yldiphenylphosphine in step (b).
LC-MS (Method A) 675 [M]+; RT 6.17 min
Example 24 - Tribenzyl (7-{[(1R,2R)-1,3-dihydroxy-1-(4-nitrophenyl)propan-2- yl]carbamoyl}heptyl)phosphonium chloride
The title compound was prepared as a white solid following the procedure of Example 21 but using tribenzylphosphine in step (b).
LC-MS (Method A) 641 [M]+; RT 5.87 min; 31 P NMR (202 MHz, DMSO-de) d (delta) ppm +27.69 (s) Example 25 - (7-{[(1R,2R)-1,3-Dihydroxy-1-(4-nitrophenyl)propan-2- yl]carbamoyl}heptyl)tris(3-methylphenyl)phosphonium chloride
The title compound was prepared as a white solid following the procedure of Example 21 but using tris(3-methylphenyl)phosphine in step (b).
LC-MS (Method A) 641 [M]+; RT 6.41 min
Example 26 - Tricyclohexyl (7-{[(1R,2R)-1,3-dihydroxy-1-(4-nitrophenyl)propan-2- yl]carbamoyl}heptyl)phosphonium chloride
he title compound was prepared as a white solid following the procedure of Example 21 , but using tricyclohexanephosphine in step (b).
LC-MS (Method A) 617 [M]+; RT 6.53 min; 31 P NMR (202 MHz, DMSO-de) d (delta) ppm +32.46 (s)
Example 27 - (7-{[(1R,2R)-1,3-Dihydroxy-1-(4-nitrophenyl)propan-2- yl]carbamoyl}heptyl)(methyl)diphenylphosphonium chloride
The title compound was prepared as a white solid following the procedure of Example 21 but using methyldiphenylphosphine in step (b). Silica column chromatography was performed using the eluting system 0-20% 7M NH3 in MeOH in DCM. LC-MS (Method A) 537 [M]+; RT 3.92 min
Example 28 (11-{[(1R,2R)-1,3-Dihydroxy-1-(4-nitrophenyl)propan-2- yl]carbamoyl}undecyl)(1 -methyl-1 H-1, 2, 3-triazol-4-yl)diphenylphosphonium chloride
4-(diphenylphosphoryl)- 1 -methyl- 1 H- 1, 2, 3-triazole
Butyllithium (2.5 M in hexanes) (1.84 mL, 4.59 mmol) was added dropwise to a solution of 4-bromo-1 -methyl-1 H-1 ,2,3-triazole (0.68 g, 4.17 mmol) in toluene (20 mL) at -78 °C. The resulting reaction mixture was allowed to warm to 0 °C. After stirring for 15 min chlorodiphenylphosphine (0.85 mL, 4.59 mmol) was added dropwise and the reaction mixture allowed to warm to room temperature. After stirring for 1 h the reaction mixture was diluted with EtOAc (10 mL) and washed with H2O (2 x 10 mL) followed by brine (10 mL). The resulting organics were dried over MgS04 and solvent removed under vacuo. The resulting residue was purified by silica column chromatography eluting with 0-40% EtOAc in hexanes to give 4-(diphenylphosphoryl)-1 -methyl-1 H-1 ,2,3-triazole (280 mg,
19% yield) as a colourless oil, which solidified on standing and was used in the next step without any further purification.
LC-MS (Method B) 268 [M+H]+; RT 1.44 min
(11 -carboxyundecyl)( 1 -methyl- 1H-1,2, 3-triazol-4-yl)diphenylphosphonium bromide
A solution of 12-bromododecanoic acid (209 mg, 0.75 mmol) and 4-(diphenylphosphoryl)- 1 -methyl-1 H-1 ,2, 3-triazole (prepared as described in Example 28 step (a)) (280 mg, 0.79 mmol) in MeCN (10 ml.) was degassed with bubbling N2. After 30 min the resulting solution was heated at 80 °C under N2for 48 h. On cooling to room temperature, the solvent was removed under reduced pressure and the resulting residue purified by silica column chromatography eluting with 0-10% 7M NH3 in MeOH in DCM to give (11- carboxyundecyl)(1 -methyl-1 H-1 ,2, 3-triazol-4-yl)diphenylphosphonium bromide (250 mg, 68% yield) as a colourless sticky oil, which was used in the next step without further purification
LC-MS (Method B) 466 [M]+; RT 1.06 min
(11 -{[(1 R,2R)-1 , 3-dihydroxy- 1 -(4-nitrophenyl)propan-2-yl]carbamoyl}undecyl)( 1 -methyl- 1H-1,2, 3-triazol-4-yl)diphenylphosphonium chloride
The title compound was prepared as a colourless glass following the procedure described in Example 1 but using (11-carboxyundecyl)(1 -methyl-1 H-1 , 2, 3-triazol-4- yl)diphenylphosphonium bromide (prepared as described in Example 28 step (b)). Silica column chromatography was performed using the eluting system 0-20% 7M NH3 in MeOH in DCM.
LC-MS (Method A) 660 [M]+; RT 5.66 min; 31 P NMR (202 MHz, DMSO-de) d (delta) ppm +12.94 (s)
Example 29 (11-{[(1R,2R)-1,3-Dihydroxy-1-(4-nitrophenyl)propan-2- yl](methyl)carbamoyl}undecyl)triphenylphosphonium chloride
The title compound was prepared as a colourless glass following the procedure described in Example 1 but using (1 R,2R)-2-(methylamino)-1 -(4-nitrophenyl)propane-1 ,3-diol.
LC-MS (Method A) 669 [M]+; RT 1 .64 min
Inhibition of proliferation assay
[00217] Cell confluence
[00218] The confluence value is a surrogate for cell proliferation and growth. The value is expressed as a percent confluence, which represents the fraction of culture dish-surface that is occupied by cells. As the number of cells in the dish increases over time due to proliferation, so will their coverage of that surface increase. Expansion of the cell population on the cell culture-dish surface and confluence have mostly a linear relationship until the cells on the plate surface begin to reach saturation or maximum density.
[00219] Confluence is determined based on image analysis. Image based software can identify objects in the image field based on changes to pixel density in a grey scale image. The software can then assign a mask to those pixels within the object. Objects can be ‘gated’ out based on size and shape. To determine cell confluence, images of cells are first masked as objects. The surface area of the image that is masked is measured and compared to the total surface area of the culture dish surface to obtain a percent confluence.
MDA-231 cancer cells were obtained from ATCC. Cells were cultured in Dulbecco’s
Modified Eagle Medium (DMEM) supplemented with 10% Fetal Bovine Serum (FBS), 2 mM Glutamax, 1 mM Non Essential Amino Acid (NEAA) solution and 1 mM sodium
pyruvate. Compounds were dissolved in DMSO at 10 mM and diluted in cellular medium and tested at 10 mM (micromolar). Final DMSO concentrations were <0.1 %. Images were acquired with an IncuCyte Live Cell Imaging microscopy (Essen Bioscience) at every 3 h under cell culture conditions with 10X objective over 4-5 d. Cell confluence was calculated from one field of view per well using the IncuCyte in-built algorithm. Relative confluence values were obtained by normalising each value to the time zero value in each sample.
Claims
1 . A compound comprising an ion of formula (I) or a pharmaceutically acceptable salt thereof:
-L1- is independently absent or is selected from -C(O)-, -C(0)0-, -S(0)2-, -C(0)NR6, and - S(0)2NR6-;
-L3- is independently at each occurrence either absent or selected from: -0-, -S-, -NR7-,- C(O)-, -OC(O)-, -0(0)0-, -S(0)2-, -S(0)-, -NR6C(0)-, -C(0)NR6, -NR6S(0)2-, -S(0)2NR6-, - 0C(0)NR6-,-NR6C(0)0-, NR6C(0)NR6, -CR8=CR8- and -CºC-;
-L2- and -L4- are each independently at each occurrence -Ci-C4-alkylene-, each alkylene group being unsubstituted or substituted with from 1 to 6 independently selected R9 groups; provided that any -l_2- or -L4- group that is attached at each end to an atom selected from oxygen, nitrogen, sulphur or phosphorous is -C2-C4-alkylene-;
n is an integer selected from 0, 1 , 2, 3, 4 and 5;
wherein L1, L2, L3, L4 and n are selected such that length of the linker formed by those groups is from 3 to 20 atoms;
R1a, R1b and R1c are each independently selected from phenyl, biphenyl, naphthyl, 5-, 6-,
9- or 10- membered heteroaryl, C3 to Cs-cycloalkyl, Ci-Cs-alkyl and 4- to 8-membered heterocycloalkyl; wherein said phenyl, biphenyl, naphthyl, 5-, 6-, 9- or 10- membered heteroaryl is optionally substituted with from 1 to 5 independently selected R10 groups; and wherein said C3 to Cs-cycloalkyl, C-i-Cs-alkyl and 4- to 8-membered heterocycloalkyl is optionally substituted with from 1 to 5 independently selected R11 groups; wherein R1a and R1b are optionally connected to each other via a bond or a group selected from -0-, - S(0)2-, NR6, and Ci-C3-alkylene;
R2 and R6 are each independently at each occurrence selected from H and Ci-C6-alkyl;
R3 is independently selected from H, halo, OR12 and NR13R14;
R4 is independently at each occurrence selected from: H, and C(0)Ci-C6-alkyl;
R5 and R10 are each independently at each occurrence selected from: Ci-C6-alkyl, C2-C6- alkynyl, C2-C6-alkenyl, Ci-C6-haloalkyl, C3-C6-cycloalkyl, 4- to 8-membered
heterocycloalkyl, 5-, 6-, 9- or 10- membered heteroaryl, phenyl, OR12, SR13, NR13R14, C(0)0R13, C(0)NR13R13, halo, cyano, nitro, C(0)R13, S(0)20R13, S(0)R13, S(0)2R13, S(0)2NR13R13, 0C(0)NR13R13 and NR13C(0)0R13;
R7 and R14 are each independently at each occurrence selected from: H, Ci-C6-alkyl, C(0)Ci-Ce-alkyl and S(0)2-Ci-C6-alkyl;
R8 is independently at each occurrence selected from H, Ci-C4-alkyl and halo;
R9 is independently at each occurrence selected from: Ci-C6-alkyl, C2-C6-alkynyl, C2-C6- alkenyl, CrCe-haloalkyl, OR12, SR13, NR13R14, C(0)0R13, C(0)NR13R13, halo, cyano, nitro, C(0)R13, S(0)20R13, S(0)2R13, S(0) R13, S(0)2NR13R13, 0C(0)NR13R13 and
NR13C(0)0R13;
R11 is independently at each occurrence selected from: oxo, Ci-C6-alkyl, C2-C6-alkynyl, C2- C6-alkenyl, Ci-C6-haloalkyl, C3-C6-cycloalkyl, 4- to 8-membered heterocycloalkyl, 5-, 6-, 9- or 10- membered heteroaryl, phenyl, OR12, SR13, NR13R14, C(0)0R13, C(0)NR13R13, halo, cyano, nitro, C(0)R13, S(0)20R13, S(0)R13· S(0)2R13, S(0)2NR13R13, 0C(0)NR13R13 and NR13C(0)0R13;
R12 is independently at each occurrence selected from: H, Ci-C6-alkyl and Ci-C6-haloalkyl; R13 is independently at each occurrence selected from: H and Ci-C6-alkyl; and
m is an integer selected from 0, 1 ,
2, 3, 4 and 5;
and wherein any of the abovementioned alkyl, alkenyl, alkynyl, cycloalkyl,
heterocycloalkyl, heteroaryl or phenyl groups is optionally substituted where chemically allowable by from 1 to 4 groups independently selected from oxo, Ci-C6-alkyl, C2-C6- alkynyl, C2-Ce-alkenyl, CrCe-haloalkyl, ORa, NRaRb, SRa, C(0)0Ra, C(0)NRaRa, halo, cyano, nitro, C(0)Ra, S(0)20Ra, S(0)2Ra, S(0)Ra and S(0)2NRaRa; wherein Ra is independently at each occurrence selected from: H and Ci-C6-alkyl; and Rb is
independently at each occurrence selected from: H, Ci-C6-alkyl, C(0)Ci-C6-alkyl and S(0)2-Ci-C6-alkyl.
A compound of claim 1 , wherein the ion is an ion of formula (II)
3. A compound of claim 1 or claim 2, wherein R2 is H.
4. A compound of any one of claims 1 to 3, wherein R4 is H.
5. A compound of any one of claims 1 to 4, wherein R3 is selected from F and OH.
6. A compound of any one of claims 1 to 5, wherein m is 1 and the R5 group is
situated para to the point of connection of the rest of the molecule and is selected from S(0)2Ci-C4-alkyl and nitro.
7. A compound of any one of claims 1 to 6, wherein L1 is -C(O)-.
8. A compound of any one of claims 1 to 7, wherein L1, L2, L3, L4, and n are selected such that length of the linker formed by those groups is from 7 to 17 atoms.
9. A compound of any one of claims 1 to 8, wherein L3 is at each occurrence absent.
1 1. A compound of claim 10, wherein L5 is unsubstituted.
12. A compound of any one of claims 1 to 11 , wherein R1a, R1b and R1c are each
independently phenyl.
13. A compound of claim 12, wherein R1a, R1b and R1c are each unsubstituted phenyl.
14. A compound of any one of claims 1 to 11 , wherein R1a and R1b are each
unsubstituted phenyl and R1c is independently selected from: substituted phenyl, biphenyl, naphthyl, 5-, 6-, 9- or 10- membered heteroaryl, C3 to Cs-cycloalkyl, C1- Ce-alkyl and 4- to 8-membered heterocycloalkyl.
15. A compound of any one of claims 1 to 11 , wherein at least one of R1a, R1b and R1c is Ci-C6-alkyl.
16. A compound of claim 15, wherein any of R1a, R1b and R1c that are not Ci-C6-alkyl are phenyl.
17. A compound of claim 1 , wherein the ion of formula (I) is an ion selected from:
18. The compound of claims 1 to 17 for use as a medicament.
19. The compound of claims 1 to 17 for use in the treatment of cancer.
20. A method for the treatment of cancer, wherein the method comprises the
administration of a therapeutically effective amount of a compound of any one of claims 1 to 17.
21. A pharmaceutical composition comprising the compound of claims 1 to 17 and one or more pharmaceutically acceptable excipients.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1809445.8A GB201809445D0 (en) | 2018-06-08 | 2018-06-08 | Compounds |
GB1809445.8 | 2018-06-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2019234228A1 true WO2019234228A1 (en) | 2019-12-12 |
Family
ID=62975636
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2019/064970 WO2019234228A1 (en) | 2018-06-08 | 2019-06-07 | Beta-amino-alpha-hydroxyalkylphenyl derivatives and their use for cancer treatment |
Country Status (2)
Country | Link |
---|---|
GB (1) | GB201809445D0 (en) |
WO (1) | WO2019234228A1 (en) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011146589A2 (en) | 2010-05-20 | 2011-11-24 | Board Of Supervisors Of Lousiana State University And Agricultural And Mechanical College | Vitamin e conjugates, and their uses as antioxidants and prodrug delivery vehicles |
-
2018
- 2018-06-08 GB GBGB1809445.8A patent/GB201809445D0/en not_active Ceased
-
2019
- 2019-06-07 WO PCT/EP2019/064970 patent/WO2019234228A1/en active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011146589A2 (en) | 2010-05-20 | 2011-11-24 | Board Of Supervisors Of Lousiana State University And Agricultural And Mechanical College | Vitamin e conjugates, and their uses as antioxidants and prodrug delivery vehicles |
Non-Patent Citations (8)
Title |
---|
CAO YWU KMEHTA R ET AL.: "Long-term use of antibiotics and risk of colorectal adenoma", GUT, vol. 0, 2017, pages 1 - 7 |
HALEBLIAN, J PHARM SCI, vol. 64, no. 8, August 1975 (1975-08-01), pages 1269 - 1288 |
M. E. AULTON: "Pharmaceuticals - The Science of Dosage Form Designs", 1988, CHURCHILL LIVINGSTONE |
P. J. KOCIENSKI: "Protecting groups", 1994, GEORG THIEME VERLAG |
SANDOVAL-ACUÑA CRISTIAN ET AL: "Destabilization of mitochondrial functions as a target against breast cancer progression: Role of TPP+-linked-polyhydroxybenzoates", TOXICOLOGY AND APPLIED PHARMACOLOGY, ACADEMIC PRESS, AMSTERDAM, NL, vol. 309, 20 August 2016 (2016-08-20), pages 2 - 14, XP029736995, ISSN: 0041-008X, DOI: 10.1016/J.TAAP.2016.08.018 * |
STAHLWERMUTH: "Handbook of Pharmaceutical Salts: Properties, Selection, and Use", 2002, WILEY-VCH |
T.W. GREENE: "Protective Groups in Organic Synthesis", 1981, A. WILEY-INTERSCIENCE PUBLICATION |
VASILOIU, MARIA ET AL: "Amino alcohol-derived chiral ionic liquids: structural investigations toward chiral recognition", TETRAHEDRON: ASYMMETRY, vol. 26, no. 18-19, 24 September 2015 (2015-09-24), pages 1069 - 1082, XP002793110, ISSN: 0957-4166, DOI: 10.1016/J.TETASY.2015.08.009 10.1016/J.TETASY.2015.08.009 * |
Also Published As
Publication number | Publication date |
---|---|
GB201809445D0 (en) | 2018-07-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10538524B2 (en) | Pyrazolopyrimidine derivatives useful as inhibitors of Bruton's tyrosine kinase | |
EP3204381B1 (en) | N-pyridinyl acetamide derivatives as wnt signalling pathway inhibitors | |
WO2016051181A1 (en) | 4h-imidazo[1,5-a]indole derivatives and their use as indoleamine 2,3-dioxygenase (ido) and/or tryptophan 2,3-dioxygenase (td02) modulators | |
EP3191477B1 (en) | Fused bicyclic (hetero)aromatic compounds useful for the treatment of cancers | |
WO2016059412A1 (en) | 6,7-heterocyclic fused 5h-pyrrolo[1,2-c]imidazole derivatives and their use as indoleamine 2,3-dioxygenase (ido) and/or tryptophan 2,3-dioxygenase (td02) modulators | |
WO2015140566A1 (en) | Pyrazolo-pyrimidines as inhibitors of btk | |
EP3612544B1 (en) | Azithromycin derivatives containing a phosphonium ion as anticancer agents | |
US11098073B2 (en) | Triphenylphosphonium-tethered tetracyclines for use in treating cancer | |
WO2020079224A1 (en) | Azithromycin derivatives containing a phosphonium ion as anticancer agents | |
US11161862B2 (en) | Phosphonium-ion tethered tetracycline drugs for treatment of cancer | |
GB2548542A (en) | Compounds | |
US11560395B2 (en) | Azithromycin derivatives containing a phosphonium ion as anticancer agents | |
WO2019234228A1 (en) | Beta-amino-alpha-hydroxyalkylphenyl derivatives and their use for cancer treatment | |
WO2018193116A1 (en) | Azithromycin derivatives containing a phosphonium ion as anticancer agents | |
WO2018193111A1 (en) | Azithromycin derivatives containing a phosphonium ion as anticancer agents |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 19730298 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 19730298 Country of ref document: EP Kind code of ref document: A1 |